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resumo 
 
 
A estirpe Bacillus licheniformis I89 possui a capacidade de produzir alguns 
compostos com actividade antibacteriana. No presente estudo, a separação 
desses compostos foi realizada através da aplicação de vários procedimentos, 
incluindo extracção em fase sólida e cromatografia liquida de alta pressão. 
Dois destes compostos bioactivos constituem o lantibiótico de classe II 
lichenicidina e são caracterizados pela massas molecular de 3250 Da (Bliα) e 
3020 Da (Bliβ). O cluster responsável pela biossíntese da lichenicidina foi 
heterologamente expresso em Escherichia coli, constituindo a primeira 
descrição da produção de um lantibiótico totalmente in vivo num hospedeiro 
Gram-negativo. Este sistema foi subsequentemente explorado com o objectivo 
de relacionar cada proteína codificada no cluster genético da lichenicidina na 
produção dos péptidos Bliα e Bliβ. O desenvolvimento do sistema de trans 
complementação possibilitou a produção de variantes destes péptidos. A 
análise das massas moleculares destas variantes assim como a análise dos 
padrões de fragmentação obtidos por MS/MS permitiu a revisão de algumas 
das características estruturais previamente proposta para Bliα e Bliβ. A análise 
dos genes hipoteticamente envolvidos na protecção da estirpe produtora 
contra a acção antibiótica da lichenicidina revelou, que em E. coli, a sua 
ausência não resulta no aumento da susceptibilidade a este composto. 
Verificou-se também que a presença destes genes não é essencial para a 
produção de lichenicidina em E. coli. Foi também confirmado 
experimentalmente que a membrana externa da E. coli constitui uma barreira 
natural para a entrada dos péptidos na célula. De facto, uma das 
características intrigantes da produção de lichenicidina por uma bactéria de 
Gram negativo reside no mecanismo de transporte dos dois péptidos através 
da membrana externa. Neste estudo foi demonstrado que na ausência da 
proteína de membrana TolC, a massa molecular de Bliα e Bliβ não foi 
identificada no sobrenadante de E. coli, demonstrando assim que a sua 
presença no ambiente extra-celular não se devia a um processo de lise 
bacteriana. Foi ainda avaliada a capacidade da maquinaria biossintética da 
lichenicidina para produzir o lantibiótico haloduracina, através do 
processamento de chimeras lichenicidina-haloduracina, contudo, os resultados 
foram negativos. Verificou-se ainda que em determinadas condições de 
incubação, a diferenciação da morfologia original da estirpe B. licheniformis I89 
pode ocorrer. Esta dissociação implicou a transição da colónia parental e 
rugosa para uma colónia de aparência mais simples e suave. Desta forma, as 
diferenças das duas morfologias em termos de taxa de crescimento, 
esporulação e actividade antibiótica foram investigadas. Considerando 
especificamente Bliα e Bliβ verificou-se que a abundância destes péptidos nas 
culturas do fenótipo fino é geralmente inferior aquela identificada nas culturas 
do fenótipo parental. Por último, a diversidade de elementos genéticos 
constituintes de péptido sintetases não ribossomais (NRPS) foi investigada em 
lagoas no centro de Portugal e em solos provenientes de caves do sul de 
Portugal, revelando a presença de potenciais novas NRPS nestes ambientes. 
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abstract 
 
Bacillus licheniformis I89 has the ability to produce some antibacterial 
compounds. In the present study, the separation of such compounds was 
achieved by the application of several procedures, including solid phase 
extraction and preparative high-pressure liquid chromatography. Two of these 
compounds constitute the class II lantibiotic lichenicidin and are characterized 
by the molecular masses of 3250 Da (Bliα) and 3020 Da (Bliβ). The lichenicidin 
gene cluster was successfully expressed in Escherichia coli, constituting the 
first report of a complete lantibiotic gene cluster heterologous expression in a 
Gram-negative host. This system was further exploited to characterize and 
assign the function of the proteins encoded in the biosynthetic gene cluster. 
Moreover, a trans complementation system was developed for the expression 
of Bliα and Bliβ mutants in vivo. The assignment of essential amino acid 
residues for bioactivity was investigated by generation of Ala-mutants. Also, 
several features of Bliα and Bliβ structures were revised by analysis of MS/MS 
fragmentation patterns obtained for wild type and mutated peptides. Regarding 
the lichenicidin self-protection in E. coli, it was found that immunity genetic 
determinants are not essential to Bliα and Bliβ production. Furthermore, it was 
experimentally confirmed that the E. coli outer membrane constitutes a natural 
barrier to the biological activity of lichenicidin. An intriguing feature of the 
lichenicidin production by E. coli lies in the export mechanism of Bliα and Bliβ 
peptides. Herein, it was demonstrated that the presence of these peptides in 
the E. coli supernatants resulted from their translocation through the bacterial 
cell wall. In fact, it was found that in the absence of the outer membrane protein 
TolC none of the lichenicidin peptides could be detected in the bacterial 
supernatants. The potential of the E. coli lichenicidin expression system to 
produce the closely related lantibiotic haloduracin through the biosynthetic 
processing of lichenicidin-haloduracin chimeras was also attempted in the 
present study, however, without success. 
It was found that under certain circumstances of incubation, B. licheniformis 
I89was able to differentiate from its parental rough phenotype to a more simple 
and smooth morphology. The differences in terms of growth, sporulation and 
antagonistic activity of both phenotypes were investigated in two different 
culture media. Regarding the production of lichenicidin peptides, it was found 
that the abundance of Bliα and Bliβ in extracts from the smooth phenotype 
cultivated in TSB was lower than that detected in the rough phenotype extracts.  
Finally, the screening of genetic elements associated with nonribosomal 
peptide synthetases was performed in Portuguese lagoons and soil from caves 
using a culture-independent approach. A wide variety of adenylation domains 
was identified, providing evidence that potentially novel NRPSs are present in 
these environments. 
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Structure of this dissertation 
 
 
 
 
The main objective of the present dissertation was to characterize the antibacterial 
compounds produced by the B. licheniformis I89 strain, considering their biosynthetic 
pathway, structure and biological activity. Also, a screening of some environments was 
performed to identify the presence of genetic determinants associated with the 
biosynthetic pathway of conventional antibiotics. 
Thus, this dissertation is composed by a general introduction (chapter I), incorporating 
the state-of-art in the field of antibacterial class I bacteriocins as well as a general 
overview of the traditional antibiotics biosynthesis. In the following chapters (chapter II-VII) 
are presented and discussed the results obtained in the studies performed. Each of these 
chapters includes a brief introduction, the results and discussion of the major findings and 
the experimental procedures. Finally, a unifying overview and discussion of all the themes 
addressed along this dissertation is presented in the final chapter (chapter VIII). 
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ore than one century ago, it was recognized for the first time that bacteria 
have the intriguing ability to inhibit the growth of other bacteria as part of 
an antibiosis process. Several years later, Sir Alexander Fleming also noticed 
that the mold Penicillium notatum had the ability to kill the bacteria 
Staphylococcus aureus and Haemophilus influenzae and related such phenomenon with 
the production of a compound designated by himself as penicillin (1929). However the 
importance of his findings was only recognized in the late 1930’s and early 1940’s by Florey 
and Chain, who would finally prompt the industrial production and clinical application of 
penicillin. The term “antibiotic” to compounds such as penicillin was attributed by the soil 
microbiologist Selman Waksman, who defined it as any substance produced by a 
microorganism that is antagonistic to the growth of other microorganisms in high dilutions 
(Waksman, 1947; Levy, 2002). Selman Waksman and his student Schatz also isolated the 
antibiotic streptomycin, that was produced by the soil bacteria Streptomyces griseus and 
was able to control the growth of the Gram-negative Mycobacterium tuberculosis, being 
the first therapeutic agent to offer hope to patients with tuberculosis (Jones et al., 1944). 
Subsequent studies resulted in the discovery of novel different antibiotics including 
gramicidin, chloramphenicol, tetracycline, polymyxin and neomycin.  
Research developments of antibacterial compounds also implied the investigation of 
their biosynthetic pathways. Considering this aspect it was found that bacteria have the 
ability to produce two distinct classes of antimicrobial compounds: those that are 
ribosomally synthesized, which are designated by bacteriocins and those that are non-
ribosomally produced by multi-enzymatic complexes called nonribosomal peptide 
synthetases (NRPSs) (Nes et al., 2007). The main focus of this thesis relies on aspects related 
with the biosynthesis of a class of bacteriocins – the lantibiotics. 
M 
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1.1 Bacteriocins - a general overview 
Bacteriocins are a highly diverse group of ribosomally compounds produced by a 
bacteria that are active against other bacteria, either from the same species (narrow 
spectrum) or across a genera (broad spectrum) (Cotter et al., 2005a). The first reported 
bacteriocin was colicin V, which was identified by Andre Gratia in 1925. Colicin V is a heat-
labile peptide present in cultures of Escherichia coli V with activity against E. coli φ (Gratia, 
1925). In 1928, another bacteriocin was also described by Rogers (1928) although it was 
only characterized in 1971, as nisin A (Gross and Morell, 1971). Nisin A is produced by 
Lactococcus lactis, a widely used bacterium in cheese production. Almost two decades 
later, Klaenhammer (1988) predicted that 99 % of all bacteria should have the ability to 
synthesize at least one bacteriocin (Maqueda et al., 2008). Nowadays and according with 
the bacteriocins database BACTIBASE (Hammami et al., 2007), at least 177 sequences of 
bacteriocins are described, of which 88 % are synthesized by Gram-positive bacteria, 10 % 
by Gram-negative bacteria and approximately 2 % by members of the Archae domain. A 
total of 31 genera were identified as producers, with the lactic acid bacteria (LAB) 
representing the most predominant group of producers (64 %), followed by Bacillus (8.5 %), 
Escherichia (6.2 %), Staphylococcus (4.5 %) and Streptomyces (2.8 %).  
The bacteriocins produced by Gram-positive are generally smaller than 6 KDa, whereas 
those produced by Gram-negative are often proteins larger than 20 KDa, being colicin V 
and microcins exceptions (smaller than 10 KDa) (Nissen-Meyer and Nes, 1997). Moreover, 
the Gram-positive antimicrobial peptides are generally non-toxic to eukaryotic cells and 
have a much broader inhibitory spectra when compared to those of Gram-negative 
bacteria (Nes et al., 2007).  
The establishment of a proper classification scheme for these compounds has been 
difficult since some authors defend that the available systematics lacks consistency and 
coherence (van Belkum and Stiles, 2000; Zouhir et al., 2010). Initially, these compounds 
were classified into two main classes: the class I, consisting of the modified bacteriocins 
lantibiotics and the class II consisting of the unmodified peptide bacteriocins (Nissen-
Meyer and Nes, 1997). Presently, the bacteriocins are grouped into different classes based 
on different characteristics such as the producer microorganisms, molecular weight, 
specific antibacterial activity, physical properties, chemical structures and mode of action 
(de Jong et al., 2006; Nes et al., 2007). According to this scheme, it has been proposed to 
divide the bacteriocins into five classes (de Jong et al., 2006):  
Class I: post-translationally modified bacteriocins, designated as lantibiotics  
Class II: non-modified heat stable bacteriocins 
Class III: non-modified large heat-labile bacteriocins 
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Class IV: non-modified circular bacteriocins  
Class V: non-modified complex bacteriocins carrying lipid or carbohydrate moieties 
In the following sections only the lantibiotics class of bacteriocins will be discussed, since 
these compounds are the main focus of the present thesis. 
 
 
1.2 Lantibiotics – class I bacteriocins 
Lantibiotics constitute the first class of bacteriocins and are described as ribosomally 
synthesized peptides, which undergo extensive post-translational modification to form their 
biologically active forms (de Vos et al., 1995; Sahl et al., 1995; Sahl and Bierbaum, 1998). 
Contrary to other classes of bacteriocins, lantibiotics are exclusively produced by Gram-
positive bacteria. Although not recognized at the time, the first report of a lantibiotic goes 
back to 1928, the same year of penicillin discovery, when Rogers observed that 
metabolites from Lactococcus lactis (LAB bacteria) could inhibit other LAB bacteria 
(Rogers, 1928). In 1944, Mattick and Hirsch (1944) partially purified and analyzed the 
antagonistic compound responsible for such phenomenon and later, Gross and Morell 
(1971) proposed a primary structure for the peptide that became known as nisin A. 
Nevertheless, the term lantibiotic was only introduced a few years later by Schnell et al. 
(1988) to describe the epidermin peptide produced by Staphylococcus epidermidis as a 
lanthionine-containing antibiotic. The characteristic lanthionine (Lan) amino acids were 
isolated for the first time by Horn and coworkers (1941) from wool (lana in latin) and consist 
of two alanines cross-linked via a thioether linkage that connects their β-carbons. As 
indicated by their designation, the presence of Lan and usually methyllanthionine (MeLan) 
aminoacids is the unifying structural motif of all the lantibiotics (Chatterjee et al., 2005). In 
the beginning of the 70’s it was proposed that the Lan and MeLan rings were generated 
by intramolecular additions of cysteines to the α, β-unsaturated amino acids 2,3-
didehydroalanine (Dha) and (Z)-2,3-didehydrobutyrine (Dhb), respectively (Figure 1). Also, 
it was hypothesized that these Dha and Dhb amino acids, which were frequently found in 
lantibiotics, originated from the dehydration of serine or threonine residues, respectively 
(Ingram, 1969; Ingram, 1970). These hypotheses were only confirmed in the late 80’s, 
beginning of the 90’s when the first biosynthetic gene clusters involved in the lantibiotics 
production were sequenced (Chatterjee et al., 2005). These clusters generally encode all 
the proteins involved in the production of the bioactive compound, including i) the 
synthesis of the prepropeptide, ii) dehydration and cross-linkage reactions, iii) cleavage of 
the leader sequence, iv) secretion and v) self-protection mechanisms (McAuliffe et al., 
2001b).  
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Lantibiotics have been considered intriguing molecules because of their unique 
characteristics such as their biochemistry, genetic regulation and biological activities 
(Willey and van der Donk, 2007). Their bactericidal activity, at nanomolar concentrations, 
against a variety of Gram-positive bacteria, including multiresistant strains, has been the 
most promising and explored of their potential applications. However, not all of these 
compounds harbor this ability.   
 
 
Figure 1: Formation of lanthionine and methyllanthionine rings. Adapted from Willey and van der Donk (2007) 
 
 
1.2.1 Classification schemes 
Two main classification schemes for lantibiotics have been proposed: the first and the 
oldest is based on the topology of the lantibiotics ring structures and their biological 
activities (Jung and Sahl, 1991) while the second is based on the peptides biosynthetic 
pathway and on their mechanism of action (Pag and Sahl, 2002; Willey and van der Donk, 
2007). According to the first system (Jung and Sahl, 1991), the lantibiotics were divided into 
two distinct groups: i) the type-A lantibiotics possessing an elongated flexible 
configuration, which are able to disturb the bacterial membrane due to the presence of a 
positive net charge and ii) the type-B lantibiotics characterized by a globular and 
compact structure (usually without a net charge), which biological activity involves the 
inhibition of bacterial enzymes (Figure 7). However, with the successive discovery of new 
peptides, the type A lantibiotics were further sub-grouped into type-A(I) and type-A(II) (de 
Vos et al., 1995). The type-A(II) lantibiotics comprise peptides characterized by a linear N-
terminus and a globular C-terminus, whereas the type-A(I) are more elongated lantibiotics 
(Figure 7). The prototypes of each class are based on those peptides with experimentally 
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established structures, such as the type-A(I) nisin, epidermin and pep5; the type-A(II) 
lacticin 481 and the type-B mersacidin and cinnamycin (Bierbaum and Sahl, 2009) (Figure 
7 and Table 1). 
 
Table 1: Overview of lantibiotics grouped according with de Vos et al. (1995) classification and their similarities to 
peptides with established structures. The producer strains and the lantibiotics molecular weights are also 
included. Adapted from Chatterjee et al. (2005) and Bierbaum and Sahl (2009). 
 Lantibiotic Producer strain MW (Da) Class Reference 
Nisin group     
Nisin A Lactococcus lactis ATCC 11454 3353 I (Gross and Morell, 1971) 
Nisin Z Lactococcus lactis N8 3330 I (Mulders et al., 1991) 
Subtilin Bacillus subtilis ATCC 6633 3317 I (Gross et al., 1973) 
Ericin S Bacillus subtilis A1/3 3442 I (Stein et al., 2002) 
Ericin A Bacillus subtilis A1/3 2986 I (Stein et al., 2002) 
Microbisporicins Microsbiospora sp. 2246/2230 I (Castiglione et al., 2008) 
Epidermin group     
Epidermin Staphylococcus epidermis Tu3298 2164 I (Allgaier et al., 1986) 
Gallidermin Staphylococcus gallinarium Tu3928 2164 I (Kellner et al., 1988) 
Mutacin III Streptococcus mutans UA787 2266 I (Qi et al., 1999b) 
Mutacin I Streptococcus mutans CH43 2364 I (Qi et al., 2000) 
Pep5 group     
Pep5 Staphylococcus epidermidis 5 3488 I (Kellner et al., 1989) 
Ty
p
e
-A
 (
I)
 
Epilancin K7 Staphylococcus epidermidis 3032 I (van de Kamp et al., 1995) 
Lacticin 481 group     
Lacticin 481 Lactococcus lactis CNRZ 481 2901 II (Piard et al., 1992) 
Lactocin S Lactococcus sakei L45 3764 II (Skaugen et al., 1997) 
Mutacin II Streptococcus mutans T8 3245 II (Novak et al., 1994) 
Nukacin ISK-1 Staphylococcus warneri ISK-1 2960 II (Sashihara et al., 2000) 
Plantaricin C Lactococcus plantarum LL441 2880 II (Turner et al., 1999) 
Ruminococcin A Ruminococcus gnavus 2675 II (Dabard et al., 2001) 
Salivaricin A Streptococcus salivarius 20P3 2315 II (Ross et al., 1993) 
Ty
p
e
-A
 (
II)
 
Variacin Micrococcus varians MCV8 2658 II (Pridmore et al., 1996) 
Cinnamycin group     
Cinnamycin Streptomyces cinnamoneus 2042 II (Fredenhagen et al., 1990) 
Duramycin 
Streptoverticillium hachijoense DSM 
40114 
2014 
II (Fredenhagen et al., 1990) 
Ancovenin Streptomyces sp. 1959 II (Kido et al., 1983) 
Mersacidin group     
Actagardine Actinoplanes linguriae ATCC 31048 1890 II (Zimmermann and Jung, 1997) 
Mersacidin Bacillus sp. HIL Y-85,54728 1825 II (Chatterjee et al., 1992) 
Ty
p
e
 B
 
Michiganin A Clavibacter michiganensis 2145 II (Holtsmark et al., 2006) 
  α β   
BHT Streptococcus rattus BHT 3375 2802 II (Hyink et al., 2005) 
Cytolysin L* Enterococcus faecalis 4164 2631 II (Gilmore et al., 1994) 
Haloduracin Bacillus halodurans C-125 2332 3099 II (McClerren et al., 2006) 
Lacticin 3147 Lactococcus lactis DPC3147 3322 2847 II (Martin et al., 2004) 
Lichenicidin Bacillus licheniformis 3250 3020 II (Begley et al., 2009) 
Plantaricin W Lactobacillus plantarum LMG 2379 3223 3099 II (Holo et al., 2001) 
Staphylococcin 
C55 
Staphylococcus aureus C55 
3339 2993 
II (Navaratna et al., 1999) 
Tw
o
-c
o
m
p
o
n
e
n
t 
Smb Streptococcus mutans GS5 
nd 
II 
(Yonezawa and 
Kuramitsu, 2005) 
Non-antimicrobial peptides/Lantipeptides   
SapB Streptomyces coelicolor 2026 III (Kodani et al., 2004) 
SapT Streptomyces tendae 2032 III (Kodani et al., 2005) 
AmfS Streptomyces griseus nd III (Ueda et al., 2002) 
O
th
e
rs
 
Labyrinthopeptin 
A2 
Actinomadura namibiensis DSM 
6313 
1065 III (Meindl et al., 2010) 
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As abovementioned, not all the lantibiotics function strictly as antimicrobial agents. For 
instance, cinnamycin and the related duramycins are potent inhibitors of phospholipase 
A2 (Fredenhagen et al., 1990). Also, duramycin increases chloride secretion in the lung 
epithelium and has been evaluated for the mucus clearing secretions from the lungs 
associated with cystic fibrosis diseases (Willey and van der Donk, 2007). Cytolysin, apart 
from the inhibition of Gram-positive bacteria, also functions as a virulence factor, 
promoting the lysis of erythrocytes and polymorphonuclear leukocytes (Cox et al., 2005). 
The SapB and SapT compounds do not exhibit antimicrobial activity and are thought to 
function as biosurfactants, releasing the surface tension at the colony-air interface to 
facilitate the emergence of nascent aerial hyphae of Streptomyces spp. strains (Tillotson et 
al., 1998; Kodani et al., 2004; Kodani et al., 2005). Regarding the recently described 
labyrinthopeptins, bioactivity assays of labyrinthopeptin A2 revealed that it has an 
excellent efficacy against neuropathic pain in an in vivo mouse model (Meindl et al., 
2010). 
 
 
 
Figure 2: Classification of lantibiotics according with the parameters established by Pag and Sahl (2002) and 
Willey and van der Donk (2007). 
 
 
1.2.2 General overview of lantibiotics biosynthesis 
The lantibiotic biosynthetic gene clusters are often present on the chromosome of the 
producer strain, however they can also be found on conjugative transposable elements 
(e.g. nisin) and plasmids (e.g. lacticin 3147) (Horn et al., 1991; Ryan et al., 1996). There is 
evidence that at least some parts of these gene clusters are organized in operons, many 
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of them consisting of several transcriptional units. Also, a weak terminator structure is often 
found in between the structural gene and its downstream ORF (McAuliffe et al., 2001b). 
Historically, the genes that constitute each lantibiotic biosynthetic cluster are generally 
describe with the suffix lan (de Vos et al., 1995). When a particularization is necessary, this 
suffix is substituted by the specific designation of the lantibiotic in question.  
 
 
 
Figure 3: Representation of the biosynthetic gene clusters involved in the production of the most representative 
lantibiotics from each class. Transcriptional units, when known, are indicated by black arrows. Dashed arrow 
represents a putative promoter. The subtilin structural gene corresponds to lanS. Adapted from Willey and van 
der Donk (2007). 
 
Although the gene order, complexity, and transcriptional organization of the various 
clusters can be different, some essential genes are always present (Figure 3) 
(Asaduzzaman and Sonomoto, 2009). These include the structural gene (lanA) encoding 
the precursor prepropeptide, which will be the target for post-translational modifications. 
For historical reasons the structural genes of subtilin and cytolysin do not follow this rule, 
being refereed as spaS and cylLL/cylLS, respectively. The post-translational modification of 
the LanA C-terminus is essential for the production of the bioactive lantibiotic. Accordingly, 
the lanB and lanC genes found in class I lantibiotic clusters encode the LanB and LanC 
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proteins responsible for the dehydration of Ser and Thr residues and the formation of the 
thioether rings, respectively (Figure 3 and Figure 4). In class II lantibiotics, a single 
bifunctional LanM protein encoded by lanM catalyzes these two reactions (Figure 3 and 
Figure 4). After the intervention of these enzymes, the leader sequences of the modified 
LanA peptides are removed during or after its translocation to the bacterial environment. 
In the biosynthesis of class I lantibiotics this step is carried out by two distinct enzymes, LanP 
and LanT, whereas in class II lantibiotics a single LanT protein combines both activities 
(Figure 3 and Figure 4) (Chatterjee et al., 2005; Willey and van der Donk, 2007).  
Additionally, some biosynthetic clusters possess two-component sensory system genes 
(e.g. lanK and lanR) encoding proteins involved in the regulation of the lantibiotic 
synthesis. Several gene clusters also contain a second transport system comprising three 
genes lanE, lanF and lanG that have been associated with the self-protection of the 
producer strain. Other genes associated with specific post-translational modifications can 
also be identified in lantibiotics’ gene clusters. Examples include the genes encoding a 
hydroxylase (ltnJ and cinX) that oxidizes an asparagine residue in β-position of some 
lantibiotics, such as lacticin 3147 and cinnamycin (Figure 3) (Willey and van der Donk, 
2007).  
 
 
 
Figure 4: General overview and comparison of the dehydration, cyclization and leader sequence removal steps 
involved in the biosynthesis of class I and class II lantibiotics. 
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The biosynthesis of two-component lantibiotics such as lacticin 3147 and haloduracin 
involves the action of the classical class II enzymes. The production of these peptides 
requires the expression of two structural genes, the lanA1 and lanA2 (Figure 3). 
Subsequently, LanA1 and LanA2 prepropeptides are modified by the distinct LanM1 and 
LanM2 enzymes, respectively. However, the export and removal of the leader sequence 
of LanA1 and LanA2 is directed by the same LanT protein. Some of these lantibiotics (e.g. 
Halβ from haloduracin and Plwβ from plantaricin W) require a second proteolysis step 
before they become completely bioactive. The protease responsible for this reaction is 
specific for one of the two peptides and it is not necessarily encoded in their biosynthetic 
gene clusters. Traditionally the mature peptide resulting from the transcription of lanA1 is 
referred as the α- peptide and that from lanA2 as the β-peptide. 
 
 
1.2.3 Biosynthetic elements 
1.2.3.1 Prepropeptides 
As previously described, the structural lanA genes encode the precursor of the mature 
lantibiotic – the prepropeptide (Willey and van der Donk, 2007). The isolation of these 
prepropeptides from the cytoplasm of the producing strain has been difficult, suggesting 
that they have a short half-life, possibly being dehydrated immediately after their synthesis. 
Prepropeptides are biologically inactive and can be dissected into the N-terminal 
leader sequence and the C-terminal propeptide regions (McAuliffe et al., 2001b). Both of 
these regions contain Ser and Thr residues, while cysteines have been found exclusively in 
the propeptide segment (Chatterjee et al., 2005). Though, only the Ser and Thr residues 
present in the propeptide are dehydrated to Dha and Dhb, respectively. The production 
of a fully modified and active (mature) lantibiotic also implies the proteolytic removal of 
the leader sequence. Thus, the first amino acid of the active peptide will be coincident 
with the first amino acid of the propeptide. That is why the enumeration of the amino 
acids constituting the leader sequence is performed with negative numbers, having the 
proteolytic position as a starting point. 
 
 
Leader Sequences 
The lantibiotics’ leader sequences do not have homology with the sec-dependent 
transport signal sequences since they lack a hydrophobic membrane-spanning core and 
their typical processing site (McAuliffe et al., 2001b). An exception was identified in the 
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leader peptide of the class II lantibiotic cinnamycin, which possesses the AXA motif 
required for the activity of type I signal peptidases of the general secretory sec-pathway 
(Widdick et al., 2003).  
The leader sequences of class I lantibiotics are about 25 amino acids long and are 
normally rich in Asp residues (Oman and van der Donk, 2010). The alignment of these 
sequences allowed the identification of a common FNLD motif between the positions -20 
and -15 and usually a Pro in the position -2 (Chatterjee et al., 2005) (Figure 5). The 
importance of this consensus sequence was shown after introduction of mutations that 
resulted in the completely abolishment or reduction of the mature lantibiotics nisin and 
pep5 production (van der Meer et al., 1994; Neis et al., 1997).  
 
 
Figure 5: Alignment of the leader peptide sequences from the prepropeptides of the most characteristic 
lantibiotics from each group. Conserved amino acids are highlighted in grey shades. The dashed arrow 
represents the cleavage of mersacidin, haloduracin A2 and plantaricin W A2 leader sequences. 
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The leader sequences of the class II lantibiotics are generally longer than those of 
class I, and they are typically rich in Asp (similarly to those of class I) and Gln residues 
(Oman and van der Donk, 2010). The C-terminus of these leader sequences is 
characterized by the presence of the conserved amino acid sequence GlyGly, GlyAla or 
GlySer/Thr, historically refereed as the “double Gly motif” (Figure 5). This motif is essential for 
the leader peptide proteolytic removal process (section 1.2.3.4, page 22). 
The importance of the leader sequence for the biosynthesis of lantibiotics has been 
largely discussed. It was demonstrated both in vivo and in vitro that an efficient 
dehydration and cyclization of the nisin and lacticin 481 propeptides requires their leader 
peptides (Kluskens et al., 2005; Li et al., 2006; Patton et al., 2008). Nevertheless, it has been 
difficult to delineate the exact factors involved in its recognition by the modifying 
enzymes, since almost all the single point mutants of the lacticin 481 leader peptide were 
still processed in vitro by the LctM enzyme (Xie et al., 2004; Oman and van der Donk, 2010). 
It has also been observed that the fully modified propeptides attached to their leader 
sequences present low or none antimicrobial activity. Thus, it is proposed that the leader 
sequences are part of a protective mechanism of the producer strain, keeping the fully 
modified propeptide inactive until it is safely outside the cell (van der Meer et al., 1994; Xie 
et al., 2004; Li et al., 2006). Another hypothesis considers that the leader peptides provide 
a signal for the transport. This is supported by the fact that some non-lantibiotic peptides 
attached to the nisin and lacticin 3147 LtnA2 leader sequences were successfully 
translocated to the producers’ supernatant (Kuipers et al., 2004; Kuipers et al., 2008).  
 
 
Propeptides and structures of mature lantibiotics 
As abovementioned, the mature lantibiotic sequence and structure results from the 
post-translational modification of the propeptide residues. Type-A propeptides normally 
possess 34 residues, whereas type-B are generally smaller (up to 19 residues) (McAuliffe et 
al., 2001b). Despite the fact that propeptides are synthesized by the ribosome, the 
composition of their mature forms is not restricted to the 20 proteinogenic amino acids as 
already confirmed by the presence of the characteristic Dha, Dhb, Lan and MeLan amino 
acids. In fact, at least more than 11 different modifications were already described (Figure 
6). For instance, the Cys residues present in the C-terminus of the propeptide can form S-
aminovinyl-D-cysteine (AviCys) or S-aminovinyl-3-methyl-D-cysteine (AviMeCys) structures. 
Also, Dha and Dhb residues that are N-terminally exposed, after the proteolysis of the 
leader sequence, can spontaneously hydrolyze to yield the 2-oxopropionyl (OPr) and the 
2-oxobutyryl (OBu) residues as observed with pep5 lantibiotic (Willey and van der Donk, 
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2007). Moreover, similarly to the non-ribosomal peptides, lantibiotics can possess D-amino 
acids, since L-Ser can be converted to D-Ala, having a Dha residue as an intermediate. This 
is a characteristic of the lacticin 3147 lantibiotic (Cotter et al., 2006b).  
 
 
Figure 6:Some posttranslational modifications described in lantibiotics. Adapted from Willey and van der Donk 
(2007). 
 
 
The structures and unique characteristics acquired by propeptides after the 
intervention of the modifying enzymes allow their clustering in at least seven groups (Figure 
7 and Table 1): i) the nisin, epidermin and pep5 groups of type-A(I), ii) the lacticin 481 
group of type-A(II), iii) the mersacidin and cinnamycin groups of type-B and iv) the lacticin 
3147 group, comprising the two-component lantibiotics (Chatterjee et al., 2005). The last 
group is characterized by the synthesis of two peptides, which are traditionally designated 
by α- and β-nomenclature after their full maturation process. Characteristically, the α-
peptides belong to the type-B lantibiotics, whereas the β-peptides resemble the type-A 
lantibiotics (Bierbaum and Sahl, 2009). The bioengineering and structure activity 
relationship (SAR) studies of some of these lantibiotics have been performed by the 
introduction of mutations in the propeptide sequence. Several in vivo and in vitro systems 
for this propose were already established for lantibiotics belonging to all of these seven 
groups (Cortes et al., 2009; Field et al., 2010).  
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Figure 7: Representative examples of lantibiotics grouped according to their structural and/or biosynthetic 
pathway. 
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1.2.3.2 Dehydratases and cyclases enzymes 
The dehydration of Ser and Thr residues in the LanA propeptide is one of the key 
reactions in the biosynthesis of lantibiotics, followed by the formation of the Lan and 
MeLan thioether rings. In Class I lantibiotics such modification is carried out by the LanB 
dehydratases and the LanC cyclases, respectively. For class II lantibiotics, the bifunctional 
enzyme LanM exhibits these two catalytic functions. In the recent years, a remarkable 
progress concerning the biochemistry of the modification reactions has been achieved, 
especially due to the in vitro reconstitution of lacticin 481 and haloduracin LanM and nisin 
LanC activities (Bierbaum and Sahl, 2009).  
 
 
Dehydratases of Class I lantibiotics 
LanB dehydratases are proteins containing approximately 1000 amino acid residues 
and possessing about 120 KDa of molecular weight, which do not reveal homology with 
any other known proteins (McAuliffe et al., 2001b; Chatterjee et al., 2005). Among the LanB 
family, the overall sequence identity is merely around 30 %. Nevertheless the homology 
increases between enzymes of structurally related lantibiotics (Chatterjee et al., 2005). The 
rather hydrophobic nature of these enzymes, associated with the presence of some 
hydrophobic domains suggested their association with the cytoplasmic membrane 
(McAuliffe et al., 2001b). This has been confirmed for the nisin and subtilin LanB proteins, 
while a loose association with the cytoplasmatic membrane was observed for the 
epidermin LanB protein (Engelke et al., 1992; Gutowski-Eckel et al., 1994; Peschel et al., 
1996). 
The first evidences that LanB proteins are involved in Ser and Thr dehydration were 
provided for the biosynthesis of pep5 and epidermin (Meyer et al., 1995). Evidence of such 
functionality was obtained by studies involving the expression and purification of His-
tagged nisin precursors in knockout mutant strains lacking the nisin dehydratase and 
cyclase, NisB and NisC, respectively. This strategy demonstrated that nisin precursors were 
totally unmodified in the absence of NisB and dehydrated but devoid of normal 
lanthionine formation when NisC was not present (Koponen et al., 2002). Regarding the 
substrate specificity of LanB proteins, it has been shown that it is rather flexible. For instance 
it was demonstrated that NisB is able to dehydrate Ser and Thr residues of non-lantibiotic 
compounds such as the human peptide hormones if they are N-terminally fused to the 
nisin leader peptide (Kluskens et al., 2005). The same study also revealed that NisB is active 
in the absence of NisC. Likewise, Kuipers and co-workers (2004) demonstrated that NisT 
presence was also not essential for the NisB activity. Additionally, it was also demonstrated 
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that the distance between the Ser and Thr residues and the nisin leader sequence should 
not influence the NisB dehydration activity (Kluskens et al., 2005). 
Information concerning the mechanistic of lantibiotic-enzyme mediated dehydration is 
not currently available for LanB proteins. Related to this aspect, the in vitro reconstitution of 
NisB, or other LanB synthetases, will be a major achievement.  
 
 
Cyclases of class I lantibiotics - LanC 
 The formation of Lan and MeLan in Class I lantibiotics has been addressed to the LanC 
cyclases. These proteins are constituted by approximately 400 residues and show no 
sequence similarity with known proteins (Nagao et al., 2006). The sequence homology 
among LanC proteins is low (20-30 %). Nonetheless, they share a number of structural 
motifs, including GXAHG, WCXG and CHG, in which the His and Cys amino acids are 
conserved (McAuliffe et al., 2001b). The hydrophobicity plots of LanC proteins revealed 
the presence of alternate hydrophobic and hydrophilic regions, suggesting also a 
membrane location for these proteins (Engelke et al., 1992; McAuliffe et al., 2001b). In fact 
this was demonstrated for NisC, whereas the epidermin cyclase EpiC could not be 
detected in membrane fractions of its producer strain (Kupke and Götz, 1996; Lubelski et 
al., 2008). 
The first experimental evidences of LanC functionality was obtained with the pep5 
biosynthetic system, where the disruption of its cyclase gene (pepC) led to the formation 
of a fully dehydrated prepropeptide (as well as some prepropeptide fragments) but 
without the correct formation of Lan and MeLan bridges (Meyer et al., 1995). Yet, this study 
also established that thioether bridges could occur spontaneously. This is explained by the 
fact that the cyclization of a nucleophilic thiolate onto an electrophilic 2,3-didehydro 
amino acid is expected to be a relatively fast and easy reaction (Chatterjee et al., 2005). 
However, the occasional occurrence of such spontaneous reactions does not substitute 
the regio- and stereochemistry of LanC activity. Regarding the directionality of processing, 
LanC cyclases incorporate the lanthionine rings solely in the N-to-C terminal, i.e., the 
cysteine involved in the cyclization is always located C-terminally of its Dha or Dhb 
reaction partner (Kaletta et al., 1991; Chatterjee et al., 2005). The in vitro reconstitution of 
NisC was presented by van der Donk and co-workers (2006). In this system, the NisC 
enzyme successfully mediated the cyclization of the previously dehydrated nisin 
prepropeptide. Moreover, after the removal of the leader sequence the in vitro produced 
peptide possessed antimicrobial activity. This study also confirmed that nisin leader 
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sequence is essential for the binding and recognition of the prepropeptide by NisC (Li et 
al., 2006).  
NisC was the first lantibiotic cyclase to be crystallized (Li et al., 2006). The analysis of its 
structure together with the previous results and mutagenesis studies on NisC and SpaC 
(subtilin LanC) enzymes allowed the recognition of some residues which are involved in the 
activation of the thiolate for nucleophilic attack as well as some residues that should 
function as catalysts of the ring formation (Okeley et al., 2003; Li et al., 2006; Helfrich et al., 
2007; Li and van der Donk, 2007). The structure of the NisC enzyme also indicated the 
presence of a possible binding site for the nisin leader sequence. This putative binding 
groove is located next to the catalytic site and is lined with a number of hydrophobic and 
negatively charged residues forming a channel in which the positively charged leader 
sequence is presumably trapped (Li et al., 2006; Lubelski et al., 2008). 
 
 
Bifunctional dehydro-cyclases of class II lantibiotics- LanM 
In Class II lantibiotics the dehydration and cyclization reactions are performed by the 
bifunctional enzymes designated LanM. These proteins possess 900 to 1000 amino acids 
and molecular weights of approximately 120 KDa. Their C-terminus contains 20-27% 
sequence identity with LanC proteins. However, no identity was found with LanB enzymes 
(Chatterjee et al., 2005; Nagao et al., 2006). Thus it was assumed that the N-terminal 
domain of LctM should be responsible for the dehydration reaction of Ser and Thr residues, 
while the C-terminal should catalyze the Lan and MeLan ring formation (You and van der 
Donk, 2007).  
The first evidences of LanM catalytic activity were obtained through the disruption of 
lanM genes in several biosynthetic clusters, including those of lacticin 481, mutacin II and 
lacticin S, which always resulted in the abolishment of the mature lantibiotic production 
(Gilmore et al., 1994; Skaugen et al., 1997; Woodruff et al., 1998; Uguen et al., 2000). Direct 
proof of such functionality was obtained with the first in vitro reconstitution of the LanM 
enzyme activity. The study was performed with the lacticin 481 LctM dehydro-cyclase, in 
which a 4-fold dehydrated peptide harboring the correct cyclization pattern and 
antimicrobial activity was obtained (Xie et al., 2004). Later, it was shown that the 
cyclization reaction occurs on a similar time scale as dehydration, since some not fully 
dehydrated intermediates also possess thioether rings within their N-terminal propeptide 
regions (Lee et al., 2009). The leader sequence is generally important for substrate 
recognition. Unexpectedly, the incubation of LctM just with the lacticin 481 propeptide 
resulted in some dehydration, suggesting that this enzyme has some basal activity in the 
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absence of the leader sequence. It was also shown that dehydration also occurs when 
the LctA propeptide is C-terminally fused with its leader peptide, albeit with much 
decreased efficiency. Also, in that situation the dehydration process was non-directional 
(Levengood et al., 2007). Recently, the dehydration of Ser and Thr residues was shown to 
be directionally performed from the N- to the C-terminus of the lacticin 481 and the 
haloduracin HalA2 prepropeptides (Lee et al., 2009). Therefore, the presence of the leader 
sequence in the propeptide N-terminal is important for the occurrence of such 
directionality. Similarly, the reactions leading to the formation of the thioether rings was 
also demonstrated to occur from the N- to the C-terminus of the HalA2 propeptide (Lee et 
al., 2009). The attempts to characterize LanM proteins through crystallography have not 
yet been successful. However, site directed mutagenesis studies of the LctM enzyme have 
shed light on important residues for the dehydration and cyclization activities of LanM 
synthetase families and a model was proposed that assigns a role to each of these 
residues (Paul et al., 2007; You and van der Donk, 2007). 
In vivo studies have shown that LanM has a high tolerance for amino acid changes in 
the propeptide region, since several processed lantibiotic variants were already obtained 
(Chatterjee et al., 2005; Alain et al., 2007). The relatively relaxed substrate specificity of 
LanM enzymes was shown to be more extensive since LctM demonstrated its ability to 
modify the propeptides of nukacin ISK-1, mutacin II and ruminococcin A lantibiotics, when 
they were N-terminally fused to the lacticin 481 leader sequence in in vitro assays (Patton 
et al., 2008). In the same way, synthetic non-lantibiotic peptides containing both 
proteinogenic and non-proteinogenic amino acids were also successfully modified by 
LctM in the same conditions (Levengood and van der Donk, 2008; Levengood et al., 2009). 
 
 
 
1.2.3.3 Other post-translational modifications 
As already mentioned, some lantibiotics possess other post-translational modifications 
besides the presence of dehydro amino acids and the thioether rings. The lantibiotics 
epidermin (class I) and mersacidin (class II) possess the unusual amino acids AviCys and 
AviMeCys, respectively, at their C-terminus (Figure 7, page 15). These amino acids are the 
product of the oxidative descarboxylation of the Cys residue at the C-terminus. It was 
shown that this reaction is catalyzed in vitro by the EpiD and MrsD enzymes for the 
epidermin and mersacidin lantibiotics, respectively (Kupke et al., 1992; Majer et al., 2002). 
The conversion of the L-Ser residues to D-Ala residues in the two lacticin 3147 peptides was 
shown to be catalyzed by LtnJ enzyme. It has been suggested that LtnJ protein should act 
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after the dehydration of the Ser residues by LtnM (Cotter et al., 2005b). All the genes 
encoding these proteins were successfully detected in the respective lantibiotic 
biosynthetic cluster. More recently, the presence of a sulfoxide group in the unique 
lantibiotic actagardine (class II) was shown to be catalyzed by the luciferase-like 
monooxygenase GarO, encoded in its biosynthetic cluster (Boakes et al., 2009). 
Several other modifications can be found in mature lantibiotics, however the enzymes 
involved in such process are still unknown. 
 
 
1.2.3.4 Proteases and transporters 
The translocation of lantibiotics across the cytoplasmatic membrane does not involve 
the use of the general secretory pathway (McAuliffe et al., 2001b) and their biological 
activity is dependent on the removal of the leader sequence. For Class I lantibiotics these 
functions are exerted by two distinct enzymes: LanP and LanT, respectively. The Class II 
lantibiotics, a single multifunctional enzyme carries out the catalysis of both reactions.  
 
 
Leader peptide processing of class I lantibiotics - LanP 
LanP are proteins with a wide variety of sizes and all of them share homology with the 
serine protease subtilisin. Their size is dependent upon the presence or absence of two 
sequences: a N-terminal sec-signal and a C-terminal cell wall anchor motif (Chatterjee et 
al., 2005). The presence of these motifs either suggests the excretion of LanP proteins to the 
extracellular environment or their functionality as membrane anchors. Both of these motifs 
are present in the nisin protease NisP. Therefore, the leader sequence of the modified nisin 
prepropeptide should be removed after its transport and in the producer cell surface. 
Indeed, it was shown that intact cells of the nisin producer L. lactis NZ9800 and intact cells 
of E. coli expressing the NisP enzyme were able to remove the leader sequence of a 
modified nisin prepropeptide. On the contrary, their cell-free supernatants or their 
membrane-free extracts did not exhibit such proteolytic activity (van der Meer et al., 
1993). However, this does not constitute the rule among class I lantibiotics. For instance, 
the proteolytic activity of the epidermin EpiP (which lacks the cell wall anchor motif) was 
detected in the supernatant of the producer strain (Geissler et al., 1996). Proteases 
belonging to other lantibiotics’ biosynthetic pathways do not harbor any of the 
abovementioned N- or C-terminus, suggesting their intracellular location. Examples include 
the ElkP, PepP and LasP encoded in the epilancin K7, pep5 and lactocin S gene clusters, 
respectively.  
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Despite the importance of the leader sequence removal for the lantibiotics bioactivity, 
the identification of a lanP gene among the lantibiotics’ gene clusters it is not always 
possible, suggesting that a variety of secreted proteases of the producer strain can also 
play this role. This is the case of subtillin, produced by B. subtilis, whose leader sequence is 
processed by proteins present in the producer supernatant, most probably by subtilisin 
(AprE), WprA or Vpr proteases (McAuliffe et al., 2001b; Corvey et al., 2003).  
The studies involving the substrate requirements of LanP enzymes suggest that the Arg-1 
residues (Figure 5 on page 12) of NisP and EpiP are essential for their proteolytic activities 
(Kuipers et al., 1993b; van der Meer et al., 1994; Siezen et al., 1995). Moreover, it was found 
that the formation of Lan and MeLan rings are essential for their activity, since dehydrated 
but linear NisA and PepA peptides were not substrates in vivo for the NisP and PepP 
proteases (Meyer et al., 1995; Kuipers et al., 2004). 
 
 
Transport of class I lantibiotics - LanT 
The LanT proteins are about 600 amino acids in length and bear significant homology to 
hemolysin B-like ATP-dependent transport proteins present in a wide variety of organisms. 
The LanT proteins are generally characterized by one hydrophobic N-terminus, a six-helix 
membrane spanning domain and a C-terminus ATP binding domain (Chatterjee et al., 
2005). However, a typical ABC-transporter should include two of each of these domains. 
Therefore, LanT is normally considered a half-transporter, which will most likely require 
another half-transporter to form an active unit. For the nisin NisT, the putative partner is 
suggested to be another molecule of NisT (Lubelski et al., 2008). 
For some lantibiotic systems, the LanT transporter encoded in the biosynthetic gene 
cluster is not essential for the lantibiotic translocation to the extracellular environment. This 
was observed for the pep5 lantibiotic where the deletion of its transporter PepT still resulted 
in the presence of the lantibiotic in the producer supernatant, despite a 10 % reduction in 
its production rate. Therefore, the PepT functionality could be partially replaced by other 
host-encoded transporters (Meyer et al., 1995). Controversially, the deletion of the nisT 
gene in the nisin producer strain led to the accumulation of nisin in the cytoplasm, while 
extracellular nisin could not be detected (Qiao and Saris, 1996).  
Regarding the substrate specificity of LanT transporters, it should be quite relaxed, since 
NisT was able to export unmodified nisin prepropeptides as well as non-lantibiotic peptides 
N-terminally fused to the nisin leader sequence (van den Berg van Saparoea et al., 2008). 
This also proved that the transport of nisin by NisT is not dependent on the presence of the 
Lan and MeLan thioether rings. Additionally, the NisT was able to secrete the fully modified 
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nisin Z propeptide N-terminally fused to the leader sequence of the subtilin lantibiotic 
produced by B. subtilis (Kuipers et al., 1993b). Consequently, either the leader sequence is 
not essential for the lantibiotic translocation or the residues involved in this process are 
conserved among nisin and subtilin leader sequences. 
 
 
Leader peptide processing and transport of class II lantibiotics - LanT 
The LanT proteins encoded in the biosynthetic clusters of Class II lantibiotics are about 
700 residues long. These are characterized by an N-terminal peptidase domain (not 
present in class I LanT proteins), an intermediary membrane spanning motif and the C-
terminus ATP-binding domain (Chatterjee et al., 2005). LanT proteins and transporters of 
class II bacteriocins (without posttranslational modifications) exhibit a degree of homology 
between them. Such transporters are able to process the N-terminal leader sequence and 
export the bacteriocins (Havarstein et al., 1995). The leader sequences of these 
bacteriocins also present significant similarity with those of class II lantibiotics such as 
lacticin 481, mutacin II and variacin, including the double Gly type cleavage site 
(Chatterjee et al., 2005). For these reasons, it was deduced that LanT proteins would 
display the same dual functions: i) proteolytic removal of the prepropeptide leader 
sequence and ii) translocation of the lantibiotic across the cytoplasmatic membrane 
(Uguen et al., 2005). By analogy, the double Gly motif (GG/GA/GS) classically present at 
the C-terminus of the leader sequences of class II lantibiotics was considered the substrate 
for the LanT N-terminal catalytic activity.   
The first studies involving LanT enzymes were performed in vivo for the mutacin II and 
lacticin 481 transporter/proteases MutT and LctT, respectively (Rince et al., 1994; Chen et 
al., 1999). It was described that in the absence of MutT, no antibacterial activity could be 
detected in the mutacin II producer supernatant (Chen et al., 1999). Identical results were 
obtained for nukacin ISK-1 producer upon the deletion of the NukT-encoding gene (Aso et 
al., 2004a). On the contrary, the inactivation of the lctT gene in the lacticin 481 producer 
was not accompanied by the abolishment of antibacterial activity. Such results suggested 
that LctT enzyme was dispensable for the lacticin 481 production (Rince et al., 1994). 
However, it was further demonstrated that the antagonistic activity was due to a smaller 
lacticin 481 derivative. Consequently, it was proved that the LctT enzyme is responsible for 
the specific cleavage of lacticin 481 leader sequence at the GG motif and that its 
functionality as transporter can be substituted by other host proteins (Uguen et al., 2005).  
The activity of the LctT N-terminal protease domain (150 amino acids) was successfully 
reconstituted in vitro by Ihnken et al. (2008). The proteolysis of lacticin 481 leader sequence 
General Introduction 
 23 
in vitro undoubtedly showed that the LanM transmembrane domain is not required for the 
substrate recognition and proteolysis. Recently, the peptidase activity of the full-length 
NukT was also demonstrated by an in vitro assay (Nishie et al., 2009). The outcome of both 
studies revealed that the LctT N-terminus protease domain and the NukT enzyme have 
distinct requirements with respect to the formation of Lan and MeLan rings prior to 
proteolysis. LctT N-terminal protease was able to remove the lacticin 381 leader sequence 
without the presence of its thioether rings, whereas NukT was not able to process the 
nukacin ISK-1 prepropeptide in the same conditions (Ihnken et al., 2008; Nishie et al., 2009).  
Some studies involving the mutagenesis of the double GG motif confirmed that it is 
essential for the in vivo proteolysis of class II leader sequences (Chen et al., 2001). This was 
also confirmed for the in vitro proteolysis activity of the LctT N-terminal (Ihnken et al., 2008). 
Also, it was shown that the modifications of the lacticin 481 propeptide after the GG 
cleave site residues did not influence the LctT peptidase activity in vitro. Though, the 
disturbance of the leader sequence helical structure seemed to affect its functionality 
(Ihnken et al., 2008).  
The flexible activity of LanT enzymes in vivo has also been described. For instance, 
several variants of class II lantibiotics such as mersacidin and lacticin 3147 were 
successfully processed and transported by their producer strains (Cooper et al., 2008; 
Appleyard et al., 2009). More surprisingly, it was possible to obtain the fully modified 
lacticin 481 lantibiotic in the host’s extracellular environment, using the co-expression of 
the lacticin 481 prepropeptide with the nukacin ISK-1 biosynthetic machinery, without any 
leader sequence fusion (Nagao et al., 2007). 
 
 
1.2.4 Regulation of biosynthesis 
Synthesis and export of lantibiotics are energetically demanding processes and 
consequently have to be closely controlled (Bierbaum and Sahl, 2009). Indeed, proteins 
that are involved in such processes are encoded in some gene clusters of class I and 
class II lantibiotics. The regulatory systems identified so far consist of two protein 
components: the receptor-histidine kinase LanK, which monitors an environmental signal, 
and the transcriptional response regulator LanR (McAuliffe et al., 2001b). It has been 
proposed that in response to an external environmental signal, the LanK protein (most 
probably present on the cell surface) initiates a signal cascade by the 
autophosphorylation of a histidine residue. During this cascade, the phosphoryl group 
should be transferred to a conserved Asp residue of LanR, that is intracellularly located, 
and which will then mediate the final adaptative response (usually a change in gene 
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expression) (McAuliffe et al., 2001b; Chatterjee et al., 2005). A general overview of this 
process is represented in Figure 8. 
 
 
 
Figure 8: General overview of the main systems involved in the regulation of lantibiotics. A represents the systems 
in which the transcription of the structural gene and immunity genes are up-regulated by the same two-system 
LanKR, triggered by the mature lantibiotic itself. This type of regulation occurs during the biosynthesis of 
lantibiotics such as nisin and subtilin. B represents those systems in which the transcription of the structural gene 
and immunity genes are not up-regulated by the same proteins. In lantibiotics such as mersacidin, the regulation 
of the structural gene is normally controlled by a LanR protein with a non-assigned histidine-kinase whereas the 
transcription of the immunity genes is controlled by a two-system LanKR, also triggered by the mature lantibiotic. 
 
 
It has been shown that the production of the lantibiotics nisin, subtilin, salivaricin, bovicin 
HJ50, ruminococcin A and mersacidin are controlled by such two-component regulation 
systems (Klein et al., 1993; Engelke et al., 1994; Altena et al., 2000; Gomez et al., 2002; 
Wescombe et al., 2006; Ni et al., 2011). For nisin, subtilin, bovicin HJ50 and salivaricin, but 
not for ruminococcin A, the lantibiotic itself acts as the sensory molecule that triggers the 
transcription of their prepropeptides and self-protection determinants (Bierbaum and Sahl, 
2009). For instance, in the case of nisin, as few as five extracellular molecules are sufficient 
to activate the transcription of nisABTCIP operon involved in its biosynthesis as well as of 
nisFEG involved in the self-immunity of the producer strain (Kuipers et al., 1995; de Ruyter et 
al., 1996). The investigation of nisin regulation mechanism also demonstrated that other 
class I lantibiotics such as subtilin and pep5 are not able to induce the NisK kinase, neither 
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the unmodified nisin, highlighting the stringent substrate specificity of NisK (Kuipers et al., 
1995). Even so, the subtilin histidine-kinase SpaK was able to phosphorylate NisR in the 
presence of subtilin (Kleerebezem, 2004). Moreover, Kuipers et al. (1995) proved that the 
transcription of a determined reporter gene fused to the nisA promoter could be induced 
in the presence of nisin and its regulatory components NisK and NisR. Such results led to the 
development of a heterologous-controlled protein expression system in L. lactis 
designated as NICE (nisin-controlled expression) (de Ruyter et al., 1996; Kuipers et al., 1997; 
Eichenbaum et al., 1998). This system has been successfully used for the overexpression of 
a variety of proteins including the notoriously difficult-to-overproduce membrane proteins 
(Lubelski et al., 2008). 
The regulation of production of the class II lantibiotic mersacidin was shown to involve 
the two-component system MrsK2/MrsR2 and the single regulatory protein MrsR1. The 
mersacidin producer Bacillus sp. HIL Y-85,54728 uses the MrsK2/MrsR2 tandem to activate 
the transcription of the immunity genes, whereas the MrsR1 protein is responsible for 
promoting the biosynthesis of the lantibiotic (Guder et al., 2002). The addition of 
mersacidin to exponentially growing cultures (before the onset of mersacidin biosynthesis) 
markedly increased the transcription of its structural gene mrsA. Therefore, alike nisin, 
mersacidin is also able to regulate its own synthesis, whereas relatively high concentration 
of this lantibiotic were required for the process (Schmitz et al., 2006). It was not clear 
whether MrsR1 needs phosphorylation to exert its activity, since a dedicated kinase was 
not identified (Guder et al., 2002). Nevertheless, the same situation have been described 
for other lantibiotics including epidermin (Peschel et al., 1993) and mutacin II (Qi et al., 
1999a).  
The systems described before involve the activation of transcription. Nevertheless, 
repressors of gene expression were also characterized for the two-component lantibiotics 
lacticin 3147 and cytolysin (McAuliffe et al., 2001a; Haas et al., 2002). In the lacticin 3147 
producer it was found that LtnR was able to bind to the promoter responsible for the 
transcription of the self-protection operon (ltnRIFE), significantly reducing its expression 
(McAuliffe et al., 2001a). Repression of the exotoxin cytolysin biosynthetic machinery by 
the CylR1 and CylR2 proteins was also described (Haas et al., 2002). Interestingly, in this 
biosynthetic system it was showed that the both cytolysin peptides were produced at 
basal levels and could associate to form an inactive complex. However, in the presence 
of their target cells, the complex dissociates and one of the peptides (CylLS) preferentially 
binds to the lipid bilayer of the eukaryotic cells, promoting the accumulation of the other 
peptide (CylLL). Subsequently CylLL peptide can trigger the cytolysin regulation 
Chapter I 
 26 
mechanism leading to the depression of synthesis via CylR2 binding to the cytolysin 
promoter region (Haas et al., 2002; Rumpel et al., 2004). 
Other systems have been identified that regulate the lantibiotics’ synthesis, which are 
not encoded in their biosynthetic clusters. Examples include the induction of lacticin 418 
production by pH decrease, via the RcfB protein (Madsen et al., 2005), whereas 
ruminococcin A production can be triggered by high cell density (Gomez et al., 2002). 
 
1.2.5 Lantibiotics’ antibacterial mode of action 
In general, class I and class II lantibiotics’ are bactericidal against a variety of Gram-
positive bacteria at nanomolar concentrations and some are active against methicillin-
resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE) and 
oxacillin-resistant Gram-positives (Willey and van der Donk, 2007). 
The type-A(I) lantibiotics such as nisin are characterized by a dual mode of action, 
targeting the cell-wall biosynthesis as well as the integrity of the cytoplasmic membrane 
(Wiedemann et al., 2001). Pore formation is a widespread property of bactericidal 
antimicrobial peptides produced by eukaryotes, such as the magainins (isolated from 
frog’s skin). Therefore, much of the initial work on the nisin mode of action involved the 
investigation of nisin aptitude in the permeabilization of bacterial membranes through the 
generation of pores (Chatterjee et al., 2005). In fact, several studies confirmed that nisin 
has such ability. However, it was noticed that the nisin MIC against intact cells was within 
the nM range, whereas much higher concentrations were required to induce pore 
formation in model membranes, suggesting that other nisin-bacteria interactions should 
contribute for the antibacterial activity of nisin. Indeed, it was shown that nisin could also 
interact in a highly specific manner with the lipid II molecule (Brötz et al., 1998; Breukink et 
al., 1999). Lipid II is a membrane-anchored molecule that is the main vehicle for transport 
of peptidoglycan subunits from the cytoplasm to the bacterial cell-wall. Thus its binding to 
nisin prevents the correct cell wall synthesis, contributing to cell death (Cotter et al., 2005a; 
Breukink and de Kruijff, 2006). Furthermore, it has been proposed that nisin exerts its 
biological activity using lipid II as a docking molecule for pore formation (Bierbaum and 
Sahl, 2009). In this process, the two N-terminally located thioether rings should form a 
binding pocket (referred as the pyrophosphate cage) that envelops the undecaprenyl 
pyrophosphate moieties of the lipid intermediates of cell wall biosynthesis (Hasper et al., 
2004; Hsu et al., 2004). After binding, the highly positively charged C-terminus of nisin 
should interact with the anionic membrane surface and should be able to insert into the 
membrane, oligomerize and form a pore (Figure 9) (Breukink et al., 2003; Hsu et al., 2004; 
Bierbaum and Sahl, 2009). However, in other type-A(I) lantibiotics such as epidermin, 
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mutacin 1140 and gallidermin, which are shorter than nisin, the ability to induce a pore in 
the cytoplasmic membrane is believed to depend on the thickness of the bacterial wall, 
which should not exceed more than 40 Å (Bonelli et al., 2006; Smith et al., 2008). Therefore, 
for the type-A(II) lantibiotics it is believed that they can act by complexing with lipid II 
optionally followed by pore membrane formation (Bierbaum and Sahl, 2009). 
The type-B lantibiotic mersacidin and actagardine are also able to interact with lipid II, 
inhibiting peptidoglycan synthesis (Brotz et al., 1997; Brotz et al., 1998), though they do not 
induce membrane pore formation. Besides, it has also been shown that, contrary to nisin, 
mersacidin can discriminate lipid I from lipid II, indicating that GlcNAc, the only difference 
between those molecules, contains part of the mersacidin recognition motif (Brotz et al., 
1998; Hsu et al., 2003). The mersacidin Glu residue present in its C-terminal was shown to 
play an essential role in its antibacterial activity (Figure 7, page 15). The substitution of this 
residue by an Ala resulted in good yields of the mutated peptide, which showed markedly 
reduced activity (Szekat et al., 2003). Therefore, it was speculated that this residue (also 
present in actagardine) might form the binding site with its target lipid II molecule 
(Zimmermann and Jung, 1997; Brotz et al., 1998).  
 
 
Figure 9: Schematic representation of the dual mode of action of type-A(I) lantibiotics e.g. nisin. The mechanism 
involves the binding of the lantibiotic to lipid II, preventing the correct cell wall synthesis. Furthermore, lipid II can 
be used as a docking molecule to initiate a process of membrane insertion and pore formation that leads to 
rapid cell death. Adapted from Cotter et al. (2005a). 
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The α-peptides of two-component lantibiotics are homologous to mersacidin, also 
possessing the Glu residue important for mersacidin activity in the C-terminally located 
TxS/TxEC conserved motif. The β-peptides seem to be more closely related to type-A 
lantibiotics. It was shown that the lacticin 3147 peptides, Ltnα and Ltnβ, could act 
synergistically and sequentially at a 1:1 molecular ratio (Morgan et al., 2005). However, 
individually, the peptides do not show a high antagonistic effect. Further studies supported 
the model proposed by Wiedemann et al. (2006) for lacticin 3147 activity, which should 
involve three steps: first, the Ltnα peptide should bind to lipid II; this binding will induce or 
stabilize the conformation of Ltnα peptide that would facilitate the interaction with Ltnβ 
peptide and enable the formation of a complex involving both peptides and the lipid II 
molecule. After binding to the Ltnα:lipid II complex, the Ltnβ peptide will be able to adopt 
a transmembrane conformation, which would allow the formation of a pore in the 
membrane, leading to cell death (Wiedemann et al., 2006). Therefore, lacticin 3147 
antibacterial mode of action is likely to be equivalent to that of mersacidin, in lipid II 
binding and nisin, in the membrane pore formation. Despite some structural differences 
between the haloduracin and lacticin 3147 components, it is believed that they share the 
same mechanism of action (Oman and van der Donk, 2009b).  
 
 
1.2.6 Self-protection of the producing strains 
The biosynthetic gene clusters of lantibiotics often possess other ORFs apart from those 
already discussed, which have been associated to a self-protection mechanism of the 
producer strain against the harmful effects of its own product. The diverse self-protection 
systems described consist of: i) individual immunity proteins, generically termed as LanI; ii) 
an ABC transporter, usually comprising two or three subunits and termed LanFE(G) and iii) 
an accessory factor LanH, which most likely acts as an ancillary protein for the assembly of 
a functioning ABC transporter (Figure 10) (Draper et al., 2008). The lanH gene is not present 
in the majority of the lantibiotic gene clusters known so far, contrary to lanI and lanFE(G) 
ORFs (Figure 3, page 9). 
Regarding the LanI elements, a very low sequence similarity is found among these 
proteins. However, they are generally hydrophilic lipoproteins harboring a hydrophobic N-
terminal domain, which can be involved in its anchoring to the cell membrane (Willey and 
van der Donk, 2007). The contribution of LanI protein for nisin self-protection was 
demonstrated when a nisin-sensitive strain was complemented with the plasmid encoding 
the NisI protein (together with NisABCT) and acquired very close immunity levels to those 
exhibited by the wild-type (Kuipers et al., 1993a). Moreover it was shown that NisI was 
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shown to exist in two forms: a lipid-free protein present in the bacterial supernatant and a 
membrane associated lipoprotein. Both of these forms had the capability to interact by 
binding with nisin molecules. In possession of these evidences, it was proposed that NisI 
could aggregate with the lantibiotic, preventing pore formation and therefore protecting 
the bacterial cell (Figure 10) (Qiao et al., 1995; Koponen et al., 2004; Draper et al., 2008). 
This contribution has also been proposed for the SpaI, PepI and CylI proteins in the self-
protection mechanisms of subtilin, pep5 lantibiotic and the two-component lantibiotic 
cytolysin, respectively (Coburn et al., 1999; Hoffmann et al., 2004; Stein et al., 2005). 
Nevertheless, and contrary to several other lantibiotics, PepI and CylI were the only 
determinants associated with the self-protection mechanisms of their producing strains.  
 
 
 
 
 
 
 
 
 
Figure 10: Structural organization of 
LanFEG and LanI peptides within the 
membrane of the lantibiotic producer. 
Two LanF peptides should combine 
either with two LanE peptides or, as 
represented above, with one LanE 
and a LanG peptide to form a 
functional ABC transporter. LanF 
functions as an ATPase, while LanE(G) 
forms the membrane spanning 
domain of the transporter (A). The LanI 
peptide can be found attached to 
the membrane via a lipid moiety or 
free in the supernatant as observed 
with NisI (B). Adapted from Draper et 
al. (2008). 
 
 
Additionally or cooperatively to LanI, lantibiotic self-protection mechanism often imply 
the action of LanF, LanE and/or LanG. These proteins are individual domains of an ABC 
transporter (not related with the previously described LanT transporters). Therefore, the 
functionality of this ABC transporter is dependent on the combination of the LanF ATPase 
subunit with the two integral membrane peptides LanE and/or LanG (McAuliffe et al., 
2001b). Considering the nisin system, the disruption of each of the genes encoding LanFEG 
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proteins had no effect in the biosynthesis of the lantibiotic. However, these mutants 
showed an increased sensitivity when incubated with nisin, demonstrating the implication 
of these proteins in the L. lactis self-protection mechanism (Siegers and Entian, 1995). Thus, 
it has been suggested that NisFEG functions by excreting the nisin molecules that, once in 
the extracellular environment, were able to reenter to the producer cell (Stein et al., 2003; 
Draper et al., 2008). Either by cooperative or additive effect (still under debate), the 
NisFEG system, together with NisI is essential to achieve the full nisin-immunity phenotype of 
the producer strain (Ra et al., 1999; Stein et al., 2003; Takala et al., 2004; Takala and Saris, 
2006). The subtilin, epidermin and nukacin ISK-1 self-protection mechanism also resembles 
that of nisin regarding the ABC transporter functionality (Peschel and Gotz, 1996; Aso et al., 
2004b; Stein et al., 2005). Even so, contrary to subtilin, in the epidermin and nukacin ISK-1 
systems a candidate for the LanI protein could not be identified. However, another 
peptide also associated with epidermin and nukacin ISK-1 immunity was recognized, 
which is commonly designated by LanH. These molecules have been characterized as 
accessory factors acting as ancillary peptides for the assembly of the functional immunity 
ABC transporter LanFE(G) (Draper et al., 2008). The studies involving LanH proteins are 
limited, however it was found that the NukH protein is able to interact with the nukacin ISK-
1 lantibiotic, however no correlation between the immunity level and the NukH binding 
activity to the lantibiotic was found (Okuda et al., 2005). 
The mersacidin self-protection mechanism consists only of the MrsFEG ABC transporter 
system, which functionality should resemble that of the nisin transporter NisFEG. Moreover, 
it has been proposed that because mersacidin is incapable of pore formation, a 
sophisticated immunity mechanism is not required (Draper et al., 2008).  
The immunity peptides of two-component lantibiotics are interesting since it is not 
apparent whether they protect the cell against one particular peptide or both (Draper et 
al., 2008). The immunity determinants encoded in the biosynthetic cluster of the two-
component lantibiotic lacticin 3147 include the LctI and LctFE proteins, and both systems 
greatly contribute to the producer strain self-protection (Draper et al., 2009). It was 
demonstrated that LtnFE has a higher ability to protect the cells against lacticin 3147 (Ltnα 
and Ltnβ together) than LtnI. However, LtnI exceeded LtnFE in its ability to protect the cell 
from the action of Ltnβ and they provided an equal level of protection to Ltnα (Draper et 
al., 2009). In these systems where the LanG peptide is absent it is believed that the 
assembly of the active ABC transporter involves two LtnE and two LanF molecules. 
Despite the similarly of structures among several lantibiotics, cross-immunity between 
lantibiotic producers is a rare event. Nevertheless, it was shown that PepI provided 
immunity to epicidin 280 (Heidrich et al., 1998); NukH could interact with lacticin 481 
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(Heidrich et al., 1998; 2005) and producers of the two-component lantibiotic 
staphylococcin C55 were shown to be cross-immune to lacticin 3147 (Draper et al., 2008). 
 
 
1.3 Nonribosomal antibiotics – a general overview 
Some bacteria also produce the so-called conventional/traditional peptide antibiotics, 
which are not considered bacteriocins. An important criterion for such distinction relies on 
their distinct biosynthetic pathway, since the first are produced by multi-enzyme 
complexes (Nes et al., 2007). These peptide antibiotics are synthesized via a template-
directed, nucleic acid-independent ribosomal mechanism (Figure 11) (Caboche et al., 
2008; Felnagle et al., 2008), which uses large multifunctional enzymes, referred as 
nonribosomal peptide synthetases (NRPSs) (Cane et al., 1998). Although not recognized at 
the time, Alexander Fleming’s discovery of penicillin in the late1920s introduced the world 
to the NRPS era, once the first step of penicillin biosynthesis involves the ACV-tripeptide 
production by a NRPS pathway (Smith et al., 1990; Felnagle et al., 2008). 
 
 
 
Figure 11: Schematic representation of the ribosomal and nonribosomal biosynthetic pathways involved in the 
production of bacteriocins and traditional antibiotics, respectively. 
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NRPS enzymes are organized in modules that are responsible for the catalysis of 
polypeptide chain elongation and possible associated functional group modifications. 
Each module can be dissected into different enzymatic units, which perform the 
necessary steps leading to the production of the final peptide (Figure 11). Therefore, at 
least three different domains can be identified in each NRPS module: i) the adenylation 
(A) domain, which selects the cognate amino acid and activates it as an amino acyl 
adenylate, ii) the peptidyl carrier protein (PCP) domain, which accepts the activated 
amino acid and transports it through the NRPS catalytic centers iii) the condensation (C) 
domain that catalyzes the formation of the peptide bond (Figure 12) (Finking and 
Marahiel, 2004). Moreover, each module can also accommodate additional domains 
generally responsible for some of the unique characteristics of nonribosomal peptides. 
Finally, the synthesis is terminated by the thioesterase (TE) domain, which is incorporated in 
the last NRPS module (Finking and Marahiel, 2004). All of these domains can be identified 
at the protein level by characteristic, highly conserved sequence motifs normally 
designated as core-motifs (Schwarzer et al., 2003). The nonribosomally-produced peptides 
can undergo futher modifications such as glycosylation, which are introduced by 
associated enzymes. These enzymes are typically encoded in the same biosynthetic gene 
cluster of the NRPS enzyme and include glycosyl transferases, halogenases and 
hydroxylases (Walsh, 2004). 
 
 
 
Figure 12: Schematic representation of the modular organization of a NRPS. Each module is responsible for the 
addition of an amino acid to the peptide chain. Thus, each domain exerts a specific activity (e.g. amino acid 
recognition and activation, transport among the catalytic centers and peptide bond formation) in the 
functionality of each module. The Te domain is only present in the termination module and is responsible for the 
release of the final peptide from the NRPS. 
 
 
The A domain is probably the most important domain from each module, since it is 
responsible for the amino acid composition of the final peptide. Therefore, these have 
been classical candidates for the NRPS bioengineering prospects (von Dohren et al., 
1999). Based on the crystal structure of the phenylalanine activating A domain of the 
gramicidin NRPS (GrsA), Conti et al. (1997) the 10 residue positions that are crucial for its 
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substrate recognition were identified (Rausch et al., 2005). The comparison of these 
residues with those of other A domains of already characterized peptides allowed the 
establishment of an association between these 10 residues and the specificity of the 
amino acid activated. This constituted the so-called nonribosomal code, where the 
residues of the substrate binding pocket constitute the codons of the nonribosomal 
synthesis (Schwarzer et al., 2003). The nonribosomal code was firstly established by 
Stachelhaus et al. (1999) and by Challis et al. (2000) and it has been constantly enlarged 
and updated since then. The specificity-conferring amino acids can be extracted from 
the primary sequence of the A domains between the two core-motifs (A4 and A5) 
(Stachelhaus et al., 1999; Challis et al., 2000). With the application of this nonribosomal 
code, the substrate specificity has been predicted with fairly high accuracy (Figure 13) 
(Schwarzer et al., 2003). 
 
 
 
 
 
Figure 13: Representation of the binding pockets extraction methodology involved in the prediction of A domain 
specificity according to Stachelhaus et al. (1999). The reference sequence for the amino acid alignment should 
be the Phe-activating domain of the gramicidin GrsA NRPS. The sequence deduced from the amino acids 
located in the defined positions, constitutes the so-called nonribosomal code. 
 
 
In bacterial systems, genes coding for NRPSs enzymes are usually organized in operons 
that can span regions of 6-45 Kb. A good example of that is the gene cluster of bacitracin 
A NRPSs. This enzyme is encoded in an operon of 42.1 Kb and synthesizes this well-known 
12 amino acid antibiotic (Figure 14)(Konz et al., 1997).  
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Figure 14: Schematic representation of the operon involved in bacitracin A production by the Bac NRPS. A total 
of twelve modules distributed between three NRPSs (BacA, BacB and BacC) are involved in the process of 
peptide chain elongation along the protein template. Adapted from Schwarzer et al. (2003). 
 
 
Thus, NRPSs are used simultaneously as template (because the amino acid to be 
incorporated is determined by the module) and biosynthetic machinery (it is the module 
that harbors all the necessary catalytic functions) (Cane et al., 1998; Finking and Marahiel, 
2004). The modular organization of NRPSs offers the possibility of artificial alterations of the 
protein template, reprogramming it for the synthesis of novel peptides. Using this 
approach, several modifications of these enzymes have been made, including i) 
replacing domains with different specificity, ii) deleting or inserting domains and iii) 
deleting or inserting entire modules, where the expected peptide has often been 
obtained (Menzella and Reeves, 2007). Nevertheless, combinatorial biosynthesis is still in 
development, but it is hoped that it could lead to the development of new bioactive 
compounds (Menzella and Reeves, 2007). 
Research in the natural products field, including peptide antibiotics has significantly 
declined during the last decade(s). However, it is still believed that unknown NRPSs can 
constitute one of the most promising sources of new classes of bioactive compounds 
(Singh and Pelaez, 2008). Two main efforts have been undertaken in order to identify some 
of these compounds: i) introduction of metagenomic techniques, that can reveal new 
NRPS gene clusters directly from culturable and unculturable microorganisms in the natural 
environments (Li and Qin, 2005) and the ii) screening for cultivable organisms from extreme 
or unusual habitats (marine, sediments, deep sea, etc.), since it is expected that these 
microbial communities will have unique adaptations to their habitats, which might be 
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linked, in some cases, with the synthesis of unusual antibacterial compounds (Pathom-aree 
et al., 2006; Zhao et al., 2008). Some studies in these fields have already proven their utility 
for such purposes (Courtois et al., 2003; Moffitt and Neilan, 2003; Schirmer et al., 2005; Zhao 
et al., 2008). 
The conventional peptide antibiotics tend to have a broader range of activity, when 
compared with the bacteriocins, which are generally active against Gram-positive but not 
Gram-negative bacteria (Nes et al., 2007; Sang and Blecha, 2008). The mechanism of 
action behind the antibacterial activity of the traditional peptide antibiotics highly 
depends on the compound family. The glycopeptides antibiotics such as vancomycin 
inhibit the transglycosylation (chain elongation) and transpeptidation (cross-linking) steps 
in the cell-wall assembly, through their binding to the C-terminal D-Ala–D-Ala peptide motif 
of the UDP-muramyl pentapeptide that is a precursor of the bacterial cell wall biosynthesis 
(UDP=uridine diphosphate) (Süssmuth, 2002). Another nonribosomal peptide antibiotic that 
interfere with the bacterial cell wall biosynthesis is bacitracin. Bacitracin prevents the 
dephosphorylation of undecaprenyl pyrophosphate (UPP) into undecaprenyl phosphate 
(UP) (Stone and Strominger, 1971), preventing the translocation of peptidoglycan 
precursors to the external side of the membrane (Bernard et al., 2005). The anti-Gram-
negative polymyxin B and colistin (polymyxin E) are pentacationic cyclic 
lipodecapeptides, which permeabilize the Gram-negative outer membrane and disrupt 
the cytoplasmic membrane. However, due to these characteristics they also tend to be 
cytotoxic, which has limited their application in clinical practice (Hancock and Chapple, 
1999; Vaara, 2010). Other antibiotic peptides of nonribosomal origin, the streptogramins, 
act at the level of inhibition of translation through binding to the bacterial ribosome 
(Johnston et al., 2002). 
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1.4 Objectives of this thesis 
The work developed in this thesis falls within the scope of the search and 
characterization of novel antimicrobial compounds. In this context a Bacillus licheniformis 
strain (I89) was isolated and identified as a producer of antibacterial compounds. One of 
those compounds was partially characterized. In the present thesis further studies were 
performed in order to clarify the following aspects:  
- Identify the diversity of antibacterial compounds produced by B. licheniformis I89.  
- Obtain insights on the structure of some of these antibacterial compounds. 
- Characterize, whenever possible, the biosynthetic clusters involved in their production. 
- Understand the biosynthetic pathways involved in the production of some of the 
major antibacterial compounds. 
Moreover, the diversity of potential novel nonribosomal synthetases (which produce a 
wide variety of antimicrobial peptides) was investigated through culture-independent 
techniques in some Portuguese lagoons and caves environments. 
The strategies employed and the main results obtained during the development of this 
study are described in the following chapters: 
 
Chapter II: the growth and antibacterial activity of B. licheniformis I89 were 
investigated. Also, the antibacterial compounds present on its supernatant were 
separated and their molecular masses determined. 
Chapter III: the morphological variants of B. licheniformis I89 were characterized and 
related with the production of the antibacterial lantibiotic lichenicidin. 
Chapter IV: the production of lichenicidin lantibiotic by E. coli is described. Using a 
heterologous expression system, the function of the ORFs involved in the lichenicidin 
biosynthetic pathway was exploited through the generation of several knockout mutants. 
Moreover, the structure-activity relationship studies were performed for each of the 
lichenicidin peptides. 
Chapter V: the involvement of lichenicidin putative immunity determinants in the self-
protection of the E. coli lichenicidin producer as well as in the rate of production was 
investigated.  
Chapter VI: the ability of the lichenicidin machinery to participate in the production of 
other lantibiotics in E. coli was investigated. 
Chapter VII: the screening of adenylation domains from water and soil samples 
collected from Portuguese lagoons and caves that can potentially be involved in the 
production of nonribosomal peptides was performed by culture-independent methods. 
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2.1 Introduction 
 
 
 
 
acillus licheniformis is a Gram-positive endospore forming and facultative 
anaerobe bacteria which belongs to the B. subtilis group (group II) of the genus 
Bacillus (Veith et al., 2004). It is widely distributed as a saprophytic organism in 
the environment (Rey et al., 2004). B. licheniformis strains produce several compounds with 
important commercial and agricultural applications. Thus, this specie is widely used in the 
fermentation industry of amylases, proteases and antibiotics (Rey et al., 2004).  
Regarding the nonribosomal antibacterials produced by B. licheniformis, bacitracin was 
the first compound of this class to be purified from this specie. At that time, it was found 
that bacitracin exhibited in vitro activity against Gram-positive organisms and a few Gram-
negative (gonococci and meningococci). It was also active in vivo against experimentally 
produced hemolytic streptococcal infections in mice and gas gangrene infections in 
guinea pigs (Johnson et al., 1945). Nowadays, bacitracin is widely used for medical 
(topical applications) and veterinary purposes (He et al., 2006). However, the production 
of bacitracin is dependent on the bacterial strain. In fact, the presence of the 
nonribosomal peptide synthetase (NRPS) responsible for the bacitracin production has 
been defined as a criterion to distinguish between different sub-groups of B. licheniformis 
strains (Manachini et al., 1998; Ishihara et al., 2002). Another well-known group of 
nonribosomally-synthesized lipopeptides produced by B. licheniformis strains and also 
exhibiting antibacterial activity are the lichenysins (Yakimov et al., 1995). Lichenysin A is the 
best characterized of these compounds. Due to its toxicity, lichenysins are not 
commercialized as antibacterial compound (Mikkola et al., 2000). However, these 
peptides represent one of the most powerful biosurfactants known so far.  Therefore, an 
increased interest has been directed to such compounds, since surfactants are of major 
interest for a variety of applications, particularly the microbial enhanced oil recovery 
B 
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(Yakimov et al., 1998). 
 
Table 2: List of antagonistic compounds produced by B. licheniformis strains, with reference to their temperature 
of production and molecular masses, when determined. a) Antibacterial compound produced anaerobically. 
b) Antibacterial compound heterologously expressed in E. coli. The molecular masses measured by MS analysis 
were represented with *. ND stands for information not available. 
Strain Source 
Temperature 
of production 
Antibacterial 
compound(s) 
Molecular 
weight (Da) References 
A12-C ND (Gálvez et al., 1993a) 
A12 Natural cave  28 ºC A12-A and 
A12-B 
1430 (Gálvez et al., 1993b) 
26L-10/3RA Buffalo rumen 39 ºC Lichenina) 1400 (Pattnaik et al., 2001) 
490/5 Dairy food 55 ºC Bacillocin 490 2000 (Martirani et al., 2002) 
P40 
Intestinal contents 
of Leporinus sp. 
26 ºC – 37 ºC Bacillocin P40 ND 
(Cladera-Olivera et 
al., 2004b; Cladera-
Olivera et al., 2004a) 
A89 Hot spring 50 ºC A89 3249.7* (Mendo et al., 2004) 
ZJU12 Soil 30 ºC ZJU12 3000 (He et al., 2006) 
SAFN031 Seaweed 28 ºC YbdN protein 30700 (Jamal et al., 2006) 
AnBa9 
Slaughterhouse 
sewage waste 
sediments 
37 ºC BhlAb) 8200* 
(Thangamani et al., 
2009) 
MKU3 Slaughterhouse 
sediments 
30 ºC MKU3 <10000 (Kayalvizhi and Gunasekaran, 2010) 
 
 
In the last twenty-years, B. licheniformis strains have also been described as producers 
of antagonistic compounds, other than those nonribosomally-synthesized (Table 2). Those 
compounds were identified as secondary metabolites of B. licheniformis strains isolated 
from several distinct environments including natural caves, dairy food, fish intestines and 
buffalo rumen (Gálvez et al., 1993a; Pattnaik et al., 2001; Martirani et al., 2002; Cladera-
Olivera et al., 2004b). The majority of these substances are produced aerobically in a wide 
variety of temperatures ranging from 26 ºC to 55 ºC. Despite that, lichenin peptide was 
found to be synthesized exclusively in the absence of oxygen (Pattnaik et al., 2001). The 
characterization of these compounds was especially focused on their chemical stability 
together with their antibacterial spectrum of activity (Table 3). Some of these studies were 
performed with extracts containing an unknown mixture of substances, rather than purified 
compounds. Regarding the spectrum of antibacterial activity, it was normally associated 
with Gram-positive bacteria, including clinically relevant specimens such as methicillin-
resistant S. aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). Still, the 
compounds produced by some strains like B. licheniformis P40 and ZJU12 were also able to 
inhibit the growth of Gram-negative isolates including Aeromonas sp., Enterobacter 
aerogenes, Erwinia carotorovora, Pasteurella haemolytica and Xanthomonas oryzae 
(Cladera-Olivera et al., 2004b; Cladera-Olivera et al., 2004a; He et al., 2006).  
Antibacterial compounds produced by B. licheniformis I89 
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Other targets of the compounds produced by B. licheniformis ZJU12 strain include the 
plant associated fungi (He et al., 2006). Also, the peptides A12A and A12B isolated from 
B. licheniformis A12 strain revealed anti-amoebicidal activity (Gálvez et al., 1993b). 
Concerning the chemical stability of these compounds, it has been described that 
bioactivity can be affected by several proteases, although is highly dependent on the 
producer strain or on the compound. 
B. licheniformis I89, object of the present study, was isolated from an hot spring 
environment in São Miguel, Azores, Portugal (Mendo et al., 2000). Cell-free supernatants of 
this strain, after fermentations at 50 ºC, were able to inhibit the growth of Gram-positive 
bacteria such as B. subtilis, M. luteus and S. aureus but not the Gram-negative E. coli and 
Pseudomonas spp. Also, activity against yeasts like Saccharomyces cerevisiae and 
Candida albicans was not detected. A peptide antibiotic referred as A89 and 
characterized by the molecular mass of 3249.7 Da was initially isolated from the strain’s 
supernatant (Mendo et al., 2004). Regarding the stability of A89 to proteases, it was found 
that the aspartic proteases cardosin A and B and the serine proteases trypsin and α-
chymotrypsin had no influence on its bioactivity. Additionally It was also shown that its 
bioactivity was extremely stable to a wide range of pH conditions (3.5 and 8) (Mendo et 
al., 2004).  
One of the objectives of this dissertation was to investigate if the antagonistic activity 
exhibited by B. licheniformis I89 strain was exclusively due to the production of the A89 
peptide or also to other compounds. Additionally, determination of A89 amino acid 
content was also one of the aims of the present study. For this purpose, pure A89 peptide 
was required. The characterization and comparison of the B. licheniformis I89 antagonistic 
activity produced at two distinct temperatures (37 ºC and 50 ºC). The results obtained are 
presented in this chapter. Moreover, a protocol for the separation of antibacterial 
compounds from the I89 cell-free supernatants was also developed. 
 
 
2.2 Results 
2.2.1 Growth and antibacterial activity of B. licheniformis I89 
Previously, it was established that B. licheniformis I89 strain produces an antibacterial 
compound, designated by A89, when it is grown in medium M at 50 ºC. However, the 
same study demonstrated that if A89 peptide was incubated at 50 ºC prior to bioassay, a 
decrease of 10 % in its activity was verified when compared with the pre-incubation at 
37 ºC, suggesting that at this temperature A89 stability and/or activity is retained (Mendo 
et al., 2004). In the present study, it was observed that B. licheniformis I89 colonies were 
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able to inhibit M. luteus growth when incubated together for at least 16 hours, on tryptic 
soy agar (TSA) plates at 37 ºC. Therefore, considering the results obtained, it was decided 
to characterize the growth, sporulation and antibacterial activity of B. licheniformis I89 also 
at 37 ºC and compare them with the previously tested temperature of 50 ºC (Figure 15 
and Figure 16). 
The bacterial growth was evaluated every four hours using two distinct indirect 
methodologies: i) measurement of the optical density and ii) viable cells counts on agar 
plates (Figure 15A/B). Analysis of the obtained curves showed that the growth of I89 strain 
could be characterized by a lag phase of approximately four hours, followed by an 
exponential phase of around eight hours at both the conditions tested. The calculated 
generation time during this period was approximately 115 and 125 minutes at 37 ºC and 
50 ºC, respectively. The stationary phase plateau was reached after approximately twenty 
hours of incubation. Overall, the growth kinetics of B. licheniformis I89 was similar at both 
temperatures. Nevertheless, the bacterial density and consequently the number of viable 
cells were generally higher at 37 ºC than at 50 ºC.  
 
 
 
 
Figure 15: Growth parameters measured in batch cultures along the B. licheniformis I89 growth in medium M 
batch cultures, incubated at 37 ºC (black circles) or 50 ºC (white circles). Parameters analyzed included the 
optical density (A), determination of viable cells (B), production of spores (C) and variation of the supernatant pH 
(D). 
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Members of Bacillus spp. are characterized by the production of endospores that can 
remain dormant for extended periods of time. Therefore, in the present study the 
sporulation activity of I89 strain over time at both 37 ºC and 50 ºC was investigated (Figure 
15C). The elimination of vegetative cells was performed by treatment at high temperature 
(80 ºC) for 20 minutes. If present, the spores could survive to such conditions and allowed 
to germinate on fresh agar plates incubated at 37 ºC or 50 ºC. It was observed that I89 
strain sporulation process initiated during the late exponential phase of growth at both of 
the temperatures tested. Along the stationary phase, the number of spores present in the 
cultures increased, reaching its plateau after 40 hours. Thus, differences on the sporulation 
rate between incubations at 37 ºC and 50 ºC were not perceptible.  
Regarding the variation of the pH supernatant along the bacterial growth, it was found 
that pH values ranged from the initial pH 6.5 up to approximately pH 8.0 after 44 hours of 
growth in an almost perfect linear progression (Figure 15D). Moreover, this behavior was 
similar in both incubation temperatures. 
 
 
 
Figure 16: Antibacterial activity of B. licheniformis I89 cell-free supernatants (A) and cell wall washes (B) fractions 
when cultured at 37 ºC (black circles) and 50 ºC (white circles). 
 
 
As previously referred, the antibacterial activity of B. licheniformis I89 was first 
investigated on its fermentation supernatants. Herein, we also evaluated the bioactivity of 
the compounds that remained associated with the bacterial cell wall through the analysis 
of cell wall associated fractions (Figure 16). It was showed that bioactivity seemed to be 
synchronized with the stationary phase at both temperatures either in the supernatants or 
the cell wall fractions. However, the inhibition zone diameters resulting from the 
fermentations at 37 ºC were generally larger (> 2 mm) than those at 50 ºC. Moreover, after 
32 hours of incubation, the fractions removed from the cultures grown at 50 ºC completely 
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lost their ability to inhibit M. luteus growth. That was not observed when the cultures were 
grown at 37 ºC regardless of some decrease in the activity observed after 20 hours of 
incubation. The A89 antibacterial peptide was previously isolated from cell-free 
supernatants cultures of B. licheniformis I89 grown at 50 ºC (Mendo et al., 2004). In the 
present study it was observed that cell-free supernatant of cultures grown at 37 ºC also 
have the ability to inhibit the growth of M. luteus. Thus, this fraction was submitted to LC-
ESI-MS analysis to confirm if the A89 peptide was also produced at this temperature. The 
characteristic molecular mass of A89 peptide (M= 3250 Da) was successfully identified, 
proving that this peptide is also contributing for the bioactivity of the cultures grown at 
37 ºC. 
 
 
2.2.2 Spectrum of antibacterial activity of B. licheniformis I89 supernatants 
The antibacterial activity of B. licheniformis I89 supernatants against M. luteus, S. aureus 
and B. subtilis was previously reported by Mendo et al. (2004). Here, the antagonistic 
activity of B. licheniformis I89 supernatants resulting from cultures grown at 37 ºC was 
tested against other Gram-positive and Gram-negative bacteria, including some clinical 
isolates (Table 4). The results showed that Listeria monocytogenes, Enterococcus faecium, 
Enterococcus faecalis and Haemophilus influenzae are also susceptible to the 
antibacterial produced by the I89 strain at 37 ºC. Interestingly and considering the 
S. aureus isolates it was observed that the inhibition diameters obtained for the MRSA 
isolate was comparable to those observed for the two methicillin-sensitive strains. 
 
Table 4: Susceptibility of Gram-positive and Gram-negative isolates to supernatant extracts of B. licheniformis I89 
fermentations. Susceptibility values are presented as a ratio between the diameter of the tested strain and the 
more susceptible strain M. luteus ATCC 9341. MRSA stands for methicillin-resistant Staphylococcus aureus, 
whereas MSSA stands for methicillin-sensitive Staphylococcus aureus. 
Strains Susceptibility 
(%) 
Observations 
Gram-positive   
Enterococcus faecalis ATCC 29212 45  
Enterococcus faecium 547261 58 Clinical isolate 
Haemophilus influenzae 121642 68 Clinical isolate 
Listeria monocytogenes  71  
Micrococcus luteus ATCC 9341 100  
Staphylococcus aureus ATCC 29213  52 MSSA 
Staphylococcus aureus 547263 55 Clinical isolate; MRSA 
Staphylococcus aureus 137109 55 Clinical isolate; MSSA 
   
Gram-negative   
Escherichia coli ATCC 35218 0  
Klebsiella pneumoniae 100603 0 Clinical isolate 
Pseudomonas aeruginosa In99 0 Clinical isolate 
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2.2.3 Separation of antibacterial compounds produced by B. licheniformis I89 
In order to understand if other compounds in addition to the A89 peptide could be 
contributing for B. licheniformis I89 bioactivity, the n-butanol supernatants extracts 
(referred as supernatant extracts) resulting from fermentations at 37 ºC were separated 
through diverse analytical procedures and systematically tested for their antibacterial 
activity. The protocols used included solid phase extraction (SPE) and preparative high-
pressure liquid chromatography (prepHPLC). 
 
2.2.3.1 Solid phase extraction of crude extracts 
The first step of this analysis involved the SPE of supernatant extracts. Briefly, after an 
incubation period of 16-18 hours the culture cell-free supernatants were extracted with n-
butanol as previously described by Mendo et al. (2004). After the evaporation of the 
organic solvent, the extracts were dissolved and applied to a pre-equilibrated C8 SPE 
column. The compounds bound to the carbon matrix were sequentially washed with 
solvents of different polarities. In order to identify with which solvent the antibacterial 
compounds were eluted, each of the fractions was bioassayed against M. luteus. 
Inhibition zones were exclusively observed in those fractions resulting from the column 
wash with 90 % and 70 % of ACN:water solutions. LC-ESI-MS analysis of these fractions 
revealed the presence of two major compounds possessing slightly different retention 
times and molecular masses of 3020 Da and 3250 Da. Thus, the A89 peptide (M= 3250 Da) 
was present in these fractions and the 3020 Da peptide was designated as B89. Since the 
antibacterial activity was confined to these two fractions, several SPE procedures were 
performed and the collected 90 % and 70 % ACN:water washes were pooled together 
and concentrated. The components of this SPE-treated extract were further separated by 
prepHPLC. 
 
2.2.3.2 prepHPLC of SPE-treated supernatant extracts 
The first prepHPLC separation consisted of a 20 min gradient, where all the eluted 
fractions were collected, concentrated and bioassayed. The results showed that the 
compounds possessing antibacterial activity were eluted from the column along seven 
minutes, starting at approximately Rt= 7 min after the beginning of the prepHPLC run 
(Figure 17). The profile of the inhibition zones measured along this period suggested the 
presence of, at least, three different antibacterial compounds, represented by the 
fractions I, II and III (Figure 17). The vial exhibiting the major inhibition zone from each of 
these fractions was analyzed by LC-ESI-MS (Figure 18). The fraction I was characterized by 
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the presence of several compounds. Therefore, in the present study this fraction was not 
subject to further analysis. On the contrary, in fractions II and III a major peak with a 
retention time of Rt= 17.9 min and Rt= 18.33 min, respectively, was identified. The molecular 
mass identified on that peak of the fraction II corresponded to the A89 peptide, while in 
fraction III the B89 molecular mass was detected. In order to obtain highly pure peptides, 
the first prepHPLC separation process was repeated several times and the vials 
corresponding to fraction II were pooled together. The same approach was used for the 
vials corresponding to the fraction III. After solvent evaporation, each fraction was 
subjected to a second prepHPLC analysis.  
 
 
Figure 17: Chromatogram resulting from HPLC separation of SPE purified supernatant extracts from 
B. licheniformis I89 obtained at A= 210nm (black line). The bioactivity observed in each fraction is represented by 
dark grey (fraction I), green (fraction II) and orange (fraction III). No bioactivity was observed in the uncolored 
areas. 
 
 
  
 
 
 
 
Figure 18: TIC chromatograms 
of the prepHPLC vials where the 
biggest inhibition zones were 
observed in the bioassay 
against M. luteus corresponding 
to fraction I (A; vial 21), fraction 
II (B, vial 29) and fraction III (C; 
vial 36) of Figure 17. 
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2.2.3.3 prepHPLC of fraction II 
The fraction II was mainly composed by the A89 peptide. Nevertheless, its components 
were further separated by a prepHPLC procedure consisting of a 40 min gradient. Over 
this period, all the eluted fractions collected were concentrated and bioassayed against 
M. luteus. The presence of antibacterial activity was mainly detected in the vials 
containing compounds with retention times between seven and twelve minutes (Figure 
19). Also, some bioactivity was identified on vials corresponding to a retention time of six 
minutes (Figure 19). According to the measured inhibition diameters, the fraction II was 
sub-divided into four sub-fractions that were further analyzed by LC-ESI-MS. The molecular 
mass of A89 was identified in all these sub-fractions. However, only the sub-fraction 
exhibiting the highest inhibition zone (sub-fraction 3) was exclusively constituted by this 
peptide. In the sub-fractions 1 and 2, apart from A89 peptide, compounds with molecular 
masses of 3284 Da and 3266 Da were also detected. The M= 3284 Da compound was the 
main constituent of sub-fraction 1, while sub-fraction 2 was primarily composed by a 
compound of M= 3266 Da. In the remaining sub-fraction 4, the most abundant peak 
corresponded to a M= 3278 Da. However, both A89 and B89 peptides were also detected 
in this fraction, although in a low abundance when compared with the M= 3278 Da 
compound. Therefore, the pure A89 peptide was obtained by pooling all the sub-fractions 
3, resulting from several prepHPLC separations of fraction II. Finally, the Edman 
degradation was attempted on the A89 peptide. However, no results could be obtained 
probably due to the blockage of the reaction by the inaccessible N-termini. 
 
 
Figure 19: Chromatogram resulting from HPLC separation of fraction II at A= 210nm (dark black line), where the 
corresponding bioactivity is represented in green shade. 
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2.2.3.4 prepHPLC of fraction III 
The fraction III was mainly composed by the B89 peptide. Even so its constituents were 
further separated involving the same prepHPLC procedure applied to the fraction II. The 
antagonistic activity observed along the applied gradient showed that antibacterial 
compounds were eluted in five distinct moments, which were designated as sub-fractions 
1-5 (Figure 20). The biggest inhibition zone was detected for the first sub-fraction. LC-ESI-MS 
analysis of this fraction revealed the presence of the A89 peptide. On the remaining sub-
fractions and also by LC-ESI-MS analysis, only the B89 peptide (sub-fractions 3 and 4) or a 
mixture of the B89 peptide with a compound possessing the molecular mass of 3038 Da 
(sub-fractions 2 and 5) could be detected. These compounds possess a difference in terms 
of molecular mass of +18 Da when compared with B89 peptide, suggesting that they 
compounds could be related with the B89 peptide, where a dehydration reaction did not 
occur. Therefore, the pure B89 peptide was finally obtained by mixing all the sub-fractions 
3 and 4 resulting from several HPLC separations of fraction III. Finally, the B89 was also 
submitted to sequencing by Edman degradation. Similarly to A89, no results could be 
obtained. 
 
 
Figure 20: Chromatogram resulting from HPLC separation of fraction III at A= 210nm (dark black line), where the 
corresponding bioactivity is represented in orange shade. 
 
 
2.2.4 Production of A89 and B89 peptides by B. licheniformis I89 at different 
temperatures 
It was previously established that the A89 peptide was produced by B. licheniformis I89 
in fermentations performed at 50 ºC. As described in the previous section, the same 
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peptide can also be detected, together with another antibacterial peptide designated as 
B89, in the supernatant of I89 cultures grown at 37 ºC. However it was not established if this 
newly identified peptide was also produced at 50 ºC. Hence, the supernatants of 
B. licheniformis I89 grown at 37 ºC and 50 ºC were analyzed by LC-ESI-MS (Figure 21 and 
Figure 22). The resultant TIC chromatogram showed the presence of a mixture of 
compounds. However, the mass corresponding to A89 peptide was successfully identified 
in both samples after an elution time of approximately Rt= 18 minutes. In addition, the B89 
peptide was also detected in both supernatants a few seconds later. The detailed analysis 
of the B89 TIC peak also revealed that the 3038 Da peptide was also present in both of the 
analyzed supernatants, demonstrating that its production also occurs at 50 ºC (Figure 23). 
 
 
 
Figure 21: TIC chromatogram obtained from LC-ESI-MS analysis of supernatant butanol extracts from 
B. licheniformis I89 fermentations at 37 ºC (A) and 50 ºC (B). The green area corresponds to the peak where A89 
the molecular mass was detected and the orange area where B89 molecular mass was identified. 
 
 
 
Figure 22: Mass spectra corresponding to the analysis of the two peaks highlighted in the Figure 21, where the 
A89 (A) and B89 (B) characteristic molecular masses could be identified. The double and triple charged ions of 
both peptides were identified in conjugation with some ions corresponding to fragments of each peptide. 
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Figure 23: Detail of the double charged ions identified in the peak corresponding to a Rt= 18.20 min. The figure 
shows that the B89 peptide and a peptide with an additional water molecule are produced at both 37 ºC (A) 
and 50 ºC (B). 
 
 
2.2.5 Nonribosomal adenylation domains present in the B. licheniformis I89 
genome 
The bacitracin and lichenysin nonribosomal peptide synthetases (NRPSs) have been 
detected in several B. licheniformis strains. Nevertheless, in the present study, the molecular 
masses of these two antibacterials were never detected in the supernatants or cell wall 
associated fractions from B. licheniformis I89 cultures. In order to investigate if I89 strain 
possessed NRPSs that could be involved in the biosynthesis of the A89 or B89 peptide, a 
library of its NRPS adenylation (A) domains was constructed. In total, only five different A 
domains were identified and designated as MT11, MT12, MT15, MT28 and MT75. The 
comparison of the amino acid sequence of these fragments with the genomes of 
B. licheniformis ATCC 14580 and B. licheniformis DSM13 was performed through the web-
based BLAST software. The results showed that MT11, MT12, MT15 and MT28 possessed high 
homology with A domains belonging to the three sub-units of the lichenysin NRPS as 
represented in Figure 24. Regarding the MT75 sequence, it was found that its closely 
related A domain belongs to a putative and uncharacterized siderophore NRPS (Figure 
24). Therefore, no potential novel NRPSs were identified in I89 strain, suggesting that A89 
and B89 peptides do not have a nonribosomal origin. 
 
 
Figure 24: Phylogenetic analysis of the 
adenylation domains amplified from B. 
licheniformis I89. LchAA. LchAB and LchAC 
represent the three subunits of lichenysin 
peptide synthetase found in B. licheniformis 
ATCC 14580/DSM13 and DhbF the putative 
siderophore synthetase. The analysis was 
performed with the amino acid sequence 
between the core motifs A3 and A6 of 
each adenylation domain. 
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2.3 Discussion 
The Bacillus subtilis-licheniformis group includes many strains used to manufacture 
industrial enzymes, antibiotics and biochemicals (Rey et al., 2004). B. licheniformis strains 
have been widely described as a natural source of antimicrobial compounds produced 
both aerobically and anaerobically. Some examples include the nonribosomal antibiotic 
bacitracin (Johnson et al., 1945) and the bacteriocin-like peptides like lichenin (Pattnaik et 
al., 2001). Therefore, it was not surprising that B. licheniformis I89 was able to inhibit the 
growth of the Gram-positive M. luteus. Such ability promoted further investigation involving 
the antibacterials produced by this strain. A previous study described that I89 strain was 
able to produce and export to its supernatant the A89 antibacterial peptide when grown 
at 50 ºC (Mendo et al., 2004). Herein, it was also observed that B. licheniformis I89 colonies 
were able to inhibit the growth of M. luteus when both bacteria were incubated together 
at 37 ºC. Moreover, it was also demonstrated by LC-ESI-MS analysis that the A89 peptide is 
also produced at this temperature. Therefore, the comparison of B. licheniformis I89 
growth, sporulation and antagonistic activity when incubated at 37 ºC and 50 ºC was 
performed. At both of the tested conditions, antagonistic activity was first detected at the 
end of the exponential phase and the maximum activity was obtained approximately four 
hours later. The same profile was observed for B. licheniformis P40 and 490/5 strains, 
producers of bacillocin P40 and bacillocin 490 antibacterial peptides, respectively 
(Martirani et al., 2002; Cladera-Olivera et al., 2004b). The abolishment of activity after 36 
hours of incubation of samples withdrawn from fermentations performed at 50 ºC was not 
observed when I89 was incubated at 37 ºC. Yet, a decrease of the antibacterial activity 
along the stationary phase of cultures incubated at 37 ºC was visible. The reasons behind 
these findings could not be established so far. However it can be suggested that it might 
be due to the degradation of some of the antibacterial compounds by enzymes also 
produced by the I89 strain. It is possible that at 50 ºC better conditions are met for the 
production and/or catalytic activity of such enzymes. Alternatively, the mixture of 
antibacterial compounds produced at 37 ºC could be different from those produced at 
50 ºC, and consequently the stability to the prospective enzymatic activity could be 
distinct. Furthermore, it should be emphasized that fractions collected from I89 
fermentations that occurred at 37 ºC resulted in larger inhibition zones than those derived 
from fermentations at 50 ºC. Thus, it appears that incubation at 37 ºC is better for the 
production of I89 antibacterial compounds. 
In the present study, production of spores was observed either at 37 ºC or 50 ºC. It is 
known that although not always directly dependent on each other, the production of 
secondary metabolites (e.g. antibiotics and proteases) and spore formation are often 
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synchronized (Hanlon and Hodges, 1981). Actually, in the present study the first spores 
were identified at the late exponential phase of growth, coinciding also with the 
beginning of antibacterial activity.  
The supernatants of B. licheniformis I89 were found to be active against the Gram-
positive strains of L. monocytogenes, E. faecium, E. faecalis, H. influenzae and S. aureus, 
including a MRSA clinical isolate, suggesting that I89 compounds exerts their activity in 
distinct targets. However, they were completely inactive against the Gram-negative 
bacteria tested so far. In fact, the majority of B. licheniformis antimicrobial compounds 
have Gram-positive bacteria or fungi generally associated with plants as preferential 
targets. Even so, bacillocin P40 is active against some Gram-negative microorganisms 
such as Aeromonas sp., Enterobacter aerogenes and Pasteurella haemolytica, which 
have been described as infection agents of economically important veterinary species, 
including fish (Cladera-Olivera et al., 2004b). 
It was not established before if the biological activity of B. licheniformis I89 supernatants 
was exclusively due to the production of the A89 peptide. Hence, in the present study the 
components of I89 supernatants were separated through the application of analytical 
procedures.  It was found that B. licheniformis I89 produces other antibacterial compounds 
in addition to A89 peptide. Apart from A89 fraction, two other main fractions containing 
antibacterial compounds were identified. One of these fractions was not further 
characterized in the present study, whereas the other fraction consisting mainly of the B89 
peptide (M= 3020 Da) and a compound(s) possessing M= 3038 Da were selected for 
additional studies. The molecular mass of the last compound(s) suggests that it could 
consist of a B89 variant possessing an additional water molecule. The pure A89 and B89 
peptides were sequenced by Edman degradation. However, no information of their 
amino acidic content was obtained due to the earlier termination of the sequencing 
cycles. Edman degradation blockage has often been associated with the presence of 
dehydrated residues (Holtsmark et al., 2006). Thus, it could be possible that A89 and B89 
peptides contain such amino acids. 
The LC-ESI-MS analysis of supernatants from B. licheniformis I89 cultures grown at 50 ºC 
revealed that B89 and its derivative (M= 3038 Da) were also produced at this temperature. 
Using this approach, it was not possible to identify the production of the well-known 
antibacterials bacitracin and lichenysin produced by certain B. licheniformis strains. Such 
results are in agreement with the fact that we were not able to identify A domains sharing 
high homology with the bacitracin operon within the B. licheniformis I89 genome. On the 
contrary, four from a total of seven A domains possessing high homology with the 
lichenysin peptide synthetase were identified. Lichenysins compounds differ in amino acid 
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composition at the positions Glx1, Asx5 and Ile/Leu/Val7 (Konz et al., 1999). The 
adenylation domain of the I89 strain sharing high homology with the first adenylation 
domain of the lichenysin synthetase should be responsible for the activation of a Gln 
residue instead of a Glu, according to the nonribosomal code proposed by Stachelhaus 
et al. (1999). Therefore, the most probable scenario is that I89 strain would produce 
lichenysin D, as the B. licheniformis ATCC 10716 strain (Konz et al., 1999). However, the 
medium composition, especially the carbon and nitrogen source are factors which 
significantly influence the production of those lipopeptides (Makkar and Cameotra, 2002). 
Therefore, unless the lichenysin NRPS present in I89 strain is non-functional, it might be able 
to produce this biosurfactant after optimization of the growth conditions. Like 
B. licheniformis ATCC 14580, I89 strain should contain a siderophore biosynthetic gene 
cluster, since MT75 A domain possessed homology with DhbF protein. The production and 
secretion of such molecules is part of a survival mechanism, which allows microorganisms 
to acquire iron when exposed to iron-limiting conditions. For instance, the siderophore 
SVK21 was isolated from B. licheniformis VK21 strain under iron deficiency conditions. 
According with the amino acid analysis and NMR spectrometry results, such compound 
was proved to be 2,3-dihydroxybenzoyl-glycyl-threonine (Temirov et al., 2003). The analysis 
of MT75 adenylation domain indicates the activation of a Thr or a Dht residue. Therefore, it 
could be possible that under iron deficiency conditions the I89 strain can also produce the 
SVK21-like siderophore or a closely related compound. 
A domains possibly incorporating novel NRPSs were not identified in the I89 strain. 
Therefore A89 and B89 peptides should not belong to the nonribosomally-synthesized 
group of peptides. In fact, it was recently demonstrated that these two peptides constitute 
the two-component lantibiotic lichenicidin (Begley et al., 2009; Dischinger et al., 2009; 
Shenkarev et al., 2010). Lichenicidin is composed by the two peptides Bliα/Lchα and 
Bliβ/Lchβ, which have the same molecular masses and share the biological characteristics 
with the A89 and B89 peptides, respectively. For this reason, the nomenclature used in their 
first description (Bliα and Bliβ) will be adopted in the following chapters. Regarding the 
other lichenicidin producers (B. licheniformis ATCC 14580 and DSM13), it was found that 
these two peptides were exclusively identified in their cell wall associated fractions of 
cultures grown at 37 ºC in LB medium or synthetic medium, respectively (Begley et al., 
2009; Dischinger et al., 2009). Nonetheless, these lantibiotics were successfully detected in 
both supernatant and cell wall washes extracts of I89 grown in very similar conditions, since 
medium M composition is similar to that of the LB medium. The lantibiotic biological origin 
of Bliα and Bliβ can justify the inability to obtain their amino acid constitution by Edman 
degradation. 
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In conclusion, in this chapter we demonstrate that B. licheniformis I89 produces a broad 
range of natural compounds which can have relevant economical and industrial interests. 
Among these is the two-component lantibiotic lichenicidin. Bliα and Bliβ structure, 
biosynthesis and self-protection will be the major focus of this thesis and will be studied and 
discussed in more detail in the next chapters. 
 
 
2.4 Experimental procedures 
2.4.1 Bacterial strains and cultivation media 
B. licheniformis I89 was first isolated from a hot spring in Azores island (Mendo et al., 
2000). Enterococcus faecalis, Haemophilus influenzae, Listeria monocytogenes, 
Staphylococcus aureus, Klebsiella pneumoniae and Pseudomonas aeruginosa strains were 
isolated from patients of the Hospital Infante D. Pedro, SA – Aveiro. All of these strains were 
maintained in tryptic soy agar plates (TSA; Merck) and propagated at 37 ºC. Microcuccus 
luteus ATCC 9341 was the indicator strain used to test antibacterials productions. 
Fermentations of B. licheniformis I89 were performed in medium M containing 10 g/L of 
NaCl, 10 g/L of trytptone, 5 g/L of yeast extract, 10 g/L of KH2PO4 and adjusted to a final 
pH of 6.5, adjusted with NaOH (Mendo et al., 2004). When extraction of DNA was 
necessary, I89 strain was grown in tryptic soy broth (TSA, Merck). 
 
 
2.4.2 Cell growth monitoring and antibacterials production 
The monitoring of cell growth was performed in medium M at 37 ºC and 50 ºC. A pre-
culture with approximately 16 hours of growth was always prepared. 1/100 volume of this 
pre-culture was used to inoculate fresh medium followed by incubation for 44 hours at 
160 rpm. Every 4 hours, 3 mL were taken from the main culture and used to measure the 
following parameters: (a) bacterial density at OD600nm (1 mL); (b) number of viable cells 
(500 µL); (c) supernatant and cell washes antibacterial activity (1 mL); (d) pH of the 
supernatant (e) production of spores.  
 
2.4.2.1 Counting of viable cells 
The total number of cells and spores present at each hour were evaluated using 
successive dilutions of the remaining culture in 1X PBS buffer (final volume of 1 mL). 50 µL of 
each dilution was platted on medium M agar plates and incubated overnight either at 
37 ºC or 50 ºC. The total number of colonies present in each dilution was counted and the 
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respective values expressed in terms of CFU/mL, considering the volume and dilution that 
were plated. 
 
2.4.2.2 Evaluation of antagonistic activity and pH determination 
For each sampling point, 1 mL of culture was centrifuged at 12000 x g, for 5 min to 
separate the cells from the supernatant. A second centrifugation in the same conditions 
was performed to ensure that no cells were present. The pH of the supernatants was 
measured before their storage at -20 ºC. The pelleted cells were dissolved in 100 µL of a 
70% solution of isopropanol/water, incubated at 4 ºC for 3 hours and finally centrifuged at 
12000 x g for 5 min. The supernatant corresponding to the cell-wall wash fraction was 
transferred to a clean 1.5 mL microcentrifuge and stored at -20ºC. The antagonistic activity 
of both supernatant and cell wall washes fractions were tested by applying 30 µL of each 
sample to the bioassay plates’ wells as described in section 2.4.8. 
 
2.4.2.3 Production of spores 
Since B. licheniformis I89 sporulates, the number of spores present at each hour of 
growth was calculated. This involved the incubation of 100 µL from the remaining 1 mL of 
culture for 20 min at 80 ºC. After this, successive dilutions were performed in 1X PBS buffer 
and 50 µL of each were platted in the agar plates of the corresponding medium and 
incubated overnight at 37 ºC or 50 ºC. The total number of colonies present in each 
dilution was counted and the respective values expressed in terms of CFU/mL, considering 
the volume and dilution that were plated. Each colony was considered to originate from 
the germination of one spore. 
 
2.4.3 Extraction of genomic DNA from B. licheniformis I89 
The extraction of genomic DNA from B. licheniformis I89 was performed with the 
Genomic DNA purification kit (Fermentas) from an overnight culture grown at 37 ºC. 4 mL 
of this culture were centrifuged for 5 min at 12000 x g, the pellet was resuspended in 200 µL 
of TE buffer, containing 10 mg/mL of lysozyme (Roche) and incubated for 30 min at 37 ºC. 
400 µL of the Lysis Solution were added to the mixture, followed by incubation at 65 ºC for 
5 min. At this time, 600 µL of chloroform were added and the solution gently emulsified by 
inversion. The sample was centrifuged for 2 min at 12000 x g and the upper aqueous 
phase transferred to a clean and sterile microtube. 800 µL of freshly prepared 1X 
Precipitation Solution were added, followed by several inversions of the tube 
approximately for 2 min. The mixture was centrifuged at 12000 x g for 2 min and the 
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supernatant completely removed. The pellet constituting the genomic DNA was gently 
dissolved in 100 µL of the provided NaCl solution (1.2 M), until the pellet was completely 
dissolved. 300 µL of cold ethanol were added and the genomic DNA was allowed to 
precipitate 10 min at -20 ºC. After centrifugation for 4 min at 12000 x g, the ethanol was 
removed and the pellet washed with 70 % ethanol. This solution was removed by 
centrifugation 5 min at 12000 x g and the pellet was allowed to dry completely in the flow 
chamber. Finally, the extracted DNA was dissolved in 100 µL of sterile distilled water. 
 
 
2.4.4 Analysis of A domains in the B. licheniformis I89 genome 
2.4.4.1 Construction of A domains library 
Adenylation (A) domains were amplified from B. licheniformis I89 genomic DNA using 
the primers MTF (5’-GCNGGYGGYGCNTAYGTNCC-3’) and MTR (5’-
CCNCGDATYTTNACYTG-3’) (Neilan et al., 1999). The degenerate primers were constructed 
to target the A2 and A8 core motifs of the A domains, respectively. Each reaction was 
performed in a final volume of 25 µL using the Thermo Extensor High-Fidelity PCR master 
mix, with each primer final concentration of 1.5 pmol/µL. The amplification parameters 
were as follows: 94 ºC for 5 min, 35 cycles of 94 ºC for 30 sec, 51 ºC for 30 sec and 68 ºC for 
1 min and a final extension step of 10 min at 68 ºC. Five independent PCR reactions were 
performed, mixed together, purified and eluted in a final elution volume of 30 µl with the 
GeneJET™ PCR Purification Kit (Fermentas), according to the manufacturer’s instructions 
(Appendix 8). The purified PCR product was ligated to the pCR 2.1 plasmid (Appendix 3) 
using the TA cloning kit (Invitrogen). Briefly, the ligation reaction contained 7 µL of PCR 
product (approximately at 50-100 ng/µL), 25 ng of the pCR 2.1 plasmid, 4 U of ligase and 
1X of ligase buffer in a final volume of 10 µL and incubated overnight at 14 ºC. 5 µL of this 
reaction were used to transform chemically competent E. coli DH5α cells, prepared as 
described in Appendix 4. Positive clones were selected based on kanamycin resistance 
and white/blue selection by incubation of LB agar containing 50 µg/mL of Kan and 
40 µg/mL of X-Gal. 
 
2.4.4.2 Sequencing of the A domains 
Approximately 50 white colonies were randomly picked and the inserted fragment was 
amplified using the universal primers M13fw (5’- GTTTTCCCAGTCACGAC-3’) and M13rv (5’-
CAGGAAACAGCTATGAC-3’). Each reaction was performed in a final volume of 12.5 µl 
containing 1.5 mM MgCl2, 200 µM dNTP’s, 1X Green GoTaq® Buffer and 0.25 U of GoTaq® 
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Buffer (Promega), using a bacterial colony as DNA template. The amplification parameters 
were as follows: 94 ºC for 5 min, 35 cycles of 94 ºC for 30 sec, 50 ºC for 30 sec and 72 ºC for 
1 min and a final extension step of 10 min at 72 ºC. The presence of the correct amplicons 
(approximately 1200 bp) was evaluated on 1 % agarose gel electrophoresis. Positive PCR 
products were subjected to restriction fragment length polymorphism (RFLP) in order to 
select distinct inserts before sequencing. Each RFLP reaction was prepared with 5 µL of 
each of these PCR reactions (without any purification step, approximately 0.1-0.5 µg of 
DNA), 1X buffer TaqI and 10 U of TaqI enzyme (Fermentas), in a final volume of 20 µL. After 
incubation at 65 ºC for 1 hour, each digestion was loaded on a 2 % agarose gel (in this 
step, the addition of loading buffer was not necessary). Electrophoresis was performed at 
120 V during 1 hour.  
The banding pattern was analyzed with the GelCompar II software (Applied Maths) 
and only one representative of each clustered group was submitted to nucleotide 
sequence determination (STABVIDA-Portugal). 
 
2.4.4.3 Phylogenetic analysis of the I89 A domains 
All the sequenced A domains were first analysed using BlastX program 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). The two sequences exhibiting the highest 
homology with the A domains obtained in this study were selected. Sequentially, all the 
deduced amino acid sequences between two conserved core motifs (A4 and A5) were 
aligned using the web-based software Clustal X. This alignment was the basis for the 
phylogenetic analysis performed with MEGA 4.1 software (Tamura et al., 2007), using as 
parameters the Poison correction model for amino acids and a bootstrap consisting of 
1000 replications as described by Stachelhaus et al. (1999). 
 
 
2.4.5 Separation of antibacterial compounds from the supernatants of 
B. licheniformis I89 strain 
B. licheniformis I89 strain was grown in medium M at 37 ºC with aeration (160 rpm) for 
approximately 16 hours. 1 mL of this culture was used to inoculate 1 L of fresh medium M 
and allowed to grow for another 16 hours in the same conditions. Subsequently, the 
cultures were centrifuged at 12000 x g for 10 min to remove the bacterial cells. The cell-
free supernatant was transferred to a clean reservoir and 100 mL of 1-Butanol (Merck) was 
added. The mixture was stirred at room temperature for 1 hour. After this period the 
solution was centrifuged for 1 min at 4000 x g and the organic upper layer collected into a 
clean tube. The organic solvent was subsequently evaporated at 50 ºC for 16 hours in an 
Antibacterial compounds produced by B. licheniformis I89 
 59 
evaporator EZ2-Standard (GeneVac). The dried pellet was used for solid phase extraction 
procedure. 
 
2.4.5.1 Solid phase extraction (SPE) 
A 10 mg/mL solution of the dried pellet was prepared in 90% acetonitrile/H2O and 
applied to a C8 solid-phase extraction (SPE) cartridge (Machenery-Nagel) previously 
conditioned with 100 % acetonitrile. The SPE cartridge matrix containing the sample 
attached was subsequently washed with the following solvent solutions: 
100% dichloromethane, 100 % ethylacetate, 100 % acetone, 100 % acetonitrile, 
90 % acetonitrile and finally 70 % acetonitrile. A vacuum of −0.5 bar was always applied 
during the procedure and all the solvents getting out of the cartridge were collected to 
distinct falcon tubes. The six different solvent solutions were evaporated at 50 ºC for 
16 hours in an evaporator EZ2-Standard (GeneVac). All the pellets were dissolved in 50 % 
acetonitrile and 50 µL were used for bioassay, as described in section 2.4.8. Following this 
procedure, it was found that antibacterial activity was exclusively detected in the 90 % 
and 70 % acetonitrile fractions. Therefore, in the following SPE procedures these two 
fractions were pooled together and concentrated by solvent evaporation as already 
described. The pelleted extract was further used for the preparative high-pressure liquid 
chromatography procedure described as follows. 
 
2.4.5.2 prepHPLC of SPE extracts 
100 mg of the SPE extract was resuspended in 1 mL of 50% acetonitrile solution and 
submitted to preparative high pressure liquid chromatography with the serie 1100 
equipment (Agilent Technologies, Waldbronn, Germany) and a C18 column. The 
components separation was performed at a flow rate of 25 ml/min with detection at A= 
210 nm using the following gradient parameters: 0–2 min (0 % solvent B), 2–3 min (0–40 % 
solvent B), 3–15 min (40–49 % solvent B) and 15 min–15 min and 10 seg (49–100 % solvent B), 
solvent A being ultrapure water containing 0.1 % formic acid and solvent B 100 % 
acetonitrile containing 0.1 % formic acid. All the fractions were automatically collected 
along the 20 min of the procedure, concentrated by complete solvent evaporation and 
finally resuspended in 1 mL of 50 % acetonitrile. 50 µL of each fraction were subjected to 
bioassay as described in section 2.4.8. According with the antibacterial activity and LC-ESI-
MS results, three different fractions were defined. The fraction I was not analyzed. The 
fraction II corresponded to the pooling of vials containing compounds with retention times 
between 8.5 min and 11.3 min. The fraction III corresponded to the pooling of vials 
containing compounds with retention times between 12 min and 14.2 min. Fraction II and 
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III were concentrated by complete solvent evaporation and each of them was applied to 
a second prepHPLC procedure as described below. 
 
2.4.5.3 prepHPLC of fraction II and III 
Fraction II and fraction III obtained in the previous section were separately dissolved in 
50 % acetonitrile to obtain a final concentration of 6 mg/mL. 1 mL of this solution was 
separated in the same preparative HPLC equipment as described in the previous section. 
However, the separation was performed at a flow rate of 25 mL/min with the following 
gradient: 2 min – 0 % solvent B, 3 min – 40 % solvent B, 35 min – 49 % solvent B, 35.5 min–
100 % solvent B and 40 min – 100 % solvent B. Solvent A consisted of ultra pure water 
containing 0.1 % of formic acid and solvent B being 100 % acetonitrile containing 0.1 % 
formic acid. All the 5 mL fractions obtained for the separation of fraction II and fraction III 
were concentrated by full evaporation of the solvent and resuspended in 1 mL of 50 % 
acetonitrile. 50 µL of each of the fractions were bioassayed as described in section 2.4.8. 
According to the antibacterial activity and LC-ESI-MS results, highly pure A89 and B89 
peptides were obtained.  
 
 
2.4.6 Mass spectrometry analysis 
The analysis of the fractions was performed firstly by LC-ESI-MS on a qTof 2 hybrid 
quadrupol time of flight ESI mass spectrometer (Micromass/Waters, Milford, USA) coupled 
to an Agilent 1100 HPLC system (Agilent, Waldbronn, Germany). The volume injected for 
each analysis varied between 10 and 20 µL. Separation was performed with a GromTM Sil 
120 ODS-5 column from Grace with the following gradient: 5 min - 5 % solvent B, 20 min – 
100 % solvent B, 25 min – 100 % solvent B, 26 min – 5 % solvent B and 30 min – 5 % solvent B 
at a flow rate of 0.2 mL/min. Solvent A being ultra pure water containing 0.1 % of formic 
acid and solvent B being 100 % acetonitrile containing 0.1 % formic acid. The qTof 
parameters were as follows: capillary at 3.0 KV, cone at 37 V, MCP of 1650 V, source 
temperature of 120 ºC and dessolvation temperature of 320 ºC. 
 
 
2.4.7 Peptide sequencing 
The purified A89/Bliα and B89/Bliβ peptides in the form of a dehydrated powder were 
subjected to sequence by automated Edman degradation at the Proteome Factory 
company (Berlin, Germany). 
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2.4.8 Antibacterial activity assays 
Antibacterial activity was always assessed on TSA agar plates seeded with the indicator 
strain M. luteus ATCC 9341 at a final concentration of 0.02 (optical density at A= 600 nm). 
For colony bioassays, testing strains were directly streaked on the surface of the bioassay 
plates. For the analysis of liquid samples, wells (5 mm diameter) were made in the 
inoculated agar plates and filled with the appropriated volume for the assay. The plates 
were always incubated at 37 ºC overnight before interpretation and measuring of 
inhibition areas. 
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3.1 Introduction 
 
 
 
 
he Koch’s postulates opened the era of single-cell, pure-culture microbiology. 
Once isolated, a certain bacterial strain is grown and its population reaches a 
certain density by the uptake of available nutrients (Lopez et al., 2009). All of the 
cells present in such a population possess identical genomes and their subculturing should 
perpetuate its clonal ancestor characteristics. However, along this process, bacterial 
dissociation has been observed. This phenomenon consists in the emergence of variants of 
the same bacterial strain, differing in a number of characteristics at the morphological, 
physiological and/or genetic level (Golovlev, 1998; Tsygankova et al., 2004). 
B. licheniformis I89 is an antibacterial producer, including the recently characterized 
lantibiotic lichenicidin (Begley et al., 2009; Bierbaum and Sahl, 2009; Shenkarev et al., 
2010). In the course of B. licheniformis I89 culturing process, two distinct morphological 
colony types were detected. For B. licheniformis, the phenotype transition has been 
described as a change of its growth phase (Bisset and Street, 1973). In other cases it is 
induced. For instance, the subculturing on nutrient broth of a 7-day-old B. licheniformis 103 
strain, previously grown under sporulation suppression media revealed its dissociation into 
several distinct phenotype variants (Tsygankova et al., 2004).  
The phenotype metastability has been described in several Gram-positive and Gram-
negative specimens, including members of Bacillus, Staphylococcus, Escherichia and 
Actinobacillus genus (Fine et al., 1999; Kravchenko et al., 2000; Doroshenko et al., 2001; 
Il'inskaya et al., 2002). Nevertheless, the reasons triggering such adaptative changes 
remain unknown, despite the efforts drove over the last three decades. For instance, the 
subculturing of the rough-type Actinobacillus actinomycetemcomitans in a daily basis 
promoted its conversion to a turbid smooth phenotype. Several studies showed the 
differences in the fimbriae abundance, in vitro ability of epithelial cells invasion and also 
T 
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the expression of outer membrane proteins between the two morphological variants 
(Inouye et al., 1990; Meyer et al., 1991; Haase et al., 1999). For B. stearothermophilus 
NCA1518 morphological variants, it was found that the same nutritional and biochemical 
capabilities were kept, despite the suspicion of variation in the heat resistance of their 
spores (Humbert et al., 1972).  
The phenotype instability of bacterial strains can have a negative impact in 
biotechnological applications, since industrially useful properties can be lost in the process 
(Berditsch et al., 2007). A good example of that relies on the gramicidin S (Gause and 
Brazhnikova, 1944) antibiotic producer Aneurinibacillus migulans ATCC 9999 (Bacillus brevis 
var. G.B.). A rough appearance characterized the original colonies of this strain. However, 
during the early applications for gramicidin S industrial production, several distinct 
phenotypes variants, which originated spontaneously from this strain, were discovered. 
Intriguingly, two of such colonies lost their ability to produce gramicidin S (Zharikova et al., 
1964; Berditsch et al., 2007). On the other hand, some interesting and useful properties can 
also arise from this variability. One of such examples is the attenuated Bacillus Calmette-
Guérin (BCG) ancestral strain, which was obtained by Albert Calmette and Camille Guérin 
through repeated subculturing of Mycobacterium bovis, responsible for bovine 
tuberculosis, on a glycerin-bile-potato mixture (Calmette, 1927). The divergent methods of 
striking and storage of the BCG strain along the years also originated many substrains 
showing phenotypic and genetic heterogeneity (Bedwell et al., 2001).Such diversification 
was accompanied by the deletion of some genetic regions (RD) which in some cases 
affected the antigenic content (Castillo-Rodal et al., 2006).  
Here, we confirmed through molecular-based techniques that both morphological 
variants detected in this study were spontaneously derived from B. licheniformis I89 
ancestor strain. The growth and sporulation activity of each variant were investigated on 
two different cultivation media often used for B. licheniformis I89 culturing in our laboratory. 
Since phenotype instability was associated to the non-production of active compounds in 
the past, the production of lichenicidin peptides (Bliα and Bliβ) by each I89 variant was 
also investigated by LC-ESI-MS analysis.  
 
 
3.2 Results 
3.2.1 Changes in B. licheniformis I89 colony morphology 
In the course of the present study, B. licheniformis I89 was routinely subcultured and 
maintained at 37 ºC on tryptic soy agar (TSA) plates. The B. licheniformis I89 phenotype 
was characterized by protrusive circular colonies with a central rough area surrounded by 
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defined borders. These cells strongly adhered to the agar, appearing partially embedded 
in it (Figure 25A). During a routine procedure, 2-days-old liquid cultures were inoculated on 
TSA plates and incubated overnight at 37 ºC to monitor the existence of potential 
contaminations. After this incubation period, colonies with two different morphologies 
could be observed: the original rough (R) colonies, strongly embedded in the agar and a 
novel colony type, consisting of non-agar embedded colonies with a smooth (S) 
appearance that consisted on a central surface delimited by swarming-like borders 
(Figure 25B). The inner section of these S-type cells could be easily removed from the agar, 
while the limiting border cells were difficult to detach. Moreover, the R-type variant 
presented a whitish-dry aspect when compared with the S-type variant. Multiple colony 
morphology is a phenomenon commonly described for some microorganisms such as 
A. migulanus and Clostridium acetobutylicum (Adler and Crow, 1987; Berditsch et al., 
2007). Even so, the S-type phenotype was at first believed to be a contaminant-borne 
microorganism. To elucidate this, different molecular procedures were applied to both 
variants and respective antibacterial activity tested.  
The amplification and sequencing of the 16S rDNA gene of both variants showed that 
their sequences shared 100 % homology at the nucleotide level. Their comparison with the 
nucleotide database through the BLAST web-based software confirmed their classification 
as B. licheniformis specie. 
 
 
 
Figure 25: Different colony morphologies identified in B. licheniformis I89. The distinctive rough (A) and smooth (B) 
phenotypes were isolated from this strain. 
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Simultaneously, the genetic relationship between the variants was investigated by PCR-
based methods of fingerprinting. Such methodologies take advantage of the repetitive 
sequences spread through the bacterial genome and the obtained fingerprints resemble 
"bar code" patterns analogous to UPC codes used in grocery stores (Lupski, 1993; 
Rademaker and DeBruijn, 1997). Here, rep-PCR analysis was performed by the application 
of the BOXA1R and ERIC primers (Rademaker and DeBruijn, 1997). This analysis showed that 
both R- and S-type colonies exhibited the same band profile (Figure 26). However, the 
pattern retrieved by B. licheniformis ATCC 10716 strain was distinctively different, even 
though some common bands could be observed by the BOX-PCR analysis. Thus, the 16S 
rDNA and rep-PCR results confirmed that R- and S-type colonies should constitute 
B. licheniformis I89 variants. Occasionally, rep-PCR analysis allows the recognition of 
deletions and/or insertions on the bacterial chromosome. However, such rearrangements 
at the DNA level were not detected by either of the methods employed.  
 
 
 
Figure 26: BOX-PCR (A) and ERIC-PCR (B) profiles obtained for B. licheniformis I89 rough (1) and smooth (2) 
phenotypes. The B. licheniformis ATCC 10716 strain was also included in the analysis (3). M represents the DNA 
molecular marker. 
 
 
The capability to affect M. luteus growth of each variant was first evaluated through 
colony-based-bioassays. It was found that both R- and S-type colonies maintained their 
antibacterial activity against M. luteus (Figure 27). Interestingly, the activity observed 
around the S-type variant seemed slightly weaker when compared with that of the R-type 
variant (Figure 27B). The phenotype reversion possibility was tested by successively 
subculturing each variant on TSA plates incubated at 37 ºC. It was found that under this 
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circunstances, morphological properties of S-type did not revert to the parental R-type 
phenotype. 
 
 
 
 
 
 
Figure 27: B. licheniformis I89 rough (A) 
and smooth (B) variants showing 
antibacterial activity against the 
M luteus indicator strain. 
 
 
 
3.2.2 Growth and antagonistic activity of B. licheniformis I89 different 
phenotypes 
The phenotypic variation is often associated with microbial adaptation to the 
laboratory environment. The bacterial fitness, growth profile and sporulation activity are 
occasionally affected in such processes. Thus, the identification of hypothetical 
differences on the growth rate, sporulation and antagonistic activity of both R- and S-type 
colonies was investigated over 44 hours (Figure 28). All the assays were performed at 37 ºC, 
since this was the temperature where phenotypic dissociation was first observed. Results 
showed that no differences on biomass production between R- and S-type colonies could 
be detected over time of growth in both media tested (Figure 28A). Also, under the tested 
conditions the growth kinetics of two-phenotype variants was characterized by a lag-
phase of approximately 4 hours, followed by an exponential phase of about 16 hours. The 
stationary phase was reached approximately after 20 and 24 hours of growth on TSB and 
medium M, respectively. Similarly, sporulation experiments showed no major differences 
between R- and S-type variants, when the same culture medium was used (Figure 28B). 
When the cultures were performed in TSB medium, spores could be detected after 8 hours 
of growth in both variants. Under these conditions, spores were slowly formed until 20 hours 
of growth. After this period their biomass values increased exponentially until the 32 hours 
of incubation. In medium M, the spores were only detected after 16 hours of incubation in 
both R- and S-type cells. Under such conditions, the accumulation of the biomass 
increased exponentially until 32 hours of growth. These results suggested that the triggering 
of the sporulation process should be influenced by the nutritional contribution from the 
cultivation medium.  
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Figure 28: Bacterial growth (A), sporulation (B) and antibacterial activity associated with the supernatant (C) and 
the cell-wall washes fractions (D) of rough (black circles) and smooth (white circles) phenotypes in medium M (M) 
and tryptic soy broth (T). 
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Regarding the antibacterial production, it was observed that in TSB medium, M. luteus 
inhibition in the supernatant as well as cell-wall washes of the R- and S-type colonies was 
detected after 16 hours of growth (Figure 28C/D). In this medium, the maximal 
antibacterial activity was achieved between 20 and 24 hours of incubation in both 
fractions of each of the phenotypic variants. Moreover, after this period, the supernatant 
bioactivity clearly decreased until no activity was observed after 44 hours. A similar 
behavior was observed on the inhibition zone diameter from cell wall washes. However 
inactive fractions were not detected, even after 44 hours of growth. Alike to what was 
observed in TSB medium, the antagonistic activity of the analyzed fractions in medium M 
was first detected after 16 hours of growth on both R- and S- phenotypes. In this culture 
medium, the maximum activity of the supernatant and cell wall washes was observed at 
20 hours of growth. After this stage, the bioactivity decreased but was never null, contrary 
to what was observed with TSB supernatant fractions.  
 
 
3.2.3 Lichenicidin production by B. licheniformis I89 phenotypic variants 
The production of lichenicidin peptides Bliα and Bliβ by the two morphological variants 
was evaluated by LC-ESI-MS analysis of total n-butanol extracts after 20 hours of growth in 
both TSB and medium M (Figure 29). 
 
 
Figure 29: TIC chromatogram of total butanol extracts from rough (R) and smooth (S) variants grown in medium M 
(A) or TSB (B) after 20 hours of incubation. The Bliα and Bliβ peptides were identified in the green and orange 
area, respectively. 
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The total ion chromatogram obtained for medium M extracts showed two defined 
peaks between the Rt= 18 min and Rt= 19 min for both R- and S- variants. In the first peak 
the Bliα peptide (M= 3250 Da) was detected, while the second peak corresponded to the 
peptides Bliβ (M= 3020 Da) and Bliβ with an additional water molecule (M= 3038 Da; Bliβ+) 
(Figure 29A). These peptides were also successfully identified on the supernatants of TSB 
cultures; the peaks corresponding to these peptides although in low abundance and less 
defined, had the same retention time as those obtained when samples produced on 
medium M were analyzed (Figure 29B). When cultured in medium M, no major differences 
were observed between the chromatogram profile of R- and S- phenotypes. On the 
contrary, the LC-ESI-MS analysis of TSB extracts revealed some discrepancies such as the 
abundance of lichenicidin peptides peaks, that were lower in the S variant extract.  
The relative abundance of the lichenicidin peptides was quantified with the values 
obtained from TICs signals (total ion chromatograms) by integration of each peak, 
considering double and triple charged molecule peaks. In TSB medium (Figure 30B) the 
values obtained for the occurrence of Bliα peptide on S-type (137.2 ± 5.7 AU; AU=arbitrary 
units) extracts were three times lower than those of the R-type extracts (397.0 ± 45.8 AU). 
Likewise, the Bliβ and Bliβ+ peptides were also less abundant in the S-type extracts (34.0 ± 
10.2 AU and 27.8 ± 6.9 AU, respectively) than in the R- phenotype extracts (Bliβ: 54.7 ± 13.8 
AU; Bliβ+: 50.0 ± 13.2 AU). In medium M (Figure 30A), the abundance of Bliα peptide did not 
differ greatly between the R- (944.2 ± 298.0 AU) and the S- variant (871.49 ± 118.8 AU) 
extracts. Regarding the other two peptides, higher abundance values were obtained from 
the R variant extracts (Bliβ: 374.3 ± 123.8 AU; Bliβ+: 307.7 ± 77.9 AU) when compared to the 
sample extracts from S-type cultures (Bliβ: 288.3 ± 123.8 AU; Bliβ+: 183.0 ± 21.1 AU). 
 
 
 
Figure 30: Comparison of relative abundance of lichenicidin peptides on butanol extracts of rough (dark grey) 
and smooth (light grey) variants in medium M (A) and TSB (B), after 20 hours of growth. Measurements were 
performed in triplicate. 
B. licheniformis I89 morphological dissociation 
 73 
3.2.4 Total protein analysis of rough and smooth phenotypes 
The abundance of lichenicidin Bliα peptide was substantially lower in TSB cultures of the 
S-type B. licheniformis I89 variant. Such difference was not so evident when medium M was 
used as the cultivation medium. Therefore, it was decided to analyze total protein profiles 
of R- and S-type phenotypes grown in TSB. The cells from both cultures were harvested and 
suspended in 1X PBS buffer, sonicated, briefly centrifuged and finally examined by SDS-
PAGE (Figure 31). The visual comparison of both profiles did not reveal major differences 
between proteins expressed by R- and S-type phenotypes. However, bands with higher 
intensity were detected around 46 kDa and 30 kDa region of the pattern banding 
obtained from S-type phenotype, when compared with the same region of R- variant. In 
opposition, some bands with lower molecular weight (between 17 and 25 kDa) and a little 
more than 30 kDa seemed to be more intense on the total protein analysis of the R-
 variant.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31: SDS-PAGE gel of total proteins from 
B. licheniformis I89 rough (R) and smooth (S) variants 
grown in TSB medium.  
 
 
 
3.3 Discussion 
The bacterial dissociation term was applied by de Kruif (1921) to denote the 
appearance of a variable colonial population derived from a pure bacterial culture. 
Generally, such variants are sufficiently stable to maintain their characteristics over several 
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generations. However, some other types can sporadically reverse to the appearance of 
the parental strain (Braun, 1947). Dissociation phenomenon was recognized for 
B. licheniformis I89 when 2-days-old cultures were subcultured on TSA plates and 
incubated at 37 ºC. In these plates, R- colonies could be observed showing the same 
morphology of the parental I89 strain, but colonies with a new S-type phenotype could 
also be observed. Previously, it has been described that small variations in medium 
composition, incubation temperature and agar content of the solid medium can 
influence the colony morphology of B. subtilis (Veening et al., 2006). However, since 
B. licheniformis I89 R- and S-type colonies were first observed in the same plate, these 
changes could not be attributed to those factors. 16S rDNA gene amplification and 
sequencing allowed the classification of both R and S-type phenotypes as members of the 
B. licheniformis specie. Furthermore, their phylogenetic relationship was investigated by 
rep-PCR. This technique proved to be useful in the subtyping of some Bacillus species, 
including B. licheniformis (de Clerck and de Vos, 2004; Whitaker et al., 2005). The exact 
same fingerprint profile was obtained for R- and S-type colonies, and yet perfectly 
distinguishable from that of B. licheniformis ATCC 10716. The evidence provided by these 
results excluded the possibility of bacterial contamination, suggesting that both 
morphological phenotypes arose spontaneously from the ancestral B. licheniformis I89 
strain. Moreover, the reversion to the initial R- phenotype was not observed after 
subsequent passages of S- colonies, suggesting the stability of the dissociation. Such 
maintenance was also observed for five different phenotype variants of 
B. licheniformis 103 (Tsygankova et al., 2004). Nevertheless, we believe that reversion of S- 
to R-type colonies can still occur as a response to external conditions such as a different 
incubation temperature or a different media composition. For instance, the laboratory 
strain B. subtilis 168 is still capable of forming colonies with vein-like structures formed by 
elevated bundles of cells when cultivated on minimal medium agar plates (Veening et al., 
2006).  
B. licheniformis I89 was first described and characterized due to its ability to produce 
antibacterial compounds able to inhibit the growth of M. luteus, including the lantibiotic 
lichenicidin. Therefore, the impact of the I89 strain phenotypic switch on growth, 
sporulation and antibacterial activity was evaluated at 37 ºC. Two different culture media 
were selected for the assays: i) medium M, traditionally used for B. licheniformis I89 
antibiotic production (Mendo et al., 2004) and ii) TSB, a general purpose medium, which is 
equivalent to the agar medium used for colony-bioassay and where I89 strain 
morphological differentiation was initially detected. Results showed that R- and S-type 
variants produced the same biomass during the growth in both culture media. Also, the 
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switching of R- to S-type morphology was not accompanied by loss of sporulation ability, 
as previously observed for other industrial important strains, as the acetone and butanol-
producer C. acetobutylicum (Adler and Crow, 1987; Berditsch et al., 2007). Nevertheless, 
sporulation activity seems to be initiated earlier when the strains were grown in TSB 
medium (Figure 28B). Regarding the antibacterial activity, no major differences were 
detected between R- and S-type phenotypes grown in medium M. On the other hand, 
cell wall washes bioactivity from R-type colonies grown in TSB were in general superior to 
those of S-type colonies. The same tendency was not observed for supernatant fractions. 
Among the bioactive compounds produced by I89 strain, our major interest relies on the 
production of the lantibiotic lichenicidin. LC-ESI-MS analysis of total n-butanol extracts 
revealed that Bliα, Bliβ and Bliβ+ (Bliβ plus one additional water molecule) are produced by 
R and S phenotypes grown in both culture media. However, a quantitative analysis of 
peptide production by these variants showed that their abundance is generally lower in S-
type extracts. This aspect was particularly evident with the Bliα peptide detected on the 
extracts of TSB cultures. Recently it was experimentally shown that Bliα and Bliβ peptides 
can interact synergistically to exert their antagonist activities (Shenkarev et al., 2010). Thus, 
the production results could be related with the decreased bioactivity observed on the 
cell wall associated fractions from the S-type colonies when compared with those of the R-
type colonies grown in TSB medium. 
The decrease and even the abolishment of antibacterial production was previously 
associated with the morphological dissociation phenomenon. For instance, the 
gramicidin S producer parental strain A. migulanus exhibited a rough-like phenotype 
dissociated into six different phenotypes, two of them possessing a smooth morphology. 
Among these, the S-type colonies lost the ability to produce the nonribosomally-
synthesized antibiotic gramicidin S (Berditsch et al., 2007). Also, to the best of our 
knowledge this is the first description of bacterial dissociation phenomenon possibly 
related with an impact on lantibiotic production, namely the two-component lantibiotic 
lichenicidin. 
The phenotypic differences have also been associated with the occurrence of 
deletions and/or insertions on the chromosome or also with molecular mechanisms as 
differential gene expression of one or more genes (Honda et al., 2006; Berditsch et al., 
2007). Anyhow, in such complex biological processes differences in protein expression 
should always been expected. With this in mind, a preliminary analysis of protein 
expression by the R- and S-type colonies in TSB medium was performed. Despite the 
complexity of the protein banding profile obtained, some differences could be visually 
identified. This study constituted a first approach for future investigations, which should 
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involve the optimization of the protein separation methodologies (possibly the application 
of 2D-gel electrophoresis), followed by protein identification in order to understand the key 
processes behind colony differentiation of the B. licheniformis I89 parental strain. 
Overall, the results obtained suggest that B. licheniformis I89 dissociation implied the 
transition of a rough and more complex to an apparently simple and smooth colony 
morphology on TSA plates. The growth of bacteria under laboratory conditions often 
culminates in the selection of strains in which the robustness of colony morphology is 
dramatically diminished (Aguilar et al., 2007). This process is often referred as 
‘domestication’ (Branda et al., 2001; Aguilar et al., 2007). Thus, S-type colonies could 
correspond to a stage of B. licheniformis I89 ‘domestication’ process, which eventually can 
culminate on a lichenicidin-deficient strain, when permanently cultivated on media such 
as TSB and/or TSA. B. licheniformis is a biotechnologically important microorganism since 
numerous commercial and agricultural applications are known for its extracellular 
products (Rey et al., 2004; Veith et al., 2004). Therefore, the pursuit and assembly of pieces 
involved on its morphological dissociation could be a useful tool to avoid its potentially 
negative impacts.  
 
 
3.4 Experimental procedures 
3.4.1 Bacterial strains and cultivation media 
Two different liquid culture media were routinely used for the cultivation of 
B. licheniformis I89: a) tryptic soy broth (TSB) (Merck); b) medium M (Mendo et al., 2004), 
constituted by 10.0 g/L of Bacto tryptone, 5.0 g/L of yeast extract, 10.0 g/L of NaCl and 
10.0 g/L of KH2PO4 and pH adjusted to 6.5 at 25 ºC (with 1M NaOH). For the cultivation on 
agar plates, 20 g/L of microbiological agar (Sigma) was added to the respective liquid 
culture medium before autoclaving. B. licheniformis ATCC 10716 and M. luteus ATCC 9341 
were maintained on TSA plates. 
 
 
3.4.2 Genetic analysis 
Identification of B. licheniformis I89 subtypes was performed by amplification and 
sequencing of the 16S rRNA gene. For the amplification, the following primers were used: 
27F (5'-AGAGTTT GATCMTGGCTCAG-3') and 1492R (5'-TACCTTGTTACGACTT-3’) (Lane, 
1991). Each reaction was performed in a final volume of 50 µL using the Thermo Extensor 
High-Fidelity PCR master mix, with each primer final concentration of 1.5 pmol/µL. The 
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amplification parameters were as follows: 94 ºC for 5 min, 35 cycles of 94 ºC for 30 sec, 56 
ºC for 30 sec and 68 ºC for 2 min and a final extension step of 10 min at 68 ºC. Bacterial 
suspensions were performed in 20 µL of sterile distilled water and 1 µL of this solution was 
used as DNA template for the amplification. The resulting amplicons of approximately 1600 
bp were submitted to sequencing reaction. The nucleotide sequences were compared to 
those available in the GenBank database using the BLAST web-based software 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
The genetic relationship of the two morphologically distinct colonies was investigated 
by repetitive extragenic palindromic-PCR (rep-PCR), using the primer BOXA1R (5'-CTA 
CGGCAAGGCGACGCTGACG-3') and the two ERIC primers ERIC1R (5'-
ATGTAAGCTCCTGGGGATTCAC-3') and ERIC2 (5'-AAGTAAGTGACTGGGGTGAGCG-3') 
(Rademaker and DeBruijn, 1997). Each BOX or ERIC reaction was performed in a final 
volume of 25µl containing 1.5 mM MgCl2, 200 µM dNTP’s, 1X Green GoTaq® buffer and 
0.25 U of GoTaq® Buffer (Promega) and 0.6 pmol/µL of BOXA1R or 0.3 pmol/µL of each 
ERIC primer. 1 µL of a bacterial suspension prepared as abovementioned was used as 
DNA template to the PCR reaction. The amplification parameters were as follows: 94 ºC for 
5 min, 35 cycles of 94 ºC for 30 sec, 50 ºC for 30 sec and 72 ºC for 8 min and a final 
extension step of 10 min at 72 ºC. The amplicons were separated in a 1 % agarose gel in 1x 
Tris-acetate-EDTA buffer (Bio-Rad) at a constant voltage of 100 V.  
 
 
3.4.3 Monitoring of bacterial growth and spore production 
The monitoring of cell growth was performed in medium M and TSB at 37 ºC. A pre-
culture with approximately 16 hours of growth was always prepared. 1/100 volume of this 
pre-culture was used to inoculate fresh medium followed by incubation for 44 hours at 
160 rpm. Every 4 hours, aliquots were withdrawn from this culture and used to determine 
the total number of viable cells, to measure the bacterial density at OD600nm and for the 
evaluation of spores’ production. The total viable counts were obtained by successively 
diluting the culture in 1X PBS buffer (final volume of 1 mL) and plating each dilution in agar 
plates of the corresponding culture medium (either TSB or Medium M). After 18 hours of 
incubation at 37 ºC the total number of colonies was calculated and expressed in terms of 
CFU/mL. Spores production was estimated by incubation of 100 µL of the bacterial culture 
at 80 ºC for 20 min (Berditsch et al., 2007). Successive dilutions of this suspension were 
performed in cold 1X PBS buffer and 50 µL of each dilution were platted on TSB or 
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medium M agar plates. After 18 hours of incubation at 37 ºC the colonies present in each 
plate were enumerated and assumed to originate from the germination of a single spore. 
 
3.4.4 Antagonistic activity monitoring 
From samples collected at different time intervals, the bacterial cells were separated 
from the supernatant by centrifugation of 1 mL of the culture at 13,500 x g for 5 min. The 
obtained supernatant was centrifuged again, in the same conditions, to remove any 
vestigial cells. The culture supernatant was transferred to a new microcentrifuge tube and 
stored at -20 ºC. The pelleted cells were dissolved in 100 µL of a 70 % solution of 
isopropanol, incubated at 4 ºC for 3 hours and centrifuged at 13,500 x g for 5 min. The 
obtained supernatant constituted the cell-wall wash, which was transferred to a clean 
microcentrifuge tube and stored at -20ºC. 30 µL of the supernatant and cell wall washes 
fraction were applied to bioassay plates to test their antagonistic activity. 
 
3.4.5 Lichenicidin production evaluation 
For lichenicidin production evaluation by LC-ESI-MS a pre-culture of each strain was 
performed in the appropriate medium and allowed to grow at 37 ºC, with aeration for 
approximately 16 hours. 500 µL of these cultures were used to inoculate 50 mL of fresh 
medium (either medium M or TSB) and grown at 37 ºC with aeration (160 rpm) for 20 hours. 
Total extracts were obtained by the addition of 5 mL of 1-Butanol (Merck) to 20 mL of each 
culture. The solution was sonicated for 15 min, stirred for 1 hour at room temperature and 
finally centrifuged at 5,000 x g for 5 min. The upper organic phase was collected and its 
solvent subsequently evaporated at 50 ºC for 16 hours in an evaporator EZ2-Standard 
(GeneVac). The pellet was dissolved in 1 mL of 50 % acetonitrile before LC-ESI-MS analysis.  
 
 
3.4.6 Total protein analysis 
B. licheniformis I89 strains were grown either in medium M or TSB as previously described 
(section 3.4.3) for 10 hours. 1 mL of culture was centrifuged for 5 min at 12,000 x g with 
refrigeration of 4 ºC. The supernatant was taken out and the pellet centrifuged again in 
the same conditions for 1 min to completely remove the remaining supernatant and the 
pellet was store at -80 ºC until further use. This procedure was performed in triplicate for 
each cultivation medium tested. 
Each pellet was dissolved in 100 µL of ice cold 1X PBS and sonicated in a cold water bath 
5 times for 10 sec with intervals of 10 sec. The protein sample was mixed with the 5X 
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sampling buffer in a proportion of 4:1 (v/v). The mixture was boiled in water for 10 min and 
10 µL of each sample was loaded into the gel. The glycine-SDS-PAGE protocol herein 
described was adapted from Laemmli (1970). Briefly, the polyacrylamide gels used were 
prepared as described in Table 5. The running buffer (1X) was added to the anode and 
cathode electrodes and the samples were loaded. The electrophoresis was started with 
an initial voltage of 30 V until the samples entered completely into the stacking gel and 
changed to 100 V until the blue dye front reached the bottom of the gel. Proteins were 
visualized directly in the gels by Comassie staining. In this procedure, the gels were 
incubated in 100 mL of Fixing Solution for 15 min with gentle shake. Subsequently, the gels 
were washed with distilled water 5 times over a period of 1 hour, with gentle shaking 
between washes. Finally, 100 mL of the Staining Solution was added and the gels were 
incubated at room temperature with agitation until visible protein bands appeared 
(approximately 30 min). For better results the gels were left in distilled water overnight with 
gentle shaking before image acquisition.  
 
Table 5: Reagents used for the preparation of monomer solutions of the gels used in this section. APS stands for 
ammonium persulphate and TEMED for N,N,N',N'-tetramethylethylenediamine. These two compounds should be 
added immediately prior to pouring the gel. 
Solutions/Reagents Stacking gel 
(4 %) 
Separating gel 
(15 %) 
AB-3  (mL) 0.67 7.5 
1.5 M Tris-HCl pH 8.8 (mL) - 3.75 
0.5 M Tris-HCl pH 6.8 (mL) 1.25 - 
20% SDS (µL) 25 75 
10% APS (µL) 25 75 
TEMED (µL) 5 10 
Distilled water (mL) 3.07 3.6 
Total volume (mL) 5 15 
 
 
 
Solutions 
5X sampling buffer: 10 %SDS, 10mM β-mercapto-ethanol, 20 % glycerol, 0.2 M Tris-HCl [pH 6.8], 0.05% 
bromophenolblue) 
AB-3 solution: Dissolve 48 g of acrylamide and 1.5 g of bisacrylamide in 100 mL of distilled water. 
1X Running buffer: 25 mM Tris-HCl, 200 mM glycine, 0.1% (w/v) SDS, pH 8.0 . 
Fixing Solution: 200 mL of 40% ethanol and 50 mL of 10% of acid acetic, in a final volume of 250 mL. 
Staining Solution: 4 mL of stock dye solution, 8 mL of phosphoric acid and 3.75 mL of ethanol, in a final volume of 
100 mL. 
Stock dye solution: 0.33 g of Comassie Blue G powder diluted in 100 mL of a phosphoric acid:ethanol (2:1) 
solution. The solution should be stored in a brown bottle and stored in the dark. 
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3.4.7 Mass spectrometry analysis and antagonistic activity 
The samples were subjected to LC-ESI-MS analysis as described in section 2.4.6 (page 
60). When required the antibacterial activity assays were performed according to section 
2.4.8 (page 61). 
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4.1 Introduction 
 
 
 
 
 
acillus licheniformis is a Gram-positive microorganism commonly found in soil, 
which belongs to the B. subtilis group. Members of this genus have been 
described as producers of biotechnologically important compounds such as 
proteases, amylases, antibiotics and surfactants. The produced antimicrobial compounds 
include predominantly peptides that are either nonribosomally or ribosomally synthesized 
(Stein, 2005).  
Lantibiotics are ribosomally synthesized as inactive prepropeptides which are post-
translationally modified to their biologically active forms (Chatterjee et al., 2005). The 
common structural feature of lantibiotics is the unusual amino acids lanthionine (Lan) 
and/or methyllanthionine (MeLan). Specific Ser and Thr residues are the precursors to 
enzymatic dehydration to yield 2,3-didehydroalanine (Dha) and 2,3-didehydrobutyrine 
(Dhb), respectively. Subsequently, Dha and Dhb form a thioether with thiol side chains of 
Cys via a Michael addition-type to yield Lan and MeLan, respectively (Willey and van der 
Donk, 2007). These post-translational modifications occur in the C-terminal region of the 
prepropeptide, while the unmodified N-terminal region (leader sequence) is proteolytically 
removed to yield the active lantibiotic (Chatterjee et al., 2005).  
Lantibiotics can be classified based on their maturation pathway and antimicrobial 
activity (Pag and Sahl, 2002; Willey and van der Donk, 2007). The release of B. licheniformis 
ATCC 14760 (isogenic to DSM13) genome (Rey et al., 2004; Veith et al., 2004) in 2004 
allowed the identification of a putative lantibiotic gene cluster, which was recently 
associated with the lichenicidin production (Begley et al., 2009; Dischinger et al., 2009). 
Moreover and as established in chapter II, B. licheniformis I89 also produces such 
lantibiotic. According to a previously suggested classification (Willey and van der Donk, 
B 
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2007), lichenicidin is a two-component lantibiotic, a subgroup of antibacterial class II 
lantibiotics. In two-component lantibiotics, two different structural genes (lanA1 and 
lanA2) are expressed and subsequently modified by two different LanM proteins (LanM1 
and LanM2). After post-translational modification both peptides are exported and their 
leader sequences removed by a single, multifunctional protein possessing an N-terminal 
protease domain designated LanT. Some of these compounds might undergo an 
additional N-terminal proteolytic step presumably by the action of an extracellular 
protease. 
Generally, α- and β-peptides of two-component lantibiotics act synergistically to exert 
their full antibacterial activity. Presently, this group includes eight lantibiotics including 
haloduracin and lacticin 3147 (Ryan et al., 1996; McClerren et al., 2006; Lawton et al., 
2007). The lichenicidin complex is active against methicillin-resistant Staphylococcus 
aureus (MRSA) and Listeria monocytogenes (Begley et al., 2009; Dischinger et al., 2009). It is 
believed that two-component lantibiotics mechanism of action involves the interaction of 
both peptides through the binding to lipid II and formation of pores in the bacterial 
membrane (Oman and van der Donk, 2009b; Schneider and Sahl, 2010).  
Apart from their antibacterial activity, other interesting bioactivities have recently been 
described for lantibiotics, e.g. type III lantibiotics possess antipain activity in a neuropathic 
pain mouse model (Meindl et al., 2010). Consequently, during the last years, the 
evaluation of lantibiotic structure-activity relationships has increased, since the information 
retrieved can be further used in the rational design of new molecules with improved 
activity (Cortes et al., 2009). Such studies, using site-directed mutagenesis, have already 
been conducted in vivo for lacticin 3147 peptides (Cotter et al., 2006a) and in vitro for 
haloduracin (Cooper et al., 2008). This approach was also useful for the revision of the 
proposed structure of the haloduracin β-peptide (Cooper et al., 2008). Moreover, a 
saturation mutagenesis library of mersacidin was recently constructed yielding the 
production of 82 new compounds in which some of them demonstrated improved activity 
against Gram-positive pathogens (Appleyard et al., 2009).  
In this chapter, we report the first heterologous expression of a type-II two-component 
lantibiotic gene cluster in E. coli at the example of lichenicidin from B. licheniformis I89. 
Apart from immunity and regulation associated genes the functions of predicted open 
reading frames in the cluster were assigned. Finally, in E. coli a trans complementation 
system was established and new lichenicidin variants were generated, which allowed the 
assignment of essential residues for expression and antibiotic activity as well as the 
characterization of structural features previously proposed (Begley et al., 2009). This is the 
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first report on lantibiotic production in Gram-negatives, opening new perspectives for the 
biotechnological studies of these compounds. 
 
 
 
Figure 32: Proposed structures of Bliα and Bliβ peptides of the lichenicidin complex (A) and of the related 
lantibiotics haloduracin, lacticin 3147 and mersacidin (B). Non-dehydrated residues are represented in green and 
the highly conserved Glu residue in purple (Ala-S-Ala= lanthionine, Abu-S-Ala= methyllanthionine and OBu= 2-
oxobutyryl). 
 
 
4.2 Results 
4.2.1 Synthesis of the two-component lantibiotics Bliα and Bliβ by Bacillus 
licheniformis I89 
In the B. licheniformis ATCC 14760 genome a putative two-component lantibiotic gene 
cluster was identified (Rey et al., 2004). The products of the structural genes licA1 and licA2 
matched with the Bliα and Bliβ molecular masses assuming 7 and 12 dehydration reactions 
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of both propeptides. Both of these structural genes were also amplified from the 
B. licheniformis I89 bacterial genome. Recently, Begley et al. (2009) suggested that 
lichenicidin peptides (Bliα and Bliβ) production was encoded by this gene cluster (Figure 
34A). However, it was Dischinger et al. (2009) experimentally proved such biosynthetic 
association. In this study (chapter II) we also demonstrated that B. licheniformis I89 strain 
was also able to produce the Bliα (M= 3249.7 Da; calculated M= 3248.58 Da) and the Bliβ 
(M= 3019.6 Da; calculated M= 3018.38 Da) peptides (Figure 33).  
 
 
 
Figure 33: ESI-TOF mass spectra of Bliα (M=3249.54 Da) and Bliβ (M=3019.38 Da) peptides detected in 
B. licheniformis I89 supernatant (A) and cell (B) extracts. licA1 and licA2 gene inactivated mutants in Lic5ΔA1 and 
Lic5ΔA2 resulted in the production of only Bliβ (C) and Bliα (D), respectively. 
 
 
4.2.2 Heterologous expression of lichenicidin in Escherichia coli 
B. licheniformis I89 exhibited low transformation efficiencies, probably due to class-I 
restriction modification systems previously identified in B. licheniformis DSM13 (Rey et al., 
2004; Veith et al., 2004). This is a severe impediment for the molecular biology procedures 
necessary for gene function analysis and also for rapid access to mutant strains. Thus, 
heterologous expression of lichenicidin was attempted in the Gram-negative host 
Escherichia coli. To access the complete gene cluster in a vector, a fosmid library of B. 
licheniformis I89 genomic DNA was constructed in E. coli EPI300 and screened with a DIG-
labelled DNA probe encoding the lichenicidin structural genes licA1 and licA2. Five 
positive clones (Lic5, Lic7, Lic8, Lic10 and Lic45) were identified, containing the lic gene 
cluster (approximately 14 Kb) (Figure 34A). All the clones inhibited the growth of M. luteus 
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and therefore one clone (Lic5) containing the fosmid pLic5 (Figure 34B) was selected as 
lichenicidin heterologous expression system.  
 
 
 
Figure 34: Organization of the lichenicidin biosynthetic gene cluster, according to the genome annotation for 
Bacillus licheniformis ATCC 14760 (A); the black circles correspond to deduced Rho-dependent terminators. 
Representation of the pLic5 fosmid map, containing the lichenicidin biosynthetic gene cluster (B). 
 
 
Lichenicidin production by Lic5 was evaluated along 36 hours in liquid cultures. LC-ESI-
MS analysis of both cell isopropanol washes and supernatant extracts after 24 hours of 
growth revealed the presence of peptides with molecular masses corresponding to Bliα 
and Bliβ. The exiting observation of successful heterologous expression of the lic cluster in a 
Gram-negative organism required closer consideration and experimental proof. Hence, 
detection of Bliα and Bliβ observed in E. coli supernatants could either be explained by 
bacterial lysis of the producing strain or by active export through the outer membrane. 
Since growth behaviour of E. coli carrying the lic gene cluster was not conspicuous the 
latter hypothesis was investigated, analyzing the influence of TolC, an outer membrane 
protein commonly involved in the export of toxins on lichenicidin production. Therefore, 
E. coli BW25113 possessing a deletion of the tolC gene was transformed with the fosmid 
pLic5 carrying the lic cluster. The resulting E. coli BW25113ΔtolC:kan-pLic5 strain did not 
show antibacterial activity against the indicator strain M. luteus (Figure 35) and the 
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molecular masses of Bliα and Bliβ were not detected by LC-ESI-MS analysis of supernatant 
extracts. Trans complementation of this strain with tolC resulted in restoration of 
antibacterial activity (Figure 35). This was further corroborated by detection of 
characteristic masses of Bliα and Bliβ by means of HPLC-ESI-MS from supernatant extracts.  
 
 
 
Figure 35: Colony bioassay of E. coli BW25113 (A) and BW25113ΔtolC:kan (B) possessing the fosmid pLic5. trans-
complementation of E. coli BW25113ΔtolC:kan strain with tolC gene resulted in the reestablishment of activity (C). 
 
 
4.2.3 Mutagenesis of the lichenicidin biosynthetic cluster 
The lic biosynthetic gene cluster (Figure 34A) is composed of 14 open reading frames 
(ORFs). Expression of these genes in E. coli Lic5 further permitted the construction of gene-
inactivated mutants using the λ RED recombinase system (Datsenko and Wanner, 2000; 
Gust et al., 2003). To that end, the fosmid pLic5 was introduced into BW25113 cells 
containing the RED recombinase expression plasmid pKD20 (Datsenko and Wanner, 2000). 
The transformed strain was used as a platform for the inactivation of all ORFs of the lic 
cluster, except those presumably associated with self-immunity. In total, nine fosmids were 
constructed, each of them containing the deletion of one gene in BW25113 cells and 
transformed into EPI300 cells (Table 6). Overall, the expression of eight ORFs was found to 
be critical for lichenicidin production (Figure 36A). Only the Lic5ΔX knockout mutant 
retained visible antibacterial activity against the indicator strain M. luteus (Figure 36A).  
According to previous studies on two-component lantibiotics, it was expected that the 
single production of either Bliα or Bliβ would result in significantly reduced antibacterial 
activity. Consequently, the loss of activity by mutational inactivation of lic genes could 
result from the absence of production of both or only one of the lichenicidin peptides. If 
the second assumption was correct, antibacterial activity should be restored if the 
complementing peptide could be externally supplied by cross-feeding. Indeed, this was 
observed when the two strains missing the respective intact structural genes (Lic5ΔA1 and 
Lic5ΔA2) were bioassayed as neighbouring colonies (Figure 36B). Moreover, no M. luteus 
inhibition was observed when Lic5ΔA1 mutant was inoculated next to Lic5ΔA1, or Lic5ΔA2 
next to Lic5ΔA2. LC-ESI-MS analysis of both clones revealed that Lic5ΔA1 synthesized 
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exclusively the Bliβ peptide and Lic5ΔA2 synthesized exclusively the Bliα peptide (Figure 
33C/D). These results showed that inhibition of M. luteus was a consequence of the 
synergistic activity of both peptides. Therefore, Lic5ΔA1 and Lic5ΔA2 were used in cross-
feeding agar-diffusion assays with the other knockout mutants. Full restoration of 
antibacterial activity was observed between the following combinations of knockout 
mutant pairs: Lic5ΔA1 with Lic5ΔM2, Lic5ΔP and Lic5ΔR; Lic5ΔA2 with Lic5ΔM1 and Lic5ΔY 
(Figure 36C). These results were predictive of peptide production in each knockout mutant 
and were unambiguously confirmed by LC-ESI-MS analysis (Table 6). 
 
 
 
Figure 36: Agar diffusion assay for the assessment of lichenicidin production by knockout mutants of the lic gene 
cluster with M. luteus as the indicator strain. Lic5 gene inactivation mutants are represented by ΔA1, ΔA2, ΔM1, 
ΔM2, ΔT, ΔP, ΔX, ΔR and ΔY, according with the inactivated gene. (A) Antibacterial activity exhibited by all 
knockout mutants produced in this study. (B) Synergetic activity of peptides Bliα and Bliβ, produced by Lic5ΔA2 
and Lic5ΔA1, respectively. (C) Restored lichenicidin activity of the knockout mutants upon interaction with Bliβ 
and Bliα peptides produced by Lic5ΔA1 and Lic5ΔA2, respectively. 
 
 
LC-ESI-MS analysis of the mutants obtained from inactivation of dehydratase-cyclases 
Lic5ΔM1 and Lic5ΔM2, showed the same results as those obtained with the mutants of the 
structural genes Lic5ΔA1 and Lic5ΔA2, respectively. Molecular masses corresponding to 
propetides or prepropeptides were not detected.  
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Sequence homology studies identified LicT from the B. licheniformis I89 lic cluster as a 
member of the ABC transporter family with an integrated protease domain, presumably 
responsible for removal of the leader sequences of Bliα and Bliβ during substrate 
translocation. In E. coli, the inactivation of licT (Lic5ΔT) resulted in the loss of visible 
antibacterial activity, which was not restored by interaction with Lic5ΔA1 or Lic5ΔA2. 
Accordingly, molecular masses of Bliα and Bliβ peptides were not identified in the Lic5ΔT 
supernatant extracts by LC-ESI-MS. However, when isopropanol washes of Lic5ΔT cells were 
analyzed by LC-ESI-MS a peptide mass corresponding to fully processed Bliβ was identified, 
albeit in extremely low concentration. It is likely that isopropanol treatment of Lic5ΔT cells 
released Bliβ propeptide to interact with the protease LicP (active in this mutant), thus 
yielding correctly processed Bliβ peptide without the leader sequence.  
 
Table 6: List of Lic5 gene inactivation mutants constructed in this study and the assigned function of the deleted 
gene. The restoration of antibacterial activity observed in cross-feeding experiments is listed, considering Lic5ΔA1 
and Lic5ΔA2 as exclusive producers of Bliβ and Bliα peptides, respectively. A comparison between the expected 
and observed lichenicidin peptide molecular masses of each mutant was included. (ND = none of the peptides 
detected). *- The Bliβ peptide was only detected in the cell-wall washes. 
Peptide masses (Da) 
E. coli 
strains 
Gene deleted 
Restore 
of 
activity 
Expected 
molecular mass  
Observed 
molecular mass  
Lic5ΔM1 licM1, modifying enzyme of LicA1 peptide LicΔA2 3019.36 3019.60 
Lic5ΔA1 licA1, Bliα peptide structural gene  LicΔA2 3019.36 3019.60 
Lic5ΔA2 licM2, modifying enzyme of LicA2 peptide LicΔA1 3249.54 3249.50 
Lic5ΔM2 licM2, Bliβ peptide structural gene LicΔA1 3249.54 3249.50 
Lic5ΔT liciT, transporter and leader sequence 
proteolysis of LicA1 and LicA2 peptides 
ND ND 3019.60* 
Lic5ΔP licP, putative peptidase responsible for Bliβ 
N-terminal processing  
LicΔA1 3249.54 3249.50 
Lic5ΔX licX, unknown function LicΔA1 3019.36 and 
3249.54 
3019.60 and 
3249.50 
Lic5ΔR licR, putative lantibiotic regulator LicΔA2 3019.36 3019.60 
Lic5ΔY licY, unknown function LicΔA1 3249.54 3249.50 
 
 
The licX gene encodes a small-uncharacterized hypothetical protein with significant 
homology to other uncharacterized Bacillus sp. proteins. The absence of conserved core 
motifs in this protein makes it difficult to predict its function. When licX was inactivated, the 
antibacterial activity of Lic5ΔX was not affected and both peptides Bliα and Bliβ were 
identified in LC-ESI-MS analysis, indicating that LicX does not play an essential role in 
lichenicidin production.  
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Upstream of licX, two other genes, licR and licY, were identified. NCBI Conserved 
Domain Searches of the licR sequence revealed a high homology to helix–turn–helix XRE 
family-like proteins. After its deletion only Bliβ was identified by LC-ESI-MS analysis of Lic5ΔR 
extracts. This result demonstrates that LicR might have an essential regulatory function in 
the biosynthesis of mature LicA2 peptide. Finally, the Lic5ΔY mutant was identified as the 
only producer of the Bliα peptide. This proved an essential involvement of LicY in the 
biosynthesis of Bliβ but not in the biosynthesis of Bliα. Three transmembrane helices 
identified in LicY point to a likely role as a membrane protein. 
 
 
 
4.2.4 LicP, a protease involved in Bliβ  biosynthesis 
Bliα and Bliβ prepropeptides both have a common proteolytic site for LicT (C-terminal of 
the GlyGly-motif). The molecular mass of the processed Bliβ peptide affords additional 
proteolysis of an N-terminal hexapeptide of the Bliβ’ peptide (corresponding to H2N-
NDVNPE-Bliβ). Such second proteolysis step has been described for other two-component 
lantibiotics, e.g. Halβ, Plwβ, CylLL and CylLS (Booth et al., 1996; Holo et al., 2001; McClerren 
et al., 2006). In the lic gene cluster, licP encodes a putative uncharacterized serine 
protease homologous to CylA (38% identity) from Enterococcus faecalis (CylLL and CylLS 
producer) and to BH1491 uncharacterized protease (30% identity) from B. halodurans C-
125 (Halβ producer). Therefore, it was considered that LicP could be the protease post-
operative to LicT responsible for the removal of the hexapeptide NDVNPE from Bliβ’. In 
fact, when licP was deleted only the production of Bliβ was negatively affected. The E. coli 
Lic5ΔP mutant lost antibacterial activity, which could be restored upon cross feeding with 
a mutant delivering correctly processed Bliβ peptide e.g. mutant Lic5ΔA1 (Figure 36C). 
Hence, in Lic5ΔP isopropanol washes of cells and supernatant extracts only the molecular 
mass of the Bliα was identified. Molecular masses corresponding to the N-terminally 
untrimmed Bliβ peptide (calculated M=3686.65 Da) or those of its derivatives could not be 
identified. However, when E. coli Lic5ΔP cell and supernatant extracts where bioassayed 
next to filter-sterilized supernatants of an E. coli strain solely expressing LicP (BL21 licP+), the 
reestablishment of antibacterial activity was observed (Figure 37). This indicated that fully 
active Bliβ was produced in situ and could act synergistically with the Bliα peptide.  
 
 
Chapter IV 
 92 
 
Figure 37: Cell isopropanol washes and supernatant butanol extracts of the knockout mutant Lic5ΔP were 
assayed side by side with the cell-free supernatants of BL21licP+ and BL21licP-. BL21licP+ corresponds to the E. coli 
strain expressing exclusively LicP protein. BL21licP- corresponds to the E. coli control strain harboring the empty 
pET24-a(+) vector. Inhibition of M. luteus is observed exclusively when Lic5ΔP extracts are in contact with the 
supernatant of BL21licP+ strain. 
 
 
 
4.2.5 A complementation system for expression of lichenicidin peptide 
derivatives in E. coli 
The construction of a system enabling generation of lichenicidin variants was 
developed, due to its usefulness for both structure-activity relationship (SAR) analysis and 
structure elucidation purposes. To that end, E. coli BL21Gold® producing exclusively one of 
the proprepeptides were obtained by transformation of these cells with pLic5ΔA1 or 
pLic5ΔA2 fosmids, generating BLic5ΔA1 and BLic5ΔA2 strains, respectively. These strains 
were complemented with the respective deleted genes (licA1 and licA2) cloned into the 
expression vector pET-24a(+). The resulting transformants BLic5ΔA1+ (BLic5ΔA1+plicA1) and 
BLic5ΔA2+ (BLic5ΔA2+plicA2) were able to inhibit the indicator strain and the molecular 
masses of both Bliα and Bliβ by LC-ESI-MS were successfully identified. Therefore, this system 
was further exploited by PCR site-directed mutagenesis of plicA1 and plicA2 in order to 
obtain E. coli strains producing Bliα and Bliβ variants. During this procedure, only one of the 
lichenicidin peptides was mutated at each time, facilitating an exact assignment of the 
impact of the introduced alteration also in production and/or bioactivity. It was 
attempted to generate 32 lichenicidin variants, which molecular masses are summarized 
in Table 7. 
In this study a systematic Ala scan was performed for all Cys, Ser and Thr residues of Bliα 
and Bliβ. Especially C-terminal substitutions of residues BliαThr24, BliβThr25, BliβCys28 and 
BliβThr29A did not yield the corresponding mutant peptide (HPLC-ESI-MS control) and 
consequently no bioactivity was observed (Figure 38). All other lichenicidin variants were 
synthesized although to a different extent. Some of the peptides variants were produced 
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in low amounts and therefore were not used in bioactivity assays (Figure 38). Peptides that 
were produced in amounts comparable to the wild type (HPLC-ESI-MS control) were 
correlated to bioactivity in agar diffusion tests. Overall, the changes introduced at the N-
terminus of Bliα and Bliβ seem to be less prejudicial for lichenicidin bioactivity and/or for 
peptide production than those at the C-terminus (Figure 38).  
 
 
Table 7: List of molecular masses obtained for alanine-scan mutants. Monoisotopic molecular masses detected 
by high-resolving ESI-TOF-MS in supernatant extracts of Bliα and Bliβ alanine-scan mutants. “Expected 1” represent 
the exact masses calculated based in previously proposed structures (Begley et al., 2009). “Expected 2” 
represents the lichenicidin exact masses accordingly with the structure proposed in this study. ND represents 
bioengineered peptides that were not detected by LC-ESI-MS analysis.  
Molecular mass (Da) Molecular mass (Da) Bliα 
peptides Expected 
1 
Expected 
2 
Observed 
 Bliβ 
peptides Expected 
1 
Expected 
2 
Observed 
Bliα  3248.53 3249.52 3249.54  Bliβ  3018.38 3019.36 3019.38 
BliαT1A 3236.53 3236.53 3236.56  BliβT1A 3006.38 3006.38 3006.42 
BliαT3A 3236.53 3237.52 3235.56  BliβT2A 3006.38 3007.36 3007.40 
BliαS5A 3250.55 3251.53 3251.58  BliβT5A 3006.38 3007.36 3007.40 
BliαT6A 3236.53 3237.52 3237.54  BliβT6A 3006.38 3007.36 3007.40 
BliαC7A 3216.56 3217.54 3217.58  BliβS7A 3020.39 3021.38 3021.42 
BliαS11A 3250.55 3251.53 3251.56  BliβS8A 3020.39 3021.38 3021.42 
BliαC21A 3216.56 3217.54 3217.58  BliβT10A 3006.38 2989.35 2989.20 
BliαT22A 3236.53 3237.52 3235.56  BliβC11A 2986.40 2987.39 2987.42 
BliαT24A 3236.53 3237.52 ND  BliβT13A 3006.38 3007.36 3007.40 
BliαE26A 3190.53 3191.51 3191.54  BliβT17A 3006.38 3007.36 3007.40 
BliαC27A 3216.56 3217.54 3217.59  BliβS19A 3020.39 3021.38 3021.42 
BliαS30A 3232.54 3233.52 3233.58  BliβS21A 3002.38 3003.37 3003.32 
BliαC31A 3216.56 3217.54 3217.59  BliβC23A 2986.40 2987.39 2987.48 
     BliβT25A 3006.38 3007.36 ND 
     BliβT26A 2988.37 3007.36 3007.40 
     BliβC28A 2986.40 2987.39 ND 
     BliβT29A 3006.38 3007.36 ND 
     BliβS30A 3002.38 3003.37 3003.40 
     BliβC32A 2986.40 2987.39 2987.60 
 
 
Homology studies of mersacidin-like two-component lantibiotics revealed the presence 
of a highly conserved glutamate (Glu17; Figure 32). Its substitution in mersacidin, Halα and 
Ltcα completely abolished antibacterial activity (Cotter et al., 2006a; Cooper et al., 2008; 
Appleyard et al., 2009). For mersacidin it was proved that Glu17 is essential for binding to 
the lipid II target (Brotz et al., 1998; Hsu et al., 2003; Szekat et al., 2003). In the case of 
lichenicidin Bliα, the substitution of homologous Glu26 by Ala yielded the expected 
peptide (M= 3191.54 Da), however antibacterial activity of BliαE26A was completely 
abolished. 
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Figure 38: Supernatant extracts activity (AU.ml-1) of Bliα (A) and Bliβ (B) alanine-scan mutants against M. luteus. 
Control strains represent the mutants BLicΔA1 and BLicΔA2, complemented with plicA1 (A) and plicA2 (B). The 
primary amino acid sequence and thioether rings of Bliα and Bliβ are represented underneath the bioactivity 
results, accordingly with the results obtained in this study (OBu = 2-oxobutyryl). Non-producer (NP) strains or low-
producer (LA) strains of mutated peptides were not integrated in the bioassay. 
 
 
 
4.2.6 Localization of the N-terminal lanthionine bridges of Bliα  and Bliβ  
The determined exact molecular masses of Bliα and Bliβ peptides (M= 3249.54 Da and 
M= 3019.6 Da, respectively) differ from the calculated masses by +1 Da, suggesting that a 
2-oxobutyryl residue could be present at the N-terminus of both peptides. This hypothesis 
was also supported by mutant peptides of Bliα and Bliβ possessing an N-terminal Thr→Ala 
replacement thus retaining a conventional N-terminus (BliαT1A: M= 3236.52 Da and BliβT1A: 
M= 3006.36 Da) and bioactivity. Hence, establishment of N-terminal A-rings of Bliα and Bliβ 
between Dhb1 and Cys7 (Bliα) and Dhb1 and Cys11 (Bliβ) seemed less likely, contrary to 
data previously proposed by (Begley et al., 2009). MS/MS analysis of the Bliα peptide from 
B. licheniformis I89 (Figure 39) and E. coli BLic5 supernatants showed the presence of the N-
terminal ions a3 and b3, excluding the possibility of A-ring formation between Cys7 and 
Dhb1 or Dhb3. Instead, either Dha5 or Dhb6 were candidates for A-ring formation with 
Cys7. This question was further investigated by MS/MS experiments of Bliα peptides 
containing an Ala5 (BliαS5A mutant) or Thr6 (BliαT6A mutant) (Figure 40).  
The identification of the y26 ion for BliαS5A but not for BliαT6A supports a Bliα structure 
with an A-ring between Dha5 and Cys7 (Figure 32A, Figure 40). The MS/MS spectra of the 
Bliβ peptide from B. licheniformis I89 (Figure 39) and E. coli BLic5 supernatant permitted the 
identification of a series of fragment ions (a2, b2, a3, b3, b5, b6, y27 and y26), suggesting that 
only Dha7 or Dhb8 were likely to be involved in A-ring formation with Cys11. The analysis of 
the bioactivity of the peptides possessing an Ala residue instead of Dhb2, Dhb5, Dhb6, 
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Dha7 and Dha8 suggests that Dha7 should be the residue reacting with Cys11 of Bliβ 
peptide (Figure 32A and Figure 38).  
 
 
 
 
 
Figure 39: ESI-MS/MS spectra of Bliα (A) and Bliβ (B) purified from the B. licheniformis I89 supernatant and assigned 
fragmentation pattern of lichenicidin peptides. 
 
 
Chapter IV 
 96 
 
Figure 40: ESI-MS/MS spectra (Agilent Triple Quad 6460) of BliαS5A (A) and BliαT6A (B) peptide mutants. 
 
 
 
4.2.7 Localization of 2,3-didehydro amino acids in the structures of Bliα  and 
Bliβ  peptides 
The found molecular masses of Bliα and Bliβ peptides are consistent with the post-
translational dehydration of seven and twelve Ser/Thr residues, respectively. Therefore, one 
and three Ser/Thr should escape the action of the dehydratase-cyclases LicM1 and LicM2, 
respectively. These residues were proposed to be Ser30 of Bliα and Ser21, Thr26 and Ser30 
of Bliβ (Begley et al., 2009). To confirm this assumption experimentally, these four residues 
were mutated to Ala. Analysis of the BliαS30A mutant revealed the presence of a seven-
fold dehydrated peptide (M= 3233.58 Da). Therefore, Ser30 from Bliα escapes 
dehydratation. The same analysis for Bliβ mutants BliβS21A and BliβS30A revealed products 
with molecular masses corresponding to the expected twelve dehydratations (M= 3003.40 
Da). Therefore, LicM2 does not modify Ser21 and Ser30. However, the peptide produced 
by BliβT26A mutant (M= 3007.40 Da) was consistent with the occurrence of only eleven, 
instead of the proposed twelve dehydratations (calculated M= 2989.37 Da) (Begley et al., 
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2009). The substitution of Thr10Ala resulted in the synthesis of a twelve-fold dehydrated 
peptide (M= 2989.72 Da; Figure 41 and Table 7). Thus, Thr10 is the candidate amino acid 
escaping LicM2 dehydration and this finding was also included in the Bliβ structure (Figure 
32A). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41: ESI-TOF-mass spectra of mutants LicA2T10A 
(M=2989.20 Da) and LicA2T26A (M=3007.40 Da), showing 
the modification of Thr26 by LicM2. Peptides 
corresponding to different stages of dehydration were 
also identified. 
 
 
 
4.3 Discussion 
In the light of recent developments in the field of lantibiotic biosynthesis, the role of 
lantibiotics for use as antimicrobials is newly weighted. This is supported by observations 
that when compared to other commonly used antibacterials the development of 
resistance is believed to be extremely low. Lichenicidin is a two-component lantibiotic (Bliα 
and Bliβ) produced by B. licheniformis. Recently, two independent studies assigned its 
production to a biosynthetic gene cluster encoded in B. licheniformis ATCC 14760 and 
DSM13 (Begley et al., 2009; Dischinger et al., 2009). Although not recognized at that time, 
Bliα production was also reported by Mendo and coworkers in B. licheniformis I89 
supernatant extracts (Mendo et al., 2004). Herein, lichenicidin peptides Bliα and Bliβ were 
detected in cell washes and supernatant extracts of this strain. Thus, in the I89 strain this 
lantibiotic is not exclusively cell wall-associated as it has been described for other strains of 
this specie (Begley et al., 2009; Dischinger et al., 2009).  
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B. licheniformis I89 was not amenable to transformation and therefore heterologous 
expression of lichenicidin was attempted in E. coli. This Gram-negative organism is a 
preferred heterologous expression host with respect to genetic manipulation, handling 
cost and time considerations. The presence of the fosmid pLic5 harboring the complete 
lichenicidin gene cluster in E. coli (Lic5) resulted in a strain able to inhibit M. luteus growth. 
Characteristic molecular masses of fully modified Bliα and Bliβ peptides were detected by 
LC-ESI-MS in E. coli Lic5 cell washes (isopropanol) and supernatant extracts. In the past, the 
heterologous production of lantibiotics in E. coli hosts was unknown. Recently, first steps 
into this direction where undertaken by the co-expression of proprepeptide and the 
corresponding modifying enzyme in E. coli, which achieved establishment of the fully 
dehydrated lantibiotic BovHJ50 (Lin et al., 2010). However, its biologically active form was 
only obtained after in vitro incubation with a specific protease (BovT150) to remove the 
leader sequence. In contrast, herein we obtained a full reconstitution of the in vivo 
synthesis of a lantibiotic in a Gram-negative host. Moreover, heterologous expression of 
the lic cluster in a tolC-deficient E. coli strain revealed the absence of Bliα and Bliβ 
peptides in supernatant extracts. This supported the assumption that TolC and/or TolC-
related proteins are likely candidates for the transport of Bliα and Bliβ through the outer 
membrane, which was further corroborated by restoration of lichenicidin activity upon 
tolC trans-complementation. 
The lichenicidin gene cluster consists of 14 ORFs and in the past, only the expression of 
licM1 and licM2 genes was associated with lichenicidin production (Dischinger et al., 
2009). Therefore, λ RED recombinase technology was employed to inactivate all lic genes 
in the pLic5 fosmid, except those putatively related with immunity. Our results showed that 
licA1 and licA2 encode the lichenicidin proprepeptides, which are post-translationally 
modified by bifunctional dehydratases-cyclases LicM1 and LicM2, respectively. In the 
absence of LicT (E. coli Lic5ΔT), it was not possible to detect the fully processed Bliα and 
Bliβ peptides in supernatant extracts, indicating that LicT protein plays an essential role in 
the maturation of both peptides. LicT protein is a member of the ABC transporter family 
with an integrated protease domain, apparently responsible for the removal of the leader 
sequences of Bliα and Bliβ during their transport. E. coli proteases and toxins are often 
exported directly from the cytoplasm to the supernatant by a sec-independent type I 
secretion system (T1S). T1S affords the presence of an ABC transporter, a membrane fusion 
protein (MFP) and an outer membrane protein (OMP; e.g. TolC) (Kostakioti et al., 2005). 
Considering this system, it could be hypothesized that LicT located in the inner membrane 
is able to closely interact with MFP and TolC (or TolC-related protein) of E. coli, forming a 
T1S-complex responsible for leader peptide removal and export of Bliα and Bliβ. It is also 
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conceivable, that LicT removes the leader peptides and transports Bliα and Bliβ to the 
periplasmatic space followed by TolC-mediated export without any interaction between 
LicT and TolC. Alternatively, Bliα and Bliβ could be exported by inner and outer membrane 
transporters provided by the E. coli host. Then LicT would only contribute a proteolytic 
function required for leader peptide removal. Nevertheless, these hypotheses have to be 
further evaluated experimentally in order to establish a comprehensive model for 
lantibiotics secretion in Gram-negative hosts. 
LicP is a serine protease homologous to the extracellular protease CylA (38% identity) 
which is responsible for the N-terminal trimming of cytolysin peptides CylLL and CylLS, after 
their export (Booth et al., 1996). In this study, LicP was also shown to be a protease involved 
exclusively in Bliβ maturation, by excising the N-terminal hexapeptide from NDVNPE-Bliβ. 
Moreover, LicP was present in the supernatants of an E. coli strain expressing exclusively this 
protease. The analogous function in Halβ peptide maturation was previously proved in 
vitro in studies performed with an undetermined protease present in supernatants of B. 
halodurans C-125 (Cooper et al., 2008). The detection of Bliβ peptide in LicΔT isopropanol 
cell washes, albeit in extremely low amounts, suggests that LicP proteolysis also can occur 
in the presence of the full leader sequence.  
The LicX sequence is similar to other uncharacterized hypothetical proteins of the 
Bacillus genus and no conserved motifs could be identified, making it difficult to predict its 
function. Yet, we could establish that LicX is not involved in the Bliα and Bliβ biosynthesis or 
its function could be complemented when using E. coli as the heterologous host. LicR is a 
predicted DNA-binding protein with high similarity (60 %) to other transcriptional regulators 
from Bacillus genus. The licR gene inactivation proved the exclusive involvement of LicR in 
Bliα production, most probably through the induction of licA1 transcription. Likewise, 
disruption of a similar gene, mrsR1 present in the mersacidin biosynthetic cluster strongly 
decreased its proprepeptide transcription rate resulting in the absence of MrsA production 
(Guder et al., 2002; Schmitz et al., 2006). Since Bliα and MrsA peptides are highly 
homologous (Figure 32) and are produced by Bacillus species, it seems possible that their 
regulation mechanisms have evolved from a common ancestor. The LicY protein has been 
found essential for production of the Bliβ peptide, but not for production of Bliα. LicY does 
not display significant similarities to other proteins available in databases, making it 
impossible to assign a functional role to this protein. Like CylR1 of the cytolysins (Coburn 
and Gilmore, 2003) the LicY secondary structure is predicted to contain three 
transmembrane helices and a function as a membrane-bound protein seems likely. CylR1 
and CylR2 have been described as a two-component regulatory system, which represses 
the expression of cytolysin genes through a quorum-sensing mechanism (Haas et al., 2002). 
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Nevertheless, it is difficult to apply this model to the regulation of Bliβ expression, since it 
was not possible to identify a gene encoding DNA-binding protein within the lic 
biosynthetic cluster, which could be associated with Bliβ production. In this study, we 
assigned for the first time the association of two putative distinct regulatory elements to 
the production of one specific single peptide, Bliα or Bliβ, of the lichenicidin two-
component system. We hypothesize, that analogous mechanisms of regulation are 
involved in the biosynthesis of other two-component lantibiotics, e.g. of haloduracin. In 
fact, the proteins BH0460 and BH0459 encoded downstream of hal biosynthetic gene 
cluster show high homology to LicR (60 %) and LicY (61 %), respectively. Further studies 
examining gene cluster transcription and protein interaction will shed light on the 
assignment of the exact role of LicR and LicY on lichenicidin production. 
The successful heterologous expression of the lic gene cluster in E. coli facilitated the 
establishment of a system for the expression of lichenicidin variants. The peptides resulting 
from Ala substitutions and subsequent MS/MS analysis (of the wild type or mutated 
peptides) allowed the revision of some structural features of both Bliα and Bliβ previously 
proposed by (Begley et al., 2009). Compared to the structurally related two-component 
lantibiotics haloduracin and lacticin, the high number of serines and threonines in 
lichenicidin propeptide sequences, particularly at the N-termini, made a clear assignment 
of dehydrated residues difficult. The Ala-scan performed for all Ser- and Thr-containing 
positions confirmed that Ser30 escapes dehydration in Bliα and likewise, Thr10, Ser21 and 
Ser30 remain unmodified in the Bliβ peptide. Herein, it was established that LicM2 
dehydrates Thr26 of Bliβ, similarly to the homologous residue in Halβ (Dhb18), but in contrast 
to Lctβ (Thr23). The exact molecular masses obtained for Bliα and Bliβ exceed those of 
previously determined peptides by +1 Da, indicating that after proteolysis, a spontaneous 
deamination of Dhb1 to Obu1 occurs in both Bliα and Bliβ, as described for Pep5 and Lctβ 
peptides (Ryan et al., 1999). This is clearly supported by mass spectrometry of peptides 
BliαT1A and BliβT1A suggesting that Thr1 of both peptides is not involved in A ring formation. 
The fragmentation pattern of lichenicidin wild type peptides (Figure 39) rather indicates 
that thioether rings are formed between Ser5 or Thr6 with Cys7 (Bliα) and Ser7 or Ser8 with 
Cys11 (Bliβ). MS/MS spectra of BliαS5A and BliαT6A, identified Bliα Ser5 as the amino acid 
involved in the Bliα A-ring formation. For Bliβ the bioactivity of BliβS7A suggests that Ser7 is 
the residue for Lan formation with Cys11. Recently, the structure of lichenicidin peptides 
Lchα and Lchβ isolated from B. licheniformis VK21 were elucidated by NMR (Shenkarev et 
al., 2010). In general, the proposed structures are in agreement with the present work 
except for the A-ring of Bliα peptide. The MS/MS spectra obtained for Bliα of both B. 
licheniformis I89, B. licheniformis DSM13 and E. coli BLic5 exclude the occurrence of a 
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thioether ring between Thr3 and Cys7 due to the presence of an a3-ion. Therefore, Bliα and 
Lchα may represent natural variants of lanthionine formation. Yet there is no experimental 
evidence that minor differences in dehydratase-cyclase could generate a structural 
variability, however, cluster alignment of LicM1 from B. licheniformis I89 (HQ290360) and 
B. licheniformis VK21 showed the presence of a 6 amino acid difference between both 
modifying enzymes. 
Overall, 28 new lichenicidin variants were generated and expressed in E. coli, showing 
that the trans complementation system can be useful to generate other lichenicidin 
variants. As expected, bioactivity but also production was generally affected negatively 
when Lan or MeLan rings particularly located at the C-terminal were disturbed. These 
results are in accordance with those of lacticin 3147 in vivo SAR studies (Cotter et al., 
2006a). Moreover, the pattern of lanthionine rings (especially B, C and D rings) seems to be 
conserved among two-component lantibiotics, indicating their importance for the 
biological activity of these compounds. 
This study showed that Gram-negative hosts are principally able to synthesize fully 
bioactive lantibiotics. Based on this system, amenable and time-saving procedures were 
developed to investigate the influence of lic-encoded proteins in the lichenicidin 
biosynthesis pathway and to produce new variants of lantibiotic peptides. Thereby, the 
present study initiates a new era in lantibiotics biosynthesis and bioengineering research 
employing Gram-negative hosts.  
 
 
4.4 Experimental procedures 
4.4.1 Bacterial strains, plasmids, general growth and procedures 
Bacillus licheniformis I89 was grown at 37 ºC with aeration in lichenicidin production 
medium M (see section 2.4.1, page55). Escherichia coli BW25113 and plasmids pIJ790 and 
pIJ733 were kindly supplied by Professor Mervyn Bibb (John Innes Centre, Norwich, UK). 
E. coli DH5α (Stratagene) was used as cloning host for plasmid constructions. Expression of 
lichenicidin variants was performed in E. coli BL21Gold® (Stratagene). The plasmid pET-
24a(+) (Novagen) was the expression vector used for complementation studies and LanP 
expression and the plasmid pET15-b for the cloning of tolC gene. Fosmid pCC2FOS™ and 
E. coli EPI300™ (Epicentre) were the vector and host strain for the construction of 
B. licheniformis genomic library. M.luteus ATCC 9341 was the indicator strain for lichenicidin 
bioactivity. The properties of bacterial strains and plasmids used in this chapter are 
described in the Appendixes information. Also, the protocols for preparation of competent 
Chapter IV 
 102 
cells, transformation, PCR purification, plasmid extraction and DNA purification from gels 
are presented in the same section.  
Luria-Bertani (LB) medium was used for general liquid growth of E. coli strains, at 37 ºC or 
30 ºC with aeration. Routine antibiotic selection was performed in LB agar plates 
containing the respective antibiotic concentrations.  
 
 
4.4.2 Transformation of B. licheniformis I89 
4.4.2.1 Transformation of B. licheniformis I89 protoplasts 
The B. licheniformis I89 protoplasts transformation was carried out according with 
procedures described by (Cutting and Vander Horn, 1990; Waschkau et al., 2008). The 
strain B. licheniformis I89 was inoculated in 25 mL of NBSG-X medium and grown overnight 
at 37 ºC, 200 rpm. The culture was diluted to an OD600nm of 0.25 in 35 mL of the same 
medium and incubated in the same conditions until the OD600nm reached 0.85-0.9. At this 
stage, the culture was transferred to a 50 mL sterile falcon and centrifuged at 4 ºC, 
3220 x g for 15 min. The supernatant was discarded and the cells resuspended in 5 mL of 
SMMP solution supplemented with 0.30 mg/mL of lysozyme (prepared with SMMP; Roche). 
The mixture was incubated at 37 ºC at 90 rpm for 30 min and 12 mL of SMMP were added 
with gentle shaking. After centrifugation at 4 ºC, 420 x g for 12 min, the protoplasts were 
washed with 12 mL of SMMP solution and centrifuged again in the same conditions. The 
pellet was finally resuspended in 3 mL of SMMP solution and maintained on ice until the 
addition of plasmid DNA. The prepared protoplasts were transferred to a 1.5 mL sterile 
microcentrifuge tube containing a mixture of 25 µL of plasmid DNA (100 ng/µL) with 25 µL 
of 2x SMM solution. A 50 mL falcon was prepared with 1.6 mL of 40 % PEG 8000 (in 1x SMM) 
and the mixture of protoplasts-plasmid was transferred to it. After gently shaking at room 
temperature for 2 min, 5 mL of SMMP+ were added. The protoplasts were centrifuged at 
8 ºC at 420 x g for 8 min, gently resuspended in 1 mL of SMMP+ solution and incubated for 
2 hours at 30 ºC with aeration (100 rpm). Finally the same protoplasts were plated on three 
different agar plates, in duplicates. The agar plates included DM3 regeneration agar 
supplemented with chloramphenicol (Clo) at 25 µg/mL and without antibiotic and in LB 
agar. One duplicate was incubated at 30 ºC and the other at 37 ºC for 2 days. 
 
 
Solutions: 
Cryopreservation buffer: CaCl2 0.1 M, 15% (v/v) glycerol. 
NBSG-X medium: Mix 500 mL of solution A with 500 mL of solution B. Shortly before use add 0.5 mL FeCl3.6H2O 
(stock 8 mg/mL), 0.1 mL MnSO4.4H2O (stock 2.5 mg/mL) and 2 mL of glycerol (stock 250 mg/mL). 
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Solution A: 56 g K2HPO4, 24 g KH2PO4, 2 g (NH4)2SO4, pH 8 in a final volume of 500 mL. 
Solution B: 3 g beef extract, 5 g bacto peptone, 1.2 g MgSO4.7H2O, 6 g trisodium citrate.2H2O in a final volume of 
500 mL. 
SMMP solution: Mix equal volume of 2x SMM and 4x PAB. 
SMMP+ solution: 100 mL of SMMP with 0.2 mL of 20% (w/v) BSA (filter sterilized). 
2x SMM: 1 M sucrose, 0.04 M sodium maleate, 0.04M MgCl2.6H2O.  
0.2 N Sodium maleate: 5.8 g maleic acid , 50 mL of 1 N NaOH, in a final volume of 250 mL.  
4x PAB: 6 g beef extract, 6 g yeast extract, 20 g peptone, 4 g dextrose, 14 g NaCl, 14.72 g K2HPO4, 5.28 g KH2PO4, 
in a final volume of 1 L. 
DM3 regeneration agar: 0,8% (w/v) agar, 0.5 M sodium succinate [pH 7.3], 0.5% (w/v) casamino acids, 0.5% (w/v) 
yeast extract, 0.35% (w/v) K2HPO4, 0.15% (w/v) KH2PO4, 0.6% (w/v) glucose, 0.02 M MgCl2. When the agar is at 
~55ºC, 0.1% (w/v) BSA was added. 
 
 
 
4.4.2.2 Transformation of B. licheniformis I89 electrocompetent cells 
The electroporation of B. licheniformis I89 cells protocol was constructed by the 
adaptation of procedures described by (Brigidi et al., 1991). The strain B. licheniformis I89 
was inoculated in 20 mL of and grown overnight at 37ºC with aeration (160 rpm). 10 mL of 
this culture was inoculated in 100 mL of SPII medium and grown until an OD600nm of 0.6. At 
this stage, the culture was centrifuged at 4000 x g at 4 ºC for 5 min and washed with 
100 mL of sterile ice-cold ultrapure water. This step was repeated three times and the final 
wash step was performed with 20 mL of ice-cold 30 % (w/v) PEG 4000 and the cells were 
centrifuged in the same conditions described above. Finally, the cells were resuspended in 
200 µL of the same solution and kept on ice until the addition of plasmid DNA. The plasmid 
DNA (5 µL of 1 mg/mL) was added to 40 µL of the prepared cells on ice. The cell-plasmid 
mixture was transferred to an ice-cold electroporation cuvette with an electrode gap of 
0.2 cm. The mixture was pulsed in the Bio-Rad GenePulser II® equipment with the following 
parameters: 2500 V, 25 µF and the parallel resistor at 400 Ohms. After the pulse, the cells 
were immediately diluted in 1 mL of ice-cold SOC broth and incubated at 30 ºC for 2 hours 
with aeration (160 rpm). Finally, the cells were centrifuged at 2500 x g for 1 min, 
resuspended in 100 µL of the same medium and plated on nutrient agar (Difco) 
supplemented with 1 % (w/v) sodium pyruvate and chloramphenicol (25 µg/mL). 
 
 
Solutions: 
SPII: 14 g K2HPO4, 6 g KH2PO4, 0.2 g MgSO4 in 1L final volume. This medium was prepared as 2X solution and the 
following components were added before bringing the medium up to its final volume: 10 mL of 10% (w/v) 
glucose, 2.5 mL of 1M MgCl2, 1 m3 of o.5 M CaCl2.  
SOC: 2% (w/v) tryptone; 0.5% (w/v) yeast extract, 10 mM NaCl; 2.5 mM KCl; 10 mM MgCl2, 10 mM MgSO4. 
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4.4.3 Construction and screnning of I89 strain fosmid library 
The construction of a fosmid library implicated the extraction of high molecular weight 
DNA from the B. licheniformis I89 strain. The screening of the library was performed by 
colony-blot hybridization using colony blot hybridization with a DIG DNA labeled probe. 
 
 
4.4.3.1 Extraction of high molecular weight DNA 
The extraction of high molecular weight DNA was performed as follows: an overnight 
culture was diluted 1/100 in 200 mL of medium M supplemented with 1 % glycerol and 
incubated at 37 ºC with aeration until OD600 of 0.5. The cells were harvested at 4,000 x g for 
5 min, resuspended in 5 mL of TES solution and incubated at 37 ºC for 2 hours. The lysate 
was slowly added to a tube containing 10 mL of EPS solution, followed by gentle mixing 
and incubated at 50 ºC for 1 hour. Deproteinization was performed by phenol/CIA 
(Invitrogen) extraction followed by centrifugation of 15 min at 2,000 x g. DNA precipitation 
was performed by an adaptation of the protocol described by Akamatsu et al. (2000). 
Briefly, 1/10 volumes of a 3 M sodium acetate solution (pH 5.2) were added to the 
aqueous phase obtained from the phenol/CIA extraction and the solution chilled on an 
ice bath. Subsequently, 2 volumes of cold ethanol (- 50 ºC) were added to the solution. 
The visible precipitated DNA was recovered from the mixture with a glass pipette, washed 
with 70 % ethanol and finally resuspended in 100 µL of sterile distilled water containing 1 
mg/mL of RNase. This DNA was used for the construction of the B. licheniformis I89 fosmid 
library using the CopyControl™ Fosmid Library Production Kit (Epicentre) according with 
the manufacturer’s instructions (Appendix 9). 
 
Solutions: 
TES: 20 mM Tris/HCl, pH8.0; 25 mM EDTA; 10% saccharose 
EPS: 100 mM EDTA, pH8.0; 1% sarcosyl; 50 µg/mL proteinase K 
 
 
4.4.3.2 Colony-blot hybridization 
The screening for the presence of licA1 gene in the clones constituting the 
B. licheniformis I89 fosmid library was performed by colony-blot hybridization using a DIG 
DNA labeled probe as an adaptation of the protocol previously described by Ferreira 
(2010) . Briefly, the nitrocelluse membranes (Amersham) with 90 mm of diameter were 
soaked for 5 min with lysis solution and placed on the plates containing the clones. The 
membranes were previously marked with a razor to allow the identification of the clone 
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numbers in the final of the procedure. The membranes were lifted off carefully and placed 
side up. Two Whatmann 3MM filters were separately soaked with lysis solution and 
denaturing solution. The membranes were placed side up in the lysis solution filter for 5 min 
and subsequently in the denaturing solution filter for another 5 min. The excess of the 
respective solutions was always removed with a clean Whatmann 3MM filter. Then, the 
membranes were floated side up on neutralizing solution for 5 min in a petri dish. After this 
period the membranes were submerged in this solution and the cellular debris was 
carefully washed with the fingers. The excess of solution was removed and the membranes 
submerged again in a 6X SSC solution for 5 min present in other petri dish. The excess of 
solution was removed and the DNA fixed for 45 sec under UV light. The membranes were 
placed into a hybridization tube and treated with 10 mL of pre-hybridization solution, 
avoiding foam formation, at 40 ºC for 3 hours. The labelled DNA probe (see section 4.4.3.3 
below) was denatured by boiling for 10 min and promptly cooled on ice. This probe was 
added to the tube and the membranes incubated overnight at 65 ºC. The membranes 
were washed twice for 5 min with washing solution I at room temperature and twice for 
15 min with washing solution II at 68 ºC, always with agitation. After what, the membranes 
were incubated with acid maleic buffer for 5 min, with 100 mL of 1X blocking solution for 
30 min and another 30 min in 200 mL of antibody solution, always at room temperature. 
The membranes were washed twice for 15 min with another 100 mL of maleic acid buffer 
and equilibrated for 5 min with 20 mL of detection buffer. Finally, the membranes were 
placed in a plain dish and for detection, were incubated in 10 mL of freshly prepared 
colour substrate solution, in the dark. The reaction was stopped washing the membrane for 
5 min with 50 mL of distilled water. 
 
Solutions: 
Lysis solution: 5% (w/v) SDS. 
Denaturing solution: 1.5M NaCl in 0.5M NaOH. 
Neutralizing solution: 0.5 M Tris-HCl, 1.5 M NaCl, pH 7.6. 
20X SSC solution: NaCl 3 M, sodium citrate 0.3 M, pH 7.0. 
Pre-hybridization solution: 40% (v/v) formamide, 5% SSC, 2% (w/v) blocking reagent (Roche), 0.02% (w/v) SDS, 
0.1% (w/v) N-lauroylsarcosine. 
Solution I: 2X SSC, 0.1% (w/v) SDS. 
Solution II: 0.5X SSC, 0.1% (w/v) SDS. 
Acid maleic buffer: 0.1 M maleic acid, 0.15 M NaCl, pH 7.5. 
1X Blocking solution: dilution of 10X blocking solution (Roche). 
Antibody solution: dilution of anti-digoxigenin-AP 1:5000 in 1X blocking solution (Roche). 
Detection buffer: 0.1 M Tris-HCl, 0.1 M NaCl, 50 mM MgCl2, pH 9.5. 
Colour substrate solution: 40 µL of NBT/BCIP solution (Roche) in 2 mL of detection buffer. 
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4.4.3.3 DNA probe labelling 
The DNA probe used for the screening of the fosmid library consisted of the DIG labeled 
licA1 gene. The licA1 gene used for the labeling was obtained by PCR in a final volume of 
25 µl containing 1.5 mM of MgCl2, 200 μM of dNTP’s, 1X Green GoTaq® Buffer, 0.25 U of 
GoTaq® Buffer (Promega) and 0.3 pmol/µL of each primer. 1 µL of I89 bacterial suspension 
was applied as DNA template. The amplification parameters were as follows: 94 ºC for 
5 min, thirty-five cycles of 94 ºC for 30 sec, 50 ºC for 30 sec and 72 ºC for 30 sec and a final 
extension step of 10 min at 72 ºC. The primers used for the amplification were mrsAfw (5’-
AAAAAGGAAATGATTCTTTCATGG-3’) and mrsArv (5’-AGCTTGGCATGCATTCTTTT-3’). The 
presence of the correct amplicon (approximately 220 bp) was evaluated on 1 % agarose 
gel electrophoresis. Approximately 1 µg of amplified DNA was diluted in distilled water for 
a final volume of 16 µL and denatured by boiling for 10 min in a water bath and quickly 
chilled on ice. 4 µL of Dig-High Prime solution (Roche) was added to the DNA. The mixture 
was incubated at 37ºC overnight. The reaction was stopped heating to 65ºC for 10 min. 
The labeled probe was stored at -20ºC until its addition to the membranes (see section 
4.4.3.2). 
 
 
4.4.4 Lichenicidin heterologous expression in E. coli 
E. coli clones which were positive for the presence of licA1 structural gene were 
screened for lichenicidin production by colony bioassay as described in 2.4.8 (page 
number 61). All the clones present antibacterial activity, indicating the presence of all the 
lichenicidin biosynthetic gene cluster in the corresponding fosmids. In order to select the 
best clone for further studies, the stability of production without selective pressure was 
assessed through sequential subcultures of the E. coli clones on bioassay agar plates. 
Based on these assays and sequencing, clone E. coli Lic5 possessing the fosmid pLic5 was 
selected. 
The evaluation of lichenicidin production by E. coli Lic5 was performed in medium M. A 
pre-culture was performed at 37 ºC along 16 hours with aeration (160 rpm). 500 µL of this 
culture were used to inoculate 50 mL of fresh medium and allowed to grow in the same 
conditions for 36 hours. Along this period, 1 mL samples were withdrawn from this culture 
and centrifuged for 5 min at 16100 x g. The cell-free supernatant was stored at -20 ºC while 
cells were resuspended in 100 µl of 70 % isopropanol containing 0.1 % of formic acid. After 
2 hours at 4 ºC, the mixture was centrifuged for 5 min at 16100 x g, the respective 
supernatant collected for a new microtube and stored at -20 ºC. The antibacterial activity 
of the supernatant and the cell wall washes was evaluated through the application of 
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40 µl of each fraction to bioassay plates as described on 2.4.8 of page 61. Samples 
exhibiting the major inhibition zone were selected for LC-ESI-MS analysis. The antibacterial 
activity and LC-ESI-MS analysis of negative controls consisting of E. coli EPI300 strain 
harboring the empty pCC2FOS vector were also performed. 
 
4.4.5 Extraction of fosmid DNA from E. coli 
The extraction of fosmid DNA was performed accordingly with an adaptation of the 
alkaline lysis procedure described by Sambrook and Russell (2001). Briefly, a 50 mL of LB 
containing 12.5 µg/mL of chloramphenicol were inoculated with the desired strain and 
cultured overnight at 37ºC, with aeration (160 rpm). 40 mL of this culture was centrifuged 
at 12000 x g for 1 min and the cells were resuspended in 1 mL of Solution I, containing 
20 µg/mL of DNase-free RNase A (Roche). To perform the cell lysis, 1.6 mL of freshly 
prepared Solution II was added and the tube shacked vigorously 5 times. 1.2 mL of the 
alkaline Solution III was subsequently added; the solution was gently mixed and incubated 
on ice for 5 min. The separation of the cell debris and chromosomal DNA was performed 
by centrifugation at top speed for 5 min. The supernatant containing the fosmid DNA was 
extracted twice with Phenol/CIA (Invitrogen). The DNA was precipitated adding 
1/10 volumes of solution III and 0.6 volumes of isopropanol. The mixture was incubated at 
room temperature for 30 min and centrifuged at top speed for 15 min at 4 ºC. The pellet 
was washed with 500 µL of 70 % of ethanol and a last step of centrifugation at top speed 
for 5 min was performed. The precipitate DNA was dried in the flow chamber for 15 min to 
evaporate the residual ethanol and resuspended in 100 µL of distilled water. Alternatively, 
it is also possible to extract efficiently fosmid DNA for transformation from 10 mL of initial 
culture, using the solutions of GeneJET™ Plasmid Miniprep Kit but without the application 
of the columns, performing the DNA precipitation with isopropanol. 
 
 
4.4.6 Lichenicidin gene cluster knockout mutants 
In frame gene deletions of lichenicidin biosynthetic cluster were performed using the λ-
Red-mediated recombination system adapted from Gust et al. (2003).  
 
4.4.6.1 Digestion of pIJ733 plasmid 
The disruption cassette chosen to inactivate genes constituting the lic gene cluster was 
amplified from the pIJ733 plasmid (Appendix 3) and was consisted by an apramycin 
(Apra) resistance gene. In order to decrease the occurrence of false positives, the pIJ733 
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plasmid was digested before its use as template for the PCR reaction. Thus, the plasmid 
was extracted from the E. coli BW25113/pIJ773 with the GenJet plasmid DNA purification 
kit (Fermentas), accordingly with manufacturer’s instructions (Appendix 6). Approximately 
10 µg of the resulting plasmid was digested with 50 U of EcoRI and 50 U of HindIII restriction 
enzymes (Fermentas) in a 100 µL total volume reaction containing 1X of buffer R 
(Fermentas). The digestion was loaded into a 1 % agarose gel and run at 90 V during 
2 hours. The band containing the apramycin cassette (approximately 1400 bp) was 
purified from the agarose gel with the QIAquick gel extraction kit (Quiagen), accordingly 
with the manufacturer’s instructions (Appendix 7). The cassette was stored at -20 ºC until 
further use as DNA template for amplification reaction. 
 
 
4.4.6.2 Design of long PCR primers and amplification of the disruption cassette 
For the amplification of the Apra cassette applied for each lic gene disruption it was 
necessary to construct of two long PCR primers (58 and 59 bp). Each one of these primers 
possessed at the 5´-end, 39 bp matching the sequence adjacent to the gene to be 
inactivated, and the 3´-sequence (19 nt or 20 nt) matching the 5’- (for forward primer) or 
the 3’- (for reverse primer) region of the Apra resistance cassette. All the constructed 
primers were compared with the pLic5 fosmid, where a perfect match was identified in 
the flanking regions of the gene to be interrupted. If other matches are identified >30 bp, 
a new primer was constructed. The primers used in this study were designed in order to 
excise the entire gene, letting stand only its start and stop codon. In some cases, this 
criterion could not be applied do to the presence of putative RBS or promoters of other 
genes. In this situation, primers were designed to in order to excise the maximum of the 
gene possible. A BmtI restriction site (GCTAGC) was also included in both primers 
between the sequence of the disruption cassette and the sequence of the flanking region 
of the target lic gene to allow posterior removal of the Apra resistance cassette. 
The primers used for amplification of each Apra resistance cassette are listed on Table 
8. Each amplification reaction was performed in a final volume of 50 µL containing 1X of 
Herculase II reaction buffer, 0.25 mM of dNTP’s, 3 pmol/µL of each primer and 0.25 µL of 
Herculase® II fusion DNA polymerase (Agilent Technologies). Approximately 100 ng of the 
purified ApraR cassette obtained in the previous section was used as DNA template for 
each reaction. The amplification parameters were as follows: one step of denaturation at 
94 ºC for 45 sec followed by 10 cycles of denaturation at 94 ºC for 45 sec, primer annealing 
at 50 ºC for 45 sec and extension at 72 ºC for 90 sec. This was followed by 15 cycles of 
denaturation at 94 ºC for 45 sec, primer annealing at 55 ºC for 45 sec and extension at 
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72 ºC for 90 sec. Finally a final extension step at 72 ºC for 5 min was included. Two reactions 
involving the same primers were purified and concentrated into a 20 µL final volume using 
the GenJet PCR purification kit. The amplification products (approximately 1400 bp) were 
always analyzed by gel electrophoresis and stored at -20 ºC until further use. 
 
Table 8: List of primers used to perform the interruption of biosynthetic genes involved in the production of 
lichenicidin peptides. The restriction site for BmtI digestion was highlighted in bold to better distinguish between 
the sequence of the disruption cassette for that of the flanking regions of the target lic gene. These primers were 
used in the procedure described in section 4.4.6.2. 
Primers Target 
gene Name Sequence (5’3’) 
lanM1_fw CGCGTTGGCATATTGATAGAAAAAGAGGTCGATAGAATGGCTAGCATTCCGGGGATCCGTCGACC 
licM1 
lanM1_rv AAAAAATCTATGGATGAAAATCCATAGATTTTGATTTTAGCTAGCTGTAGGCTGGAGCTGCTTC 
lanA1_fw GACAAAAAATTATAAATTTTCTAGGAGGTGGAATATATGGCTAGCATTCCGGGGATCCGTCGACC 
licA1 
lanA1_rv ATGCCAACGCGGGAGCAGGGCCCCCGCGTTGGGAACTTAGCTAGCTGTAGGCTGGAGCTGCTTC 
lanA2_fw TGCAAGGATGGATTCTTTTGAATTTTTTATGATTCCCTAGCTAGCATTCCGGGGATCCGTCGACC 
licA2 
lanA2_rv ATTTCGATAGTTTGCCCGTTCTAGGAGGTGAGAATCATGGCTAGCTGTAGGCTGGAGCTGCTTC 
lanM2_fw CTATAAACGGTGTCTTATGAAAAAACAAGCCTTATCTCAGCTAGCATTCCGGGGATCCGTCGACC 
licM2 
lanM2_rv GCAGGGATGGTTTTCTTCGCCAAAGGGATGACGAGAATGGCTAGCTGTAGGCTGGAGCTGCTTC 
lanT_fw TTTTTTCATAAGACACCGTTTATAGAACAGATGCAGCAGGCTAGCATTCCGGGGATCCGTCGACC 
licT 
lanT_rv TTGAATGTCATCGTATATTTGCGCCATTTTTGCGACTTCGCTAGCTGTAGGCTGGAGCTGCTTC 
lanP_fw GGCGGAAAGACGGCTCAAGCAAAAGAACAAGCAGGAGAAGCTAGCATTCCGGGGATCCGTCGACC 
licP 
lanP_rv AGCTACCTGCGGGGCGGCCAAGCTTGTTCCGTATGAGAGGCTAGCTGTAGGCTGGAGCTGCTTC 
lanX_fw TCAAGCGCTGAAAATGATGAACAAGGAGTGAAGGGTATGGCTAGCTGTAGGCTGGAGCTGCTTC 
licX 
lanX_rv CTTCACGTGATGATTGTGTGAAGATCTTTTCGACAATCAGCTAGCATTCCGGGGATCCGTCGACC 
lanR_fw TTTTTGTTATAAACTCTTTACAATGTGTAAAAAACATTGGCTAGCTGTAGGCTGGAGCTGCTTC 
licR 
lanR_rv TCCTTCTCAAATAACGCGGCAATGCGAAACCCCATTAACGCTAGCATTCCGGGGATCCGTCGACC 
lanY_fw GGTATTTCAATACCAACTAGAGGAGGATGATCGCTGATGGCTAGCTGTAGGCTGGAGCTGCTTC 
licY 
lanY_rv TGTGACCATGTTTTTATAATTGGCGAACGACAAATCGACGCTAGCATTCCGGGGATCCGTCGACC 
 
 
 
4.4.6.3 Disruption of lic genes 
The disruption of lichenicidin biosynthetic genes was performed in the fosmid pLic5. This 
plasmid was transformed in electrocompetent E. coli BW25113/pKD20 cells resistant to 
ampicillin (Amp) due to the plasmid pKD20, which replication is sensitive to temperatures 
superior to 32 ºC. This strain is amenable to the introduction of foreign linear DNA. The 
resulting strain E. coli BW25113/pKD20/pLic5 was characterized by AmpR and CloR and 
were always grown at 30 ºC. The introduction of each amplified disruption cassette in the 
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E. coli BW25113/pKD20/pLic5 strain was performed as follows: a pre-culture of this strain 
was performed in LB medium containing 100 µg/mL of Amp and 12.5 µg/mL of Clo 
antibiotics. 10 mL of fresh LB medium containing the same concentration of the selective 
markers, 20 mM of MgSO4 and 10 mM of L-arabinose (Sigma) were inoculated with 100 µL 
of the previously prepared culture. The cells were grown at 30 ºC at 160 rpm until an OD600 
of approximately 0.4 (between 3 to 4 hours). The cells were collected by centrifugation at 
6000 x g for 5 min at 4 ºC and washed with 10 mL of ice cold 10 % glycerol. This procedure 
was repeated once and the cells finally resuspended on 100 µL of the same solution.  
 
 
Table 9: Sequence of primers used for the confirmation of the substitution of the lic genes by the apramycin 
resistance cassette and PCR parameters for the corresponding amplifications. The same primers were used for 
the confirmation of the resistance cassette deletion. 
Primers PCR parameters 
Target gene 
Designation Sequence (5’3’) Annealing 
temperature 
Extension 
time 
licM1 
licA1 
check_licM1_fw 
check_licM1_rv 
CTAGAACGGGCAAACTATCG 
ACGGCGGATACTGAATGGTG 
licA2 
licM2 
check_licM2_fw 
check_licM2_rv 
ATACAGCACAGTCCGCATTC 
GTTCCCTGCTGGATGATAAG 
licT 
licP 
check_licT_fw 
check_licT_rv 
TGCTCCTACAGCGATTGAAA 
AATAGCCTACGGGCTTTTGC 
52 ºC 3 min 30 sec 
licX 
licR 
licY 
check_Reg_fw 
check_Reg_rv 
TTTCCCGATCCGTTTTCTCC 
CCTGAGGAAATCGGCATTAG 
54 ºC 45 sec 
 
 
Table 10: Molecular size of the amplifications expected for the screnning of the substitution of the Apra resistance 
cassette for each lic gene and for its posterior removal. 
Amplification expected 
Target gene 
Gene intact Apra substitution Apra removal 
licM1 2100 bp 640  bp 
licA1 
3800 bp 
5030 bp 3570 bp 
licA2 2011 bp 551  bp 
licM2 
3668 bp 
4800 bp 3420 bp 
licT 4055 bp 2595 bp 
licP 
3616 bp 
3370 bp 1914 bp 
licX 2320 bp 920  bp 
licR 2230 bp 830  bp 
licY 
1108 bp 
2221 bp 821  bp 
 
 
Lichenicidin production in E. coli 
 111 
For transformation, 50 µL of the prepared cells were mixed with 100-150 ng of the Apra 
disruption cassette obtained in section 4.4.6.2. The cells were subject to electroporation, 
where the one hour expression step was performed at 30 ºC and the transformants finally 
selected on LB agar plates containing Apra at 50 µg/mL and Clo at 12.5 µg/mL grown at 
37 ºC (since no other interruptions were intended). The substitution of the target lic gene 
by the ApraR cassette was confirmed by colony PCR using the primers described on Table 
9. The amplification was performed as follows: 94 ºC for 5 min, 35 cycles of 94 ºC for 30 sec, 
amplification temperature for 30 sec and 72 ºC for extension time and a final extension 
step of 10 min at 72 ºC, where the amplification temperature and extension times applied 
were described on Table 9. The size of the expected amplifications is presented on Table 
10. The DNA template used corresponded to one colony of each transformant to be 
screened. In all the reactions, the unchanged pLic5fosmid was used as control. 
 
 
4.4.6.4 Elimination of Apra disruption cassette 
The disrupted fosmids produced in the previous section were extracted by alkaline lysis 
as described in section 4.4.5 and digested with the restriction enzyme BmtI (New England 
Biolabs). The reaction was performed in a final volume of 80 µL, containing 1-3 µg of fosmid 
DNA, 1X of NEBuffer 2 and 20 U of enzyme. The mixture was incubated at 37 ºC for 3 hours. 
Subsequently, sterile distilled water as added to the digestion for a final volume of 600 µL. 
This mixture was extracted once with Phenol/CIA (Invitrogen) and 1/10 vol of potassium 
acetate (3 M, pH 5.5) and 0.6 vol of isopropanol were added to the aqueous DNA-
containing phase. The mixture was incubated at room temperature for 15 min and 
centrifuged at 4 ºC, 12000 x g during 15 min. The pelleted DNA was washed with 100 µL of 
70 % ethanol and completely dried for 15 min in the flow chamber. The final elution was 
performed in 10 µL of sterile distilled water. The complete digestion of the fosmid was 
confirmed by gel electrophoresis analysis, loading 1 µL of the digested DNA. If the fosmid 
was not completely digested, a new reaction was performed as described above. The 
religation of the BmtI-digested fosmid was performed in a total volume of 50 µL containing 
approximately 1-2 µg of DNA, 1X ligase buffer and 10 U of T4 DNA ligase (Fermentas). The 
reaction was incubated at 20 ºC for 15 min and 5 µL of this ligation was use to transform 
chemically competent E. coli EPI300 cells. The transformants were selected on LB agar 
plates containing Clo (12.5 µg/mL). The obtained colonies were further cultured on plates 
containing Clo (12.5 µg/mL) and Apra (50 µg/mL). The clones presenting the phenotype 
CloRApraS were selected as those containing the desired gene deletion without the ApraR 
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cassette. The absence of this cassette was further confirmed by colony-PCR as described 
in section 4.4.6.3. Finally, the PCR product was submitted to sequencing reaction in order 
to confirm the deletion of each gene.  
The strains resulting from this procedure were E. coli Lic5ΔA1, Lic5ΔA2, Lic5ΔM1, Lic5ΔM2, 
Lic5ΔT, Lic5ΔP, Lic5ΔX, Lic5ΔR and Lic5ΔY knockout mutants where the licA1, licA2, licM1, 
licM2, licT, licP, licX and licY genes were deleted from pLic5, respectively. 
 
4.4.6.5 Preparation of extracts for LC-ESI-MS analysis and bioassays 
A pre-culture of each knockout strain was performed in medium M supplemented with 
the appropriate selective agent. 500 µL of this culture were added to 50 mL of fresh 
medium M without addition of antibiotics and allowed to grow at 37 ºC for 24 hours with 
aeration (160 rpm). The supernatant was collected by centrifugation at 10,000 x g for 5 
min, filter-sterilized and stored at 4 ºC. The cells were collected by centrifugation at 
10,000 x g for 5 min and resuspended with 70 % of isopropanol containing 0.1 % of formic 
acid. The solution was stored at 4 ºC for 1 hour and subsequently centrifuged at 10,000 x g 
for 5 min. The obtained supernatant corresponded to the cell wall wash fraction. To the 
cell-free culture supernatant (40 mL), 2 mL of 1-butanol (Merck) was added and the 
solution stirred for 3 hours at room temperature. Then the mixture was centrifuged for 1 min 
at 3,000 x g and the upper organic phase collect to a new tube, constituting the butanol 
extract. In order to investigate the production of lichenicidin peptides by the knockout 
strains, both extracts from each strain were analyzed by LC-ESI-MS. 
All the lichenicidin knockout strains were tested for their antagonistic ability by colony-
bioassay as described in section 2.4.8 of page 61. Complementation of bioactivity was 
also tested, where knockout mutants’ colonies were inoculated next to E. coliLic5ΔA1and 
E. coli Lic5ΔA2 colonies on bioassay agar plates (section 2.4.8 of page 61). 
E. coli Lic5ΔA1and E. coli Lic5ΔA2 represented the exclusive production of Bliβ and Bliα, 
respectively. 
 
 
4.4.7 LicP proteolysis analysis 
In order to investigate the potential extracellular location and involvement of LanP 
enzyme in Bliβ proteolysis, a simple experiment involving the single expression of lanP in 
E. coli and also the exposition of E. coli Lic5ΔP cell wall washes and supernatant extracts to 
LanP was performed. 
 
Lichenicidin production in E. coli 
 113 
4.4.7.1 Construction of BL21licP+ strain 
The lanP gene (approximately 1300 bp) was amplified with comp_lanPfw (5’-
TATACATATGAAAAGAATATATATTT-3’) and comp_lanPrv (5’-
TTTTATCTCGAGTCACTCCTTGTTCATCATTTT-3’) primers, which contained the NdeI and XhoI 
restriction enzymes recognition sequence (bold), respectively. Each amplification reaction 
was performed in a final volume of 50 µL containing 1X of Herculase II reaction buffer, 0.25 
mM of dNTP’s, 3 pmol/µL of each primer and 0.25 µL of Herculase® II fusion DNA 
polymerase (Agilent Technologies). The amplification parameters were as follows: 94 ºC for 
5 min, thirty-five cycles of 94 ºC for 30 sec, 48 ºC for 30 sec and 72 ºC for 1 min 30 sec and a 
final extension step of 10 min at 72 ºC. 1 µL of a B. licheniformis I89 suspension was used as 
DNA template. Two of such reactions were performed, pooled together and 
concentrated by final elution with 30 µL of sterile distilled water with the GenJet PCR 
purification kit (Fermentas). The PCR product was further digested with 10 U of NdeI and 20 
U of XhoI (Fermentas). The reaction contained approximately 1-2 µg of purified PCR 
product and 1X of Buffer O (Fermentas), in a final volume of 40 µL. The pET24-a(+) vector 
was also digested in the same conditions. The reactions were incubated at 37 ºC for 3 
hours, and purified with the GenJet PCR purification kit (Fermentas). Approximately 50 ng 
of the linear vector was ligated to 150 ng of digested PCR-product in a 20 µL reaction 
containing approximately 1-2 µg of DNA, 1X ligase buffer and 10 U of T4 DNA ligase 
(Fermentas). 5 µL of this reaction was used to transform chemically competent E. coli 
BL21Gold cells and the correspondent transformants selected on LB agar plates 
containing kanamycin (Kan) at 50 µg/mL. Positive clones were screened by colony-PCR 
using the T7prom (5’-TAATACGACTCACTATAGGGAGACCAC-3’) and T7term (5’- 
CAAAAAACCCCTCAAGACCC-3’) primers. Each PCR reaction was performed on a final 
volume of 12.5 µL containing containing 1.5 mM of MgCl2, 200 µM of dNTP’s, 1X Green 
GoTaq® Buffer, 0.25 U of GoTaq® Buffer (Promega) and 0.3 pmol/µL of each primer. The 
amplification parameters were as follows: 94 ºC for 5 min, 35 cycles of 94 ºC for 30 sec, 54 
ºC for 30 sec and 72 ºC for 1 min 30 sec and a final extension of 10 min at 72 ºC. The 
resulting plicP plasmid was extracted from its harboring BL21licP+ strain and sequenced to 
confirm the absence of mutations. The empty pET24-a(+) vector was also transformed into 
chemically competent E. coli BL21Gold cells to obtain the control strain BL21licP-. 
 
4.4.7.2 Preparation of LicP-containing extracts and bioassay 
Both BL21licP+ and BL21licP- strains were separately cultivated in 50 mL of medium M 
without antibiotic selection, at 37 ºC during 24 hours with aeration (160 rpm). The 
supernatant was collected by centrifugation at 10,000 x g for 5 min, filter-sterilized and 
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stored at 4 ºC. The E. coli Lic5ΔP knockout mutant was cultured and its extracts obtained 
as described in section 4.4.6.5. The E. coli Lic5ΔP cell wall washes and butanol extracts 
were bioassayed side by side with the E. coli BL21licP+ and E. coli BL21licP– supernatants on 
plates containing the indicator strain. 
 
 
4.4.8 trans complementation system 
In order to produce lichenicidin peptides variants, a trans complementation system in 
E. coli BL21Gold® for the Lic5ΔA1 and Lic5ΔA2 knockout mutants was established. 
To archive this, the fosmids pLic5ΔA1 and pLic5ΔA2 fosmids were extracted from E. coli 
Lic5ΔA1 and E. coli Lic5ΔA2 strains respectively as described in section 4.4.5. Subsequently 
they were transformed into chemically competent E. coli BL21Gold cells and positive 
clones were selected on LB agar plates containing Clo at 12.5 µg/mL. The resultant strains 
were designated as E. coli BLic5ΔA1 and BLic5ΔA2, which were subsequently transformed 
with the plasmids plicA1 and plicA2, respectively.  
The plicA1 and plicA2 plasmids were obtained by amplification of licA1 and licA2 with 
the primers listed on Table 11. Each PCR reaction was performed in a final volume of 50 µL 
containing 1X of Herculase II reaction buffer, 0.25 mM of dNTP’s, 3 pmol/µL of each primer 
and 0.25 µL of Herculase® II fusion DNA polymerase (Agilent Technologies). The 
amplification parameters were as follows: 94 ºC for 5 min, 35 cycles of 94 ºC for 30 sec, 
amplification temperature for 30 sec and 72 ºC for 45 sec and a final extension step of 10 
min at 72 ºC. The amplification temperature applied is listed on Table 11. 1 µL of a B. 
licheniformis I89 suspension was used as DNA template. Two of each of such reactions 
were performed, pooled together and concentrated by final elution with 30 µL of sterile 
distilled water with the GenJet PCR purification kit (Fermentas). Each PCR product was 
further digested with 10 U of BamHI and 20 U of XhoI (Fermentas). The reaction contained 
approximately 1-2 µg of purified PCR product and 1X of Buffer BamHI (Fermentas), in a final 
volume of 40 µL. The pET24-a(+) vector was also digested in the same conditions. The 
reactions were incubated at 37 ºC for 3 hours and purified with the GenJet PCR 
purification kit. 50 ng of linear vector was ligated to 150 ng of digested PCR-product in a 
20 µL reaction containing 1X ligase buffer and 10 U of T4 DNA ligase (Fermentas). 5 µL of 
this reaction was used to transform chemically competent E. coli DH5α cells and the 
correspondent transformants selected on LB agar plates containing Kan at 50 µg/mL. 
Positive clones were screened by colony-PCR using the T7prom (5’-
TAATACGACTCACTATAGGGAGACCAC-3’) and T7term (5’- 
CAAAAAACCCCTCAAGACCC-3’) primers. Each PCR reaction was performed on a final 
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volume of 12.5 µL containing containing 1.5 mM MgCl2, 200 µM dNTP’s, 1X Green GoTaq® 
Buffer, 0.25 U of GoTaq® Buffer (Promega) and 0.3 pmol/µL of each primer. The 
amplification parameters were as follows: 94 ºC for 5 min, thirty-five cycles of 94 ºC for 30 
sec, 54 ºC for 30 sec and 72 ºC for 45 sec and a final extension of 10 min at 72 ºC. One 
positive clone for each construction was selected and the plicA1 and plicA2 plasmids 
extracted with the GenJet plasmid purification kit (Fermentas). Both plasmids were 
sequenced in order to confirm the absence of mutations.  
Approximately 50 ng of the plasmids plicA1 and plicA2 were transformed into 
chemically competent E. coli BLic5ΔA1 and BLic5ΔA2 strains. Positive clones were selected 
on LB agar plates supplemented with 12.5 µg/mL of Clo and 50 µg/mL of Kan with 
incubation at 37 ºC. From each transformation plate five clones were randomly selected 
and tested for presence of antibacterial activity by colony bioassay as described in 
section 2.4.8 (page 61). One representative of each transformation possessing restored 
antibacterial activity was selected for further applications and designated as 
BLic5ΔA1plicA1 and BLic5ΔA2plicA2. The production of both lichenicidin peptides by 
BLic5ΔA1plicA1 and BLic5ΔA2plicA2 strains was also evaluated by LC-ESI-MS analysis. The 
extracts used for this analysis were prepared as described in section 4.4.6.5. 
 
Table 11: List of primers and respective amplification temperatures used for amplify licA1 and licA2 genes to 
clone into the vector pET24-a(+). The expected amplification was also included. 
Primer 
Target  
Designation Sequence (5’   3’) 
Amplification 
temperature 
Expected size 
of amplification 
Comp_licA1fw AGGTGGGATCCATGTCAAAAAAGGAAATG 
licA1 
Comp_licA1rv CCCGCCTCGAGAACTTAGTTACAGCTTGGC 
50 ºC 250 bp 
Comp_licA2fw ATCAGGATCCATGAAAACAATGAAAAATTCAG 
licA2 
Comp_licA2rv TTTTATCTCGAGCTAGCATCGGCTTGTACAC 
59 ºC 239 bp 
 
 
4.4.9 Production of lichenicidin variants 
Alanine scanning of Bliα and Bliβ peptides was performed by site-directed mutagenesis 
of licA1 and licA2 genes, using a modification of the two-step reactions method described 
by Wang et al. (1999), using plicA1 and plicA2 as templates. Primers used to insert the 
desired mutation were designed with web-based software PrimerX 
(http://www.bioinformatics.org/primerx/) and are listed on Table 12 and Table 13.  
The site-directed mutagenesis PCR was performed in two distinct reactions, each one 
containing exclusively the forward or the reverse primer. Each reaction was performed in a 
final volume of 25 µL containing 1X of Herculase II reaction buffer, 0.25 mM of dNTP’s, 
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3 pmol/µL of the primer, 50 ng of plicA1 or plicA2 DNA and 0.25 µL of Herculase® II fusion 
DNA polymerase (Agilent Technologies). The of amplification was performed by a initial 
denaturation step of 95 ºC for 3 min, followed by 5 cycles of denaturation at 95 ºC for 
20 sec, primer annealing at 55 ºC for 30 sec and amplification at 72 ºC for 3 min and a final 
amplification step of 3 min. At the end, both reactions were mixed together in the same 
tube and a second stage of amplification was executed with the same parameters 
described for the first stage, however including 20 cycles of amplification. Subsequently, 
each PCR reaction was digested with 10 U of DpnI (Fermentas) and incubated at 37 ºC for 
1 hour, in order to digest the parental methylated plasmid DNA. Finally, 5 µL of this reaction 
was used to transform chemically competent E. coli DH5α cells and transformants selected 
overnight on LB agar plates containing 50 µg/mL of Kan. For each reaction, 3 KanR clones 
were selected and plasmid DNA extracted with the GenJet plasmid DNA Miniprep kit 
(Fermentas). Each plasmid was sequenced using the primers T7prom and T7term to 
confirm the presence of the desired mutation. The mutated plasmid was used to transform 
chemically competent BLic5ΔA1or BLic5ΔA2 cells, depending if permutation of amino acid 
was done for licA1 or licA2 genes, respectively. The transformants were selected on LB 
agar plates containing 12.5 µg/mL of Clo and 50 µg/mL of Kan antibiotics. 
 
Table 12: List of primers designed on PrimerX web-based software used to introduce the desired mutation on licA1 
peptide, where the first letter represents the aminoacid to be substituted by an alanine residue. 
Mutation Primers (5’   3’) 
T1A 
A1T1Afw: CATCGCCGGAGGCGCAATCACGCTCAG 
A1T1Arv: GTAGCGGCCTCCGCGTTAGTGCGAGTC 
T3A A1T3Afw: CATCGCCGGAGGCACAATCGCACTCAGCACTTGTGCCATC A1T3Arv: GATGGCACAAGTGCTGAGTGCGATTGTGCCTCCGGCGATG 
S5A A1S8Afw: GCACAATCACGCTCGCCACTTGTGCCATC A1S8Arv: GATGGCACAAGTGGCGAGCGTGATTGTGC 
T6A A1T6Afw: CAATCACGCTCAGCGCTTGTGCCATCTTG 
A1T6Arv: CAAGATGGCACAAGCGCTGAGCGTGATTG 
C7A A1C7Afw: CAATCACGCTCAGCACTGCTGCCATCTTGAGCAAG A1C7Arv: CTTGCTCAAGATGGCAGCAGTGCTGAGCGTGATTG 
S11A A1S11Afw: GCACTTGTGCCATCTTGGCAAAGCCGTTAGGAAATAAC A1S11Arv: GTTATTTCCTAACGGCTTTGCCAAGATGGCACAAGTGC  
C21A A1C21Afw: GAAATAACGGATACCTGGCTACAGTGACAAAAGAATG A1C21Arv: CATTCTTTTGTCACTGTAGCCAGGTATCCGTTATTTC 
T22A A1T22Afw: GAAATAACGGATACCTGTGTGCAGTGACAAAAGAATGCATG A1T22Arv: CATGCATTCTTTTGTCACTGCACACAGGTATCCGTTATTTC 
T24A A1T24Afw: GATACCTGTGTACAGTGGCAAAAGAATGCATGCC 
A1T24Arv: GGCATGCATTCTTTTGCCACTGTACACAGGTATC 
E26A A1E26Afw: GTACAGTGACAAAAGCATGCATGCCAAGCTG  A1E26Arv: CAGCTTGGCATGCATGCTTTTGTCACTGTAC  
C27A 
A1C27Afw: GTACAGTGACAAAAGAAGCCATGCCAAGCTGTAAC 
A1C27Arv: GTTACAGCTTGGCATGGCTTCTTTTGTCACTGTAC 
S30A A1S30Afw: CAAAAGAATGCATGCCAGCCTGTAACTAAGTTCCC  A1S30Arv: GGGAACTTAGTTACAGGCTGGCATGCATTCTTTTG 
C31A A1C31Afw: CAAAAGAATGCATGCCAAGCGCTAACTAAGTTCCCAACGCG A1C31Arv: CGCGTTGGGAACTTAGTTAGCGCTTGGCATGCATTCTTTTG 
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Table 13: List of primers designed on PrimerX web-based software used to introduce the desired mutation on licA2 
peptide, where the first letter represents the aminoacid to be substituted by an alanine residue. 
Mutation Primers (5’   3’) 
T1A A2T1Afw:  GACGTCAATCCTGAAGCAACTCCTGCTACAAC  A2T1Arv:  GTTGTAGCAGGAGTTGCTTCAGGATTGACGTC  
T2A A2T2Afw:  GTCAATCCTGAAACAGCTCCTGCTACAACC  A2T2Arv:  GGTTGTAGCAGGAGCTGTTTCAGGATTGAC  
T5A A2T5Afw:  GAAACAACTCCTGCTGCAACCTCTTCTTGG  A2T5Arv:  CCAAGAAGAGGTTGCAGCAGGAGTTGTTTC  
T6A A2T6Afw:  CAACTCCTGCTACAGCCTCTTCTTGGAC  A2T6Arv:  GTCCAAGAAGAGGCTGTAGCAGGAGTTG  
S7A A2S7Afw:  CTCCTGCTACAACCGCTTCTTGGACTTG  A2S7Arv:  CAAGTCCAAGAAGCGGTTGTAGCAGGAG 
S8A A2S8Afw:  CTGCTACAACCTCTGCTTGGACTTGCATC  A2S8Arv:  GATGCAAGTCCAAGCAGAGGTTGTAGCAG 
T10A A2T10Afw:  CAACCTCTTCTTGGGCTTGCATCACAGC  
A2T10Arv:  GCTGTGATGCAAGCCCAAGAAGAGGTTG 
C11A A2C11Afw:  CTCTTCTTGGACTGCCATCACAGCCGGTG  A2C11Arv:  CACCGGCTGTGATGGCAGTCCAAGAAGAG  
T13A A2T13Afw:  CTTGGACTTGCATCGCAGCCGGTGTAAC  A2T13Arv:  GTTACACCGGCTGCGATGCAAGTCCAAG 
T17A A2T17Afw:  CACAGCCGGTGTAGCGGTTTCTGCTTC  A2T17Arv:  GAAGCAGAAACCGCTACACCGGCTGTG  
S19A A2S19Afw:  CCGGTGTAACGGTTGCTGCTTCATTATGC  A2S19Arv:  GCATAATGAAGCAGCAACCGTTACACCGG  
S21A A2S21Afw:  GTAACGGTTTCTGCTGCATTATGCCCAACAAC  A2S21Arv:  GTTGTTGGGCATAATGCAGCAGAAACCGTTAC 
C23A A2C23Afw:  CGGTTTCTGCTTCATTAGCCCCAACAACTAAGTGTAC  A2C23Arv:  GTACACTTAGTTGTTGGGGCTAATGAAGCAGAAACCG 
T25A A2T25Afw:  GCTTCATTATGCCCAGCAACTAAGTGTACAAG  A2T25Arv:  CTTGTACACTTAGTTGCTGGGCATAATGAAGC 
T26A A2T26Afw:  CATTATGCCCAACAGCTAAGTGTACAAGCC  A2T26Arv:  GGCTTGTACACTTAGCTGTTGGGCATAATG  
C28A A2C28Afw:  CATTATGCCCAACAACTAAGGCAACAAGCCGATGCTAGGGAATC  A2C28Arv:  GATTCCCTAGCATCGGCTTGTTGCCTTAGTTGTTGGGCATAATG 
T29A A2T29Afw:  CAACAACTAAGTGTGCAAGCCGATGCTAGG  A2T29Arv:  CCTAGCATCGGCTTGCACACTTAGTTGTTG  
S30A A2S30Afw:  CAACAACTAAGTGTACAGCCCGATGCTAGGGAATC  A2S30Arv:  GATTCCCTAGCATCGGGCTGTACACTTAGTTGTTG  
C32A A2C32Afw:  CAACTAAGTGTACAAGCCGAGCCTAGGGAATCATAAAAAATTC  A2C32Arv:  GAATTTTTTATGATTCCCTAGGCTCGGCTTGTACACTTAGTTG  
 
 
All the complemented strains constructed were screened for their antagonist capability 
by colony-bioassay (section 2.4.8, page 61). The production of Bliα and Bliβ peptides was 
confirmed by LC-ESI-MS (section 2.4.6, page 60) and HR-ESI-MS (4.4.11) analysis of the 
butanol extract of each strain obtained as described in section 4.4.6.5 (page 112).  
 
 
4.4.10 Evaluation of tolC influence on lichenicidin production 
Electrocompetent cells of E. coli BW25113 and BW25113ΔtolC:kan (kindly provided by 
Prof. Dr. Klaus Hantke, Tübingen) were transformed with the fosmid pLic5 generating the 
E. coli strains BWLic5 and BWΔtolCLic5, respectively. E. coli BWLic5 strain was obtained by 
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selection with 12.5 µg/mL of Clo and the E. coli BWΔtolCLic5 strain with 12.5 µg/mL of Clo 
and 50 µg/mL of Kan. Both strains were tested for antibacterial activity by colony-bioassay. 
Moreover, extracts of both strains prepared as previously described (section 4.4.6.5 on 
page 112) were analyzed by LC-ESI-MS. 
Since no antibacterial activity was observed for the E. coli BWΔtolCLic5 strain and none 
of the lichenicidin peptides were successfully identified, the reinstatement of tolC gene in 
this strain delivered by a plasmid vector was performed. Therefore, the tolC gene was 
amplified from a bacterial suspension of the E. coli BW25113 strain using the primers 
comp_tolCfw (5’-ACTGCATATGAAGAAATTGCTCCCCATT-3’) and comp_tolCrv (5’-
TAGATCTCGAGTCAGTTACGGAAAGGGTTATGA-3’), possessing the NdeI and XhoI 
recognition sequence (bold). The PCR reaction was performed in a final volume of 50 µL 
containing 1X of Herculase II reaction buffer, 0.25 mM of dNTP’s, 3 pmol/µL of each primer, 
1 µL of bacterial suspension and 0.25 µL of Herculase® II fusion DNA polymerase (Agilent 
Technologies). The parameters of amplification were as follows: 94 ºC for 5 min, 35 cycles 
of 94 ºC for 30 sec, 54 ºC for 30 sec and 72 ºC for 2 min and a final extension step of 10 min 
at 72 ºC. Two of such reactions were performed, pooled together and concentrated by 
final elution with 30 µL of sterile distilled water with the GenJet PCR purification kit 
(Fermentas). The PCR product was further digested with 10 U of NdeI and 20 U of XhoI 
(Fermentas). The reaction contained approximately 1-2 µg of purified PCR product and 1X 
of Buffer O (Fermentas), in a final volume of 40 µL. The pET15b (Novagen) vector was also 
digested in the same conditions. The reactions were incubated at 37 ºC for 3 hours, and 
purified with the GenJet PCR purification kit (Fermentas). Approximately 50 ng of the linear 
vector was ligated to 150 ng of digested PCR-product in a 20 µL reaction containing 
approximately 1-2 µg of DNA, 1X ligase buffer and 10 U of T4 DNA ligase (Fermentas). 5 µL 
of this reaction was used to transform chemically competent E. coli DH5α cells and the 
correspondent transformants selected on LB agar plates containing Amp at 100 µg/mL. 
Positive clones were screened by colony-PCR using the T7prom (5’-
TAATACGACTCACTATAGGGAGACCAC-3’) and T7term (5’- 
CAAAAAACCCCTCAAGACCC-3’) primers. Each PCR reaction was performed on a final 
volume of 12.5 µL containing 1.5 mM of MgCl2, 200 µM of dNTP’s, 1X Green GoTaq® Buffer, 
0.25 U of GoTaq® Buffer (Promega) and 0.3 pmol/µL of each primer. The amplification 
parameters were as follows: 94 ºC for 5 min, 35 cycles of 94 ºC for 30 sec, 54 ºC for 30 sec 
and 72 ºC for 2 min and a final extension of 10 min at 72 ºC. The resulting ptolC plasmid 
was extracted and sequenced to confirm the absence of mutations.  
Finally, the ptolC plasmid was transformed into electrocompetent 
E. coli BWΔtolCLic5cells and positive transformants selected on agar plates containing 
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Amp (100 µg/mL), Kan (50 µg/mL) and Clo (12.5 µg/mL). The obtained strain was 
designated as E. coli BWΔtolCLic5ptolC. The restoration of antibacterial activity was 
investigated by colony bioassay. Also, its extracts prepared as previously described 
(section 4.4.6.5, page 112) were analyzed by LC-ESI-MS. The empty pET15-b vector was 
also transformed into E. coli BWΔtolCLic5to obtain a control strain. 
 
 
4.4.11 Mass spectrometry analysis 
Routine LC-ESI-MS analytics was performed as described on section 2.4.6 (page 60).  
The HR-ESI-MS experiments were obtained on an Orbitrap XL mass spectrometer 
(Thermo Scientific, Bremen, Germany) coupled to an Agilent 1200 HPLC system (Agilent 
Technologies, Waldbronn, Germany).  Separations were performed using an Eclipse XDB 
C-18 column (Agilent) with a linear solvent gradient (5 % methanol containing 0.1 % of 
formic acid to 100 % methanol containing 0.1 % of formic acid in 25 min staying 10 min at 
100 % methanol).  
MS/MS experiments were performed on an Agilent triple quadrupole Mass 
spectrometer 6460 coupled with an Agilent 1290 HPLC, equipped with Agilent 
thermostatted column compartment SL+, autosampler and binary pump. The injection of 
pure compounds was accomplished via loop injection. For extracts, an Agilent column 
Eclipse plus C18 RRHD was used for separations with a gradient from 5 % to 100 % 
acetonitrile in 6 min and staying 2 min at 100 % acetonitrile. Fragment voltage and collision 
energy was optimized for each sample. 
 
 
4.4.12 Antibacterial activity assays 
Antibacterial activity plates, colony and liquid bioassays were performed as described 
on section 2.4.8 (page 61). For colony bioassays, testing strains were directly streaked into 
the bioassay plates.  
The impact of lichenicidin mutations on bioactivity was determined by an adaptation 
of the critical dilution assay (Ryan et al., 1996). Briefly, the volume of resuspension of each 
complemented strain extract was performed in order to normalize the quantity of mutated 
peptide in solution. The normalization was performed according to peak integration values 
(considering both double and triple ions) obtained for each peptide from LC-ESI-MS 
analysis. The extracts used for this analysis were obtained as described in section 3.4.5 on 
page 78. After the solvent evaporation, the pellets were resuspended in 70 % acetonitrile 
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accordingly with the obtained peak integration values. Each sample was diluted and 
dispensed into the wells of bioactivity agar plates. Inhibition zones were evaluated after 18 
h incubation at 37 ºC. Arbitrary units (AU ml-1) were determined accordingly with the last 
dilution for which antibacterial activity was visible. Non-producing strains or strains 
producing low levels of the mutated peptide were not considered for the assay.  
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5.1 Introduction 
 
 
 
 
 
antibiotic’s self-protection mechanisms of the Gram-positive producers typically 
involve an individual immunity protein (LanI) and/or an ABC transporter, usually 
composed of two or three subunits (LanFE(G)). An ancillary protein for the 
assembly of a functional ABC transporter has also been described (LanH) (Draper et al., 
2008). The presence of the genetic determinants associated with these mechanisms 
diverge depending on the lantibiotic that is being produced. Strains belonging to genus 
Bacillus are well known to produce several lantibiotics such as subtilin (B. subtilis ATCC 
6633), mersacidin (Bacillus sp. HIL Y-85,54728) and haloduracin (B. halodurans C-125) 
(Banerjee and Hansen, 1988; Chatterjee et al., 1992; McClerren et al., 2006; Lawton et al., 
2007). In the class I lantibiotic subtilin, immunity is mediated by the lipoprotein SpaI and the 
ABC translocator SpaFEG (Stein, 2005). SpaI protein should sequester subtilin at the 
cytoplasmic membrane level, preventing the accumulation of subtilin molecules, which 
could lead to pore formation. The ABC transporter SpaFEG complex should function by 
pumping the lantibiotic from the cell to the environment (Stein et al., 2005; Draper et al., 
2008). The self-protection mechanism of the class II lantibiotic mersacidin involves solely the 
MrsFGE ABC transporter (Guder et al., 2002) and no lanI-like gene could be identified in 
the mrs biosynthetic cluster. Despite the lack of experimental data regarding the immunity 
mechanism of the two-component lantibiotic haloduracin, two sets of LanFEG proteins are 
encoded within the hal gene cluster (Lawton et al., 2007). For other two-component 
lantibiotics as cytolysin, only CylI protein was associated with a protective effect for the 
producer strain (Coburn et al., 1999). None of the abovementioned systems require the 
presence of a LanH protein. In fact, lanH genes are absent in the majority of the operons 
associated with lantibiotics production (Draper et al., 2008). Still, Aso and co-workers (2005) 
L 
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showed that NukH could cooperate with NukFEG to provide the nukacin ISK-1 immunity. 
Moreover, it has also been suggested that NukH has the ability to inactivate nukacin ISK-1 
after binding it, thus providing immunity in a unique way (Okuda et al., 2005; Draper et al., 
2008). 
All the machinery necessary for the expression, modification, transport and regulation 
of the two-component lantibiotic lichenicidin are encoded in 14 contiguous open reading 
frames found on B. licheniformis chromosome. In the previous chapter, the lic gene cluster 
was cloned and successfully expressed in Escherichia coli (BLic5 strain). This system was 
further exploited to investigate the role of all the ORFs constituting the lic gene cluster, 
except those encoding the putative immunity genes. The five polypeptides previously 
associated with lantibiotic self-protection are putatively encoded within the lic 
biosynthetic cluster by licFGEHI ORFs (Rey et al., 2004; Veith et al., 2004). In this chapter, the 
impact of licFGEHI deletion for the lichenicidin self-protection of BLic5 strain was 
evaluated. Also, the production of the lichenicidin peptides Bliα and Bliβ was investigated 
in the absence of these ORFs. Moreover, it was experimentally confirmed that Gram-
negative OM constitutes a natural barrier that prevents the bactericidal action of 
lichenicidin peptides on the cytoplasm membrane. 
 
 
5.2 Results 
5.2.1 Deletion of licFGEHI genes in E. coli BLic5 
Although antimicrobial effects of individual peptides Bliα and Bliβ were within the 
micromolar concentration range, biological activity of their mixture at a 1:1 ratio was 
shown to be much higher than the sum of their individual contributions (Shenkarev et al., 
2010). Thus, Bliα and Bliβ should interact synergistically to exert their antagonist activity 
against Gram-positive bacteria within the nanomolar concentration range. Taking this 
information into consideration, the deletion of licFGEHI ORFs was firstly performed on the 
pLic5ΔA1and pLic5ΔA2 fosmids, in which licA1 and licA2 structural genes were deleted, 
respectively to decrease the possibility of bacterial self-killing caused by the synergetic 
activity of Bliα and Bliβ peptides. The strategy involved the replacement of the five ORFs by 
an apramycin resistance cassette using the λ RED redirect system as described in the 
Chapter IV. The constructed fosmids pLic5ΔA1ΔFGEHI:apra and pLic5ΔA2ΔFGEHI:apra 
conferring resistance to chloramphenicol (12.5 µg/mL) and apramycin (50 µg/mL) were 
transformed into chemically competent E. coli BL21 Gold (Stratagene). The obtained 
strains E. coli BLic5ΔA1ΔFGEHI and E. coli BLic5ΔA2ΔFGEHI were characterized by the 
absence of bioactivity against the indicator strain Micrococcus luteus (Figure 42B/C). 
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These mutants were also subjected to colony cross-feeding either with Bliα (through the 
strain BLic5ΔA2) or Bliβ (through the strain BLic5ΔA1) as described in the previous chapter. 
Since bioactivity was restored, it was shown that E. coli BLic5ΔA1ΔFGEHI retained the ability 
to produce Bliβ and E. coli BLic5ΔA2ΔFGEHI to produce Bliα (Figure 43). Such results were 
also confirmed by LC-ESI-MS analysis of butanol extracts (Figure 42B/C). 
 
 
 
Figure 42: Bioassay of E. coli mutants BLic5ΔFGEHI (A), BLic5ΔA1ΔFGEHI (B) and BLic5ΔA2ΔFGEHI (C) against the 
indicator strain M. luteus. LC-ESI-MS analyses of butanol extracts from the respective mutant liquid culture are also 
shown. 
 
 
In order to understand if the bacterial survival of these mutants accompanied by the 
production of the peptides resulted from Bliα or Bliβ absence, the deletion of licFGEHI was 
attempted in the fosmid pLic5 possessing both licA1 and licA2 intact structural genes. The 
resulting plasmid pLic5ΔFGEHI was constructed and transformed as abovementioned. 
Surprisingly, it was possible to obtain E. coli BLic5ΔFGEHI mutants producing both Bliα and 
Bliβ peptides, as confirmed by bioassay and LC-ESI-MS analysis (Figure 42A). Subsequently, 
the susceptibility to lichenicidin of both BLic5 and BLic5ΔFGEHI strains was accessed. Agar 
plates containing each of these strains were prepared the same way as those of the 
M. luteus indicator strain. The lichenicidin sample was obtained from the growth of the 
BLic5 strain at 37 ºC for 24 hours. After overnight incubation, no inhibition zones were 
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detected for both BLic5 and BLic5ΔFGEHI strains around the lichenicidin extract, 
suggesting that in E. coli, the immunity genes are not essential for the lichenicidin self-
protection mechanism.  
 
 
 
Figure 43: Cross-feeding agar diffusion assay of E. coli BLic5ΔA1ΔFGEHI and BLic5ΔA2ΔFGEHI mutants with Bliα 
(BLic5ΔA2) and Bliβ (BLic5ΔA1) peptides. The bacterial activity restored between BLic5ΔA1 and BLic5ΔA2ΔFGEHI 
suggested that this mutant was able to produce the Bliα peptide. Similarly, the M. luteus inhibition zone observed 
between BLic5ΔA2 and BLic5ΔA1ΔFGEHI suggested that this mutant was able to produce the Bliβ peptide. 
 
 
5.2.2 Lichenicidin production by E. coli BLic5 and E. coli BLic5ΔFGEHI 
The abundance of both lichenicidin peptides was investigated by LC-ESI-MS analysis of 
butanol extracts of BLic5 and BLic5ΔFGEHI cultures after 24 hours of growth and performed 
in triplicate. The values obtained from the TIC (total ion current) peak integration of each 
peptide were generally higher for BLic5 cultures (Bliα: 585.7±64.0 AU; Bliβ: 236.0±16.6 AU; 
AU= arbitrary units) than for BLic5ΔFGEHI cultures (Bliα: 400.7±169.5 AU; Bliβ: 125.7±41.8 AU) 
(Figure 44). 
 
 
 
 
 
 
 
Figure 44: Comparison of Bliα and Bliβ abundance 
on total butanol extracts of E. coli Blic5 (dark 
green/dark salmon) and E. coli Blic5ΔFGEHI (light 
green/light salmon) strains. 
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5.2.3 Outer membrane and lichenicidin self-protection 
It is believed that lichenicidin exerts its activity by inhibiting the cell-wall synthesis 
followed by the dissipation of the membrane target, similarly to haloduracin and 
lacticin 3147 (Wiedemann et al., 2006; Oman and van der Donk, 2009b). Thus, its inability 
to inhibit the Gram-negatives E. coli and Klebiella pneumoniae (Mendo et al., 2004; 
Dischinger et al., 2009) is consistent with the presence of an OM, which prevents the 
diffusion of lantibiotic peptides through the periplasmic space. In this situation, an E. coli 
with permeable OM should be sensible to the extracellular feeding of Bliα and Bliβ 
peptides mixture. To prove this hypothesis, E. coli BLic5 lichenicidin total butanol extracts 
(containing both Bliα and Bliβ) were dissolved in 70 % ACN/dH2O and bioassayed against 
E. coli imp4213 and the respective wild-type strain E. coli MC4100. E. coli imp4213 possesses 
a mutation in the imp gene (imp4213), which causes an OM permeability defect (Braun 
and Silhavy, 2002). Inhibition zones were observed on plates containing the imp4213 strain, 
but not on those containing the MC4100 strain (Figure 45). The activity of each peptide 
alone on these two strains was also examined. Thus, E. coli BLic5ΔA1 (producing exclusively 
Bliβ) and E. coli BLic5ΔA2 (producing exclusively Bliα) butanol extracts dissolved in 70 % 
acetonitrile were bioassayed side by side on plates containing either the imp4213 or the 
MC4100 strain. It was observed that imp4213 growth was affected only if both Bliα and Bliβ 
peptides were present (Figure 45). This suggests that when both Bliα and Bliβ reach the 
E. coli periplasmic space, they can act synergistically on their cellular targets.  
 
 
 
Figure 45: Bioassay of lichenicidin peptides against the E. coli imp4213 and MC4100 strains. E. coli imp4213 is 
susceptible to E. coli BLic5 cell-free supernatant, containing both Bliα and Bliβ peptides (A). E. coli imp4213 growth 
is only inhibited if both peptides are present (B). The extracts of BLicΔA1 and BLicΔA2 strains include only Bliβ or 
Bliα, respectively (B). 
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5.2.4 Sub-cellular location of LicP in E. coli 
The biosynthesis of the mature Bliβ peptide involves two proteolysis steps, similarly to 
what was described for the Halβ peptide (McClerren et al., 2006). Firstly, the LicA2 leader 
peptide must be removed by the LicT protein C-terminally from the GlyGly motif, 
presumably during its translocation through the cytoplasmic membrane. The second step, 
in the Gram-positive B. licheniformis should occur outside the bacterial cell, where the N-
terminus of the LicA2 propeptide (NDVNPE) is removed by the extracellular protease LicP, 
as mentioned in chapter IV. When the lic gene cluster was expressed in E. coli, the 
completely processed Bliβ peptide was identified in culture supernatants. Also, the LicP 
proteolytic activity was detected in culture supernatants of cells expressing the licP ORF, 
but not the other remaining genes of the lic biosynthetic cluster. Those results raised the 
question of whether LicP was being exported to the E. coli supernatant or if its extracellular 
activity was a result of OM leaking (being the periplasm the actual location of LicP). 
Therefore, the determination the sub-cellular localization of LicP in E. coli would be 
extremely useful for the elucidation of the complete lichenicidin biosynthesis on BLic5 
strain. With this in mind, the E. coli BLic5ΔP strain possessing the deleted licP gene was 
complemented with plicPHis6 plasmid to generate the BLic5ΔPlicPHis strain. That vector was 
based on the pET24-a+ plasmid, expressing the LicP protein with a C-terminal His-Tag. The 
functionality of LicP protein was confirmed by colony bioassay, where the antibacterial 
activity of BLic5ΔPlicPHis against M. luteus was restored. The presence of Bliβ peptide in 
BLic5ΔPlicPHis culture supernatants was also confirmed by LC-ESI-MS analysis. 
Subsequently, liquid cultures of BLic5ΔPlicPHis strain were performed. The bacterial cells 
were precipitated by centrifugation and subsequently divided into their periplasmic and 
spheroplastic fractions. Finally, the protein profile of these fractions and the bacterial pellet 
before fractionation was analyzed on SDS-PAGE gels after Comassie Blue staining. The 
same fractions obtained from BLic5ΔP strain cultures were also included in the SDS-PAGE 
gels for a comparative analysis. With the adopted methodology, no protein bands were 
visibly detected on samples corresponding to the cultures’ supernatants. Regarding the 
profile obtained for periplasmic and spheroplastic fractions it was found that the first 
fraction was highly contaminated with cytoplasmic proteins. Moreover, no differences in 
protein expression were visually detected between the extracts of BLic5ΔPlicPHis and 
BLic5ΔP strains. Therefore, in order to detect the LicP protein, a Western-blot analysis with 
anti-His-Tag antibodies was performed. A positive signal was obtained only with 
BLic5ΔPlicPHis strain samples corresponding to the bacterial pellet before fractionation. 
The signal was detected between 40 and 55 kDa and it was stronger in the sample 
resulting from the culture induced with IPTG. In fact, the predicted molecular weight for 
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LicP was approximately 49 kDa and 46 kDa before and after proteolysis of the six N-
terminally located amino acids of LicA2 propeptide, respectively. Thus, these results 
suggest that, when induced with IPTG, a higher proportion of LicP seems to aggregate into 
inclusion bodies. Consequently, less biologically active protease would be available for 
the Bliβ’ proteolysis. This result can also explain the decreased antibacterial activity, 
observed in colony-bioassay in presence of IPTG.  
 
 
5.3 Discussion 
Presently, little information is available with respect to the two-component lantibiotics’ 
immunity systems. Yet, the polypeptides involved in this self-protection mechanism are of 
particular interest, since it has not been clarified whether they are involved in the 
protection of the producer cell against one of the two peptides or both (Draper et al., 
2008). For lacticin 3147, the best studied two-component lantibiotic, it was demonstrated 
that LtnI is an essential protein for Lactococcus lactis immune phenotype most probably 
preventing the insertion of the bacteriocins in the membrane or by interacting directly with 
the peptides, inactivating them (McAuliffe et al., 2000). More recently, Draper et al. (2009) 
showed that both components of the ABC transporter LtnFE are also involved in lacticin 
3147 self-protection. In this case, LtnFE should be involved in the export of Ltnα and Ltnβ 
peptides allowing them to cross the Gram-positive producer strains cell wall (Draper et al., 
2009). 
In the present study, it was established that in E. coli, the expression of the genes 
involved in the lichenicidin self-protection (licFGEHI) of the producer survival is not 
essential. Moreover, our results demonstrated undoubtedly that E. coli cells are able to 
produce both lichenicidin peptides without the expression of such immunity genes. Yet, it 
was not clear if this genetic manipulation had a negative impact on the lichenicidin 
production rate caused for example by a decrease in the bacterial fitness. Although the 
exact mode of action of lichenicidin peptides was not elucidated so far, it is believed that 
it would be similar to that of lacticin 3147 (Martin et al., 2004) and haloduracin (Oman and 
van der Donk, 2009b). This would imply the binding of Bliα to lipid II (a central component 
in bacterial wall synthesis). Subsequently, the binding of the helical Bliβ to this complex 
should occur in a 1:1 stoichiometry, promoting the formation of ion-conducting pores in 
the cytoplasmic membrane, finally leading to cell death (Shenkarev et al., 2010). This 
model application implies that, in E. coli, these peptides can exert their activity only if they 
are able to reach the periplasmic space. In fact, this was experimentally confirmed in the 
present study, where an E. coli mutant possessing a compromised OM (imp4213) had its 
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growth inhibited by lichenicidin extracts, whereas that was not observed with the wild-type 
strain with an intact OM. The imp4213 mutation has been associated with the susceptibility 
of E. coli to a variety of antibiotics, including vancomycin, which are normally inactive 
against Gram-negative strains (Ruiz et al., 2005; Wu et al., 2005). Taking all these factors 
into consideration, lichenicidin self-protection of BLic5 and BLic5ΔFGEHI strains should be 
naturally due to the Gram-negative cell-wall structure, i.e. the presence of an OM, rather 
than the expression of licFGEHI genes. This aspect is also supported by the fact that the 
growth of BLic5ΔFGEHI strain was not susceptible to lichenicidin extracts. In fact, when Bliα 
and Bliβ are present in the extracellular space, they are not able to cross the OM and thus 
cannot access their cellular targets. Consequently, the functions that have been atributed 
to LanFGEHI polypeptides would be dispensable in E. coli lichenicidin expressing systems. 
As previously reported in chapter IV, the OM-protein TolC seems to be involved in the 
translocation of the lichenicidin peptides to the extracellular environment. Therefore, Bliα 
and Bliβ peptides are likely to be exported from the cell by a sec-independent type-I 
transport system. Nonetheless, the exact transport system through the complex Gram-
negative cell wall is still under investigation and debate. The results herein presented 
contribute to the further elucidation of that mechanism. Overall, it was shown that Bliα and 
Bliβ are active against E. coli if they contact with its periplasm. Even so, lichenicidin 
peptides were still produced by a licFGEHI-deficient strain (BLic5ΔFGEHI). The association of 
all these facts strongly suggests that Bliα and Bliβ transport system in E. coli should not 
involve the coexistence of both mature peptides in the periplasmic space. Yet, a 
periplasmic sublocation of an inactive complex as Bliα and the untrimmed Bliβ’ peptide 
could not be discarded. In such a scenario, LicP protein would be exclusively an 
extracellular protease. The attempt to identify the LicP location did not retrieve satisfactory 
results in the course of the present study. Yet, the bacterial system, which can be used in 
future studies for this purposes was established. The optimization of the concentration of 
the supernatant samples as well as the cellular fractionation would be determinant for the 
success of such investigation and would constitute an essential piece for the puzzle of 
lichenicidin export system in E. coli.   
 
5.4 Experimental procedures 
5.4.1 Bacterial strains and growth conditions 
The E. coli MC4100 and MC4100imp4213 were kindly supplied by Prof. Dr. Silhavy from 
Princeton University (USA). The strains were grown at 37 ºC and maintained on LB agar 
plates. 
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Luria-Bertani (LB; Merck) medium was used for general growth of E. coli strains, at 37 ºC 
or 30 ºC with aeration. Routine antibiotic selection was performed in LB agar plates 
containing the respective antibiotic concentrations. Medium M (section 2.4.1, page 55) 
was used for lichenicidin production. M. luteus ATCC 9341 was used as the indicator strain 
to test lichenicidin bioactivity. Also, the protocols for preparation of competent cells, 
transformation, PCR purification, plasmid extraction and DNA purification from gels are 
presented in the same section.  
 
5.4.2 Deletion of licFGEHI genes 
The deletion of licFGEHI genes from the fosmids pLic5, pLic5ΔA1 and pLic5ΔA2 were 
performed as described in section 4.4.6, 107. The primers used for the amplification of the 
apramycin resistance cassette were licFGEHIfw (5’-
TGACGTGACAATATCCCGCTTTTGAAAAACCCAAAAGGAGCTAGCATTCCGGGGATCCGT
CGACC -3’) and licFGEHIrv (5’- AAAGGGAGCCGGGTTTTGCTCAAAGGAGAAAACGGATC 
GGCTAGCTGTAGGCTGGAGCTGCTTC -3’). The primers used for the screening of the 
successful substitution of licFGEHI genes by the Apra cassette were check_licFfw (5’- 
CAGCCTTGACGGAAAGGATG-3’) and check_licIrv (5’- AGCTTGGCGCAAGCTATCAC-3’). 
The amplification temperature used for the PCR reactions involving these primers was 
52 ºC and the extension time amplification was 4 min. The expected amplicon before and 
after the substitution of licFGEHI genes by the Apra cassette was of approximately 3900 bp 
and 1500 bp, respectively. In these fosmids, the Apra resistance cassette was not excised.  
The final strains BLic5ΔFGEHI, BLic5ΔA1ΔFGEHI and BLic5ΔA2ΔFGEHI resulted from the 
transformation of chemically competent E. coli BL21 Gold cells with the fosmids 
pLic5ΔFGEHI, pLic5ΔA1ΔFGEHI and pLic5ΔA2ΔFGEHI, respectively. Each of these strains was 
subject to colony bioassay.  
 
 
5.4.3 Construction of BLic5ΔP complementation strain 
The E. coli BLic5ΔP was obtained by the extraction of the pLic5ΔP fosmid from the 
E. coliLic5ΔP strain (constructed in chapter IV) according to section 4.4.5 (page 107). For 
the construction of the plicPHis plasmid, the licP gene was amplified from a bacterial 
suspension of B. licheniformis I89 with the primers comp_licPHis_fw (5’-
AAGGAGATATACATATGAAAAGAATATATATTTTTCTC-3’) and comp_licPHis_rv (5’-
GGTGGTGGTGCTCGAGCTCCTTGTTCATCATTTTCAG-3’). Each PCR reaction was 
performed in a total volume of 50 µL, containing 1X of Herculase II reaction buffer, 0.25 mM 
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of dNTP’s, 3 pmol/µL of each primer, 1 µL of bacterial suspension and 0.25 µL of 
Herculase® II fusion DNA polymerase (Agilent Technologies). The parameters of 
amplification were as follows: 94 ºC for 5 min, 35 cycles of 94 ºC for 30 sec, 50 ºC for 30 sec 
and 72 ºC for 1 min and a final extension step of 10 min at 72 ºC. Two of such reactions 
were performed, pooled together and concentrated by final elution with 20 µL of sterile 
distilled water with the GeneJet PCR purification kit (Fermentas). The plasmid pET24-a(+) 
was extracted and 5 µg of its DNA were digested in a reaction containing 1 X of FastDigest 
buffer (Fermentas), 3 µL of FastDigest XhoI (Fermentas), 3 µL of FastDigest NdeI (Fermentas) 
in a final volume of 60 µL. The reaction was incubated for 5 min at 37 ºC, purified and 
concentrated with the GeneJet PCR purification kit (Fermentas) to a final volume of 20 µL. 
The licP PCR product (approximately 1300 bp) was ligated to the digested vector using the 
In-Fusion Advance PCR cloning kit (Clontech). Each reaction was performed on a final 
volume of 10 µL containing 100 ng of the linearized vector, 200 ng of the PCR product, 1 X 
of the In-Fusion reaction buffer and 1 µL of In-Fusion enzyme. The mixture was incubated at 
37 ºC for 15 min, followed by 15 min at 50 ºC and then placed on ice. Finally, 40 µL of TE 
buffer were added. 10 µL of the reaction were used to transform E. coli DH5α chemically 
competent cells. The transformants were selected on LB agar plates containing Kan (50 
µg/mL) and the positive clones screened by colony PCR as described in section 4.4.7.1 
(page 113). After purification and sequencing the plicPHis plasmid was transformed into 
chemically competent E. coli BLic5ΔP cells. Positive transformants were selected on LB 
agar plates containing Kan (50 µg/mL) and Clo (12.5 µg/mL). The final complemented 
strain was designated as BLic5ΔPlicPHis. Its antagonistic activity was evaluated by colony 
bioassay. The production of lichenicidin peptides was confirmed by LC-ESI-MS analysis, 
where total extracts were prepared as described on section 3.4.5 (page 78). 
 
 
5.4.4 Sub-cellular location of the LicP protease 
5.4.4.1 Cell fractionation 
A pre-culture of the strains E. coli BLic5ΔPlicPHisand BLic5ΔP was prepared in medium M 
supplied with the appropriate selective marker. 50 mL of fresh medium without the 
addition of antibiotics were inoculated with 500 µL of the pre-cultures and grown at 37 ºC 
with aeration (160 rpm). Two distinct cultures were performed for each strain. When the 
bacterial density reached the OD600nm of 0.6, one culture of each strain was induced with 
IPTG at a final concentration of 0.5 mM. 3 mL of the bacterial culture with an OD600nm of  2 
were centrifuged for 5 min at 12,000 x g. The pelleted cells were divided into their 
periplasmic and spheroplastic fractions with the PeriPreps™ Periplasting Kit (Epicentre). The 
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cells were resuspended with 150 µL of PeriPreps periplasting buffer containing omnicleave 
endonuclease (Epicentre) by mixing up and down and incubated at room temperature 
for 5 min. Subsequently, 150 µL of sterile purified water at 4 ºC was added, followed by 
mixing inversion and incubation on ice for 5 min. The cells were again centrifuged at 12000 
x g for 2 min at room temperature. The resulting supernatant containing the periplasmic 
fraction was transferred to a clean microtube and the pellet resuspended with 300 µL of 
lysis buffer (Epicentre). 3 µL of MgCl2 (1 M) was then added, the solution was mixed by 
inversion and incubated at room temperature for 5 min. The debris was centrifuged at 
12000 x g for 5 min at room temperature and the supernatant containing the spheroplastic 
fraction was transferred to a new tube. Finally, 6 µL of EDTA (500 mM) were added to this 
fraction. The 3 mL of culture supernatant were applied to an Amicon Ultra-4Ultracel-30 
column (Millipore) and centrifuged at 4,000 x g for 10 min in order to concentrate proteins 
with a molecular weight above 30 KDa. The concentrated volume constituted the 
supernatant fraction. Moreover, the pelleted cells of each culture were also resuspended 
with 300 µL of 1 X SDS-PAGE loading buffer and processed as described in the following 
section. 
The protein content of these four fractions (supernatant, periplasmic, spheroplastic and 
whole cells) was analyzed by SDS-PAGE and the identification of LicP protein performed 
by Western-blot.  
 
 
5.4.4.2 SDS-PAGE analysis 
For the protein analysis, the supernatant, periplasmic and spheroplastic fractions were 
mixed with 5 X SDS PAGE loading buffer at a proportion of 5:1. These samples, together 
with the previously prepared whole cell samples were boiled at 100 ºC for 10 min and 
applied to the polyacrylamide gel. The running gel was prepared as described in Table 15. 
The running buffer (1X) was added to the anode and cathode electrodes and the 
samples were loaded. The electrophoresis was performed 30 min at 50 mA, 30 min at 
60 mA followed by 1 hour and 30 min at 80 mA. The protein content was visualized directly 
in the gels by Comassie staining as described in section 3.4.6 of page 78.  
 
 
Solution 
5 X SDS loading buffer: 1.5 g of SDS, 3.75 mL of 1M Tris (pH 6.8), 0.015 g of bromophenol blue, 7.5 mL of distilled 
water and 7.5 mL of glycerol. DTT was added to a final concentration of 0.1 M to the sample before boiling. 
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Table 14: Reagents used for the preparation of monomer solutions of the gels used in this section. APS stands for 
ammonium persulphate and TEMED for N,N,N',N'-tetramethylethylenediamine. These two compounds should be 
added immediately prior to pouring the gel. The volumes presented are for the preparation of two gels. 
Solutions/Reagents Stacking gel 
(4 %) 
Separating gel 
(15 %) 
AB-3  (mL) 1.03 5.3 
1.5 M Tris-HCl pH 8.8 (mL) - 5 
0.5 M Tris-HCl pH 6.8 (mL) 3.15 - 
10% SDS (µL) 60 200 
10% APS (µL) 40 50 
TEMED (µL) 15 20 
Distilled water (mL) 1.5 9.3 
Total volume (mL) 5.8 20 
 
 
 
5.4.4.3 Western-blot analysis 
For Western blot analysis, the SDS-PAGE gel was incubated approximately 20 min with 
the transfer buffer, together with two pieces of blotting paper (Roth; 6 x 9 cm) and the 
nitrocellulose membrane (Wathman; 6 x 9 cm). After this period the gel was assembled 
with the membrane and the blotting paper in the Trans-blot SD cell (Bio-Rad) in the 
following order, starting from the bottom of the apparatus: blotting paper, membrane, gel, 
blotting paper. The transfer was carried out at 100 mA for approximately 1 hour. 
Subsequently, the membrane was incubated with the blocking solution for 1 hour at room 
temperature and with the primary anti-His tag antibody solution at 4 ºC for 16/18 hours. 
After this period, the membrane was washed three times with 30 mL of TNT buffer 
containing 1% of BSA. Each of these washes were performed for 20 min and were followed 
by the incubation of the membrane with 30 mL of the TNT solution containing the 1 % of 
BSA and 6 µL of the secondary antibody (anti-rabitt-AP; Sigma) at 4º C for 1 hour and 30 
min. The membrane was finally washed three times with 30 mL of TNT solution, each time. 
The membrane was performed in 10 mL of AP buffer containing 300 µL of BCIP (Roche) 
and 135 µL of NBT (Roche). The membrane was incubated in the dark and the reaction 
was stopped with distilled water.  
 
Solutions 
TNT buffer: 50 mM of Tris/HCl (pH 7.6), 500 mM of NaCl and 0.5 % of Triton X-100. 
Transfer buffer: 25 mM of Tris, 195 mM of glycine and 20 % of methanol. 
Blocking buffer: TNT buffer containing 3% of BSA. 
Primary antibody buffer: TNT buffer containing 1% of BSA and 0.02 % of thimerosal containing 1/1000  of the anti-
His tag polyclonal rabbit antibody (Sigma). 
AP buffer: 12.1 g of Tris/HCl, 5.8 g of NaCl and 1 g of MgCl6.H2O at final pH of 9.5. 
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BCIP: Preparation of 1 mg/µL solution in DMF. 
NBT: Dilution of 6.75 mg in 135 µL of 70 % DMF. 
 
 
5.4.5 Antagonistic bioassays 
The E. coli MC4100, E. coli imp4213, E. coli BLic5 and E. coli BLic5ΔFGEHI bioassay plates 
were prepared as those containing M. luteus as described in section 2.4.8 (page 61). 
Likewise, colony-bioassays and liquid samples bioassays were also performed according 
with the same section. 
 
5.4.6 LC-ESI-MS analysis 
The LC-ESI-MS analysis of total extracts were performed as described on section 3.4.6 
(page 78).  
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6.1 Introduction 
 
 
 
 
 
 
he biological activities of lantibiotics, especially their antibacterial activity, has 
been of much interest (Cortes et al., 2009). These compounds are a class of 
ribosomally synthesized peptides that undergo extensive posttranslational 
modifications (Chatterjee et al., 2005; Willey and van der Donk, 2007). The biosynthetic 
nature of these compounds represents a key advantage over classical antibiotics (of 
nonribosomal and polyketide origin) for the development of bioengineering strategies 
(Field et al., 2010). Therefore, several in vivo systems have been developed to express new 
variants of lantibiotics, either by homologous or heterologous expression systems. Some 
examples include the class 1 lantibiotics nisin (Dodd et al., 1992; Kuipers et al., 1992) and 
subtilin (Liu and Hansen, 1992) as well as the class 2 lantibiotics mersacidin (Szekat et al., 
2003), nukacin ISK-1 (Aso et al., 2004a) and lacticin 3147 (Cotter et al., 2006a). Studies 
involving site-directed mutagenesis and more recently random mutagenesis of lantibiotics 
structural genes have been helpful to establish some guidelines for rational peptide 
design. Moreover, several peptides with enhanced activity were already obtained as a 
result of these procedures. Interesting examples include nisin variants active against Gram-
negative bacteria (Yuan et al., 2004), mersacidin variants exhibiting twofold increased 
activity against important pathogens such as MRSA and VRE (Appleyard et al., 2009). Also, 
the generation of nukacin ISK-1 derivatives which are over produced when compared 
with the wild-type peptide (Islam et al., 2009). Some of these studies also showed that the 
biosynthetic enzymes for both class 1 and 2 lantibiotics can tolerate several amino acid 
changes in the respective prepropeptides (Patton et al., 2008). Even so, some of such 
alterations did not yield the desrired peptide variant at all. Under these circumstances it 
T 
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was not clear if the modifications were not compatible with the host biosynthetic, transport 
and/or immunity system (Cortes et al., 2009; Field et al., 2010). Therefore, the recognition of 
the catalytic flexibility as well as the nature of the enzymatic interactions of the other Lan 
proteins, apart from LanA prepropeptides, became a prerequisite for the bioengineering 
of lanbiotics. In this context, the recognition of the in vitro activity of some of these 
enzymes, especially LanM, LanB and LanC greatly contributed to the knowledge in this 
field.  
For class 2 lantibiotics, the in vitro reconstitution of the lacticin 481 modifying-enzyme 
LctM revealed its permissive substrate specificity (Xie et al., 2004). The importance of such 
characteristics in peptide engineering was already proved by the production of synthetic 
non-lantibiotic peptides containing both natural and non-proteinogenic amino acids 
(Levengood et al., 2009). In addition, LctM enzyme was able to process the lacticin 481-
like lantibiotics nukacin ISK-1, mutacin II and ruminococcin A to active compounds 
through the fusion of their propeptides with the LctA leader sequence (Patton et al., 2008). 
The same study proved that LctM was capable of processing the LctA propeptide N-
terminally fused with the MutA (mutacin II prepropeptide) and NukA (nukacin ISK-1) leader 
sequences (Patton et al., 2008). These findings were in agreement with those in vivo 
experiments conducted for the class 1 lantibiotics nisin and subtilin (Kuipers et al., 1993b; 
Chakicherla and Hansen, 1995). To the best of our knowledge, similar studies for class 2 
lantibiotics were performed with the nukacin ISK-1 and lacticin 3147 whole-cell expression 
systems (Aso et al., 2004a; Nagao et al., 2007; Kuipers et al., 2008). 
Equally important are the LanT biosynthetic enzymes of class 2 lantibiotics, comprising 
the N-terminal peptidase domain and the C-terminal ATP-binding domain (Chatterjee et 
al., 2005). Their bifunctional activity involves the removal the leader sequence as well as 
the transport of the lantibiotic peptides. In vivo studies with lacticin 3147 (Kuipers et al., 
2008) and lacticin 481 (Uguen et al., 2005) biosynthetic machineries indicated that both 
LtnT and LctT exhibit relaxed substrate specificity. Nonetheless, the presence of the double 
glycine domain cleavage site (GG/GA) was always found to be indispensable for the 
leader sequence removal (Uguen et al., 2005). This was also indispensable for the catalytic 
process of the LctT protease domain involving in vitro assays (Ihnken et al., 2008). 
In chapter IV a heterologous expression system was developed for the class II lantibiotic 
lichenicidin. With that system some lichenicidin variants were produced for the first time, 
through a trans complementation approach. In this chapter the same strategy was 
employed to investigate the flexibility of the lichenicidin machinery to interact with the 
haloduracin biosynthetic elements in the heterologous host E. coli.  
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6.2 Results 
6.2.1 Complementation of lichenicidin mutants with haloduracin-biosynthetic 
genes 
Haloduracin HalA1 and HalA2 propeptides are highly related to the prepropeptides 
LicA1 and LicA2, with homologies of 46 % and 44 %, respectively. However, if the analysis is 
narrowed to their leader sequences, lower similarities were observed, being 31 % between 
LicA1 and HalA1 (Figure 46A) and 22 % between LicA2 and HalA2 (Figure 46B). Regarding 
propeptides sequences, LicA1 and HalA1 and LicA2 and HalA2 share a similarity of 47 % 
and 56 %, respectively (Figure 47). This is mostly due to the conserved amino acid residues 
located at the C-terminus. Beholding the analysis of LicM modifying enzymes, the highest 
similarity scores were obtained with HalM1 (35 % homology) and HalM2 (35 % homology). 
The lichenicidin transporter/peptidase LicT shared the highest homology (50 %) with its 
counterpart involved in the haloduracin biosynthetic pathway, HalT. Thus, the 
polypeptides and enzymes intervening in haloduracin production were found to be more 
related to those intervening in the lichenicidin synthesis.  
 
 
 
 
 
 
 
 
Figure 46: Alignment of the leader sequences of lichenicidin (LicA1 and LicA2) and haloduracin (HalA1 and 
HalA2) prepropeptides. The conserved residues between the two sequences are highlighted in grey. 
 
 
 
 
 
 
 
 
Figure 47: Alignment of the lichenicidin (LicA1 and LicA2) and haloduracin (HalA1 and HalA2) propeptides. The 
conserved residues between the two sequences are highlighted in grey. 
 
Based on these findings, E. coli BLic5 knockout mutants lacking each of the 
abovementioned lic genes were complemented with its counterpart of the haloduracin 
A 
A 
B 
A 
B 
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biosynthetic operon. For that, competent cells of E. coli BLic5ΔA1, BLic5ΔA2, BLic5ΔM1, 
BLic5ΔM2 and BLic5ΔT strains were transformed with the plasmids phalA1, phalA2, phalM1, 
phalM2 and phalT, respectively to obtain the BLic5ΔA1phalA1, BLic5ΔA2phalA2, 
BLic5ΔM1phalM1, BLic5ΔM2phalM2 and BLic5ΔTphalT complemented strains (Table 15). 
The same approach was used for plasmids encoding the licA1, licA2, licM1, licM2 and licT 
genes to obtain the positive controls for this experiment (Table 15). Subsequently, all the 
constructed strains were bioassayed against M. luteus and LC-ESI-MS analysis of extracts 
recovered from medium M cultures (hereafter referred as “extracts”) was performed.  
As established in chapter IV, the deletion of the genes encoding the lichenicidin 
prepropeptides (licA1 or licA2), the modifying enzymes (licM1 or licM2) and the dual 
transporter/protease (licT) resulted in the abolishment of visible M. luteus growth inhibition. 
That was a consequence of the abrogation of the production of either Bliα or Bliβ (except 
for ΔT, where the synthesis of both peptides was abolished). Thus, the complementation of 
these mutants with each of the plicA1, plicA2, plicM1, plicM2 and plicT plasmids should 
result on strains with restored biosynthesis of the lichenicidin peptides and consequently 
possessing antagonistic activity. Indeed, that was observed in the present study, where the 
molecular masses of both Bliα (M= 3250 Da) and Bliβ (M=3020 Da) peptides were always 
detected in the lic complementation strains extracts (Table 15). Regarding the 
complementation of the same knockout mutants with the haloduracin genetic 
determinants, restoration of colony-bioactivity was only observed for the BLic5ΔTphalT 
strain, indicating that both peptides Bliα and Bliβ were synthesized (Table 15). Actually, the 
LC-ESI-MS analysis of BLic5ΔTphalT extracts revealed the presence of both peptides in its 
bacterial supernatant. The analysis of BLic5ΔA1phalA1 and BLic5ΔA2phalA2 strains implied 
that lichenicidin-modifying enzymes could process the lichenicidin prepropeptides and 
therefore the Halα/Bliβ and Bliα/Halβ peptides’ complexes, respectively, would be 
produced. However, only the molecular masses of Bliβ and Bliα peptides in the extracts of 
these two bacterial strains were identified (Table 15). The Halα (M= 2331 Da) and Halβ (M= 
3043 Da) peptides or some of their derivatives (with different levels of dehydration or 
proteolysis) could not be detected in the same extracts.  
The ability of haloduracin modifying enzymes HalM1 and HalM2 to replace the LicM1 
and LicM2 functionality was tested by the construction of BLic5ΔM1phalM1 and 
BLic5ΔM2phalM2 strains. The LC-ESI-MS analysis of their extracts revealed that 
BLic5ΔM1phalM1 and BLic5ΔM2phalM2 produced only Bliβ and Bliα peptides, respectively 
(Table 15). Consequently, none of the lichenicidin peptides (or their derivatives) whose 
biosynthetic pathway was initially disrupted could be identified. 
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Table 15: Results obtained for the E coli BLic5 knockout mutants complemented with haloduracin biosynthetic 
determinants, regarding their antagonistic activity as well as the results of LC-ESI-MS analysis. + and – symbols 
represent the presence or absence of antibacterial activity of the complemented strain against M. luteus. The 
genes which were allocated in the pET24-a(+) vector in the complementation strains are highlighted with bold 
characters. 
MS outcome (Da) Strain lanA lanM lanT Colony bioassay Expected Outcome 
BLic5ΔA1plicA1 licA1 licA2 licM1 licM2 licT + 3250 and 3020 3250 and 3020 
BLic5ΔA2plicA2 licA1 licA2 licM1 licM2 licT + 3250 and 3020 3250 and 3020 
BLic5ΔM1plicM1 licA1 licA2 licM1 licM2 licT + 3250 and 3020 3250 and 3020 
BLic5ΔM2plicM2 licA1 licA2 licM1 licM2 licT + 3250 and 3020 3250 and 3020 
BLic5ΔTplicT licA1 licA2 licM1 licM2 licT + 3250 and 3020 3250 and 3020 
BLic5ΔA1phalA1 halA1 licA2 licM1 licM2 licT - 2331 and 3020 3020  
BLic5ΔA2phalA2 licA1 halA2 licM1 licM2 licT - 3250 and 3043  3250  
BLic5ΔM1phalM1 licA1 licA2 halM1 licM2 licT - 3250 and 3020 3020  
BLic5ΔM2phalM2 licA1 licA2 licM1 halM2 licT - 3250 and 3020 3250  
BLic5ΔTphalT licA1 licA2 licM1 licM2 halT + 3250 and 3020 3020 and 3250  
 
 
6.2.2 Production of haloduracin peptides directed by lichenicidin leader 
sequences 
As shown in the last section, the in vivo production of haloduracin peptides using the 
lichenicidin biosynthetic machinery, directed by halA1 and halA2 structural genes was not 
successful. The leader sequences have been described as important factors for the 
correct dehydration and cyclization of lantibiotics’ propeptides. With that in mind, the 
synthesis of haloduracin bioactive peptides directed by LicA1 and LicA2 leader sequences 
was attempted. To accomplish this objective, two genes encoding the chimeric peptides 
LicA1LHalA1P and LicA2LHalA2P (Figure 48) were synthetically produced. Their respective 
ORFs were further cloned on the pET24-a(+) vector to obtain the plasmids pchimeraA1 
and pchimeraA2. Subsequently, these two plasmids were transformed into BLic5ΔA1 and 
BLic5ΔA2 knockout mutants to originate the BLic5ΔA1pchimA1 and BLic5ΔA2pchimA2 
strains, respectively. Finally, these two strains were bioassayed against M. luteus and their 
extracts obtained from fermentations in medium M cultures were further analyzed by LC-
ESI-MS. 
It was observed that both strains were not able to inhibit M. luteus growth. However, 
antagonistic activity was observed when BLic5ΔA1pchimA1 was incubated next to 
BLic5ΔA2 and BLic5ΔA2pchimA2 next to BLic5ΔA1, suggesting the production of Bliβ by 
BLic5ΔA1pchimA1 and Bliα by BLic5ΔA2pchimA2 strains. In fact, the molecular masses of 
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Bliβ and Bliα were successfully detected on the extracts of BLic5ΔA1pchimA1 and 
BLic5ΔA2pchimA2, respectively. None of the haloduracin peptides or some of their 
derivatives could be identified (Table 16).  
 
 
Figure 48: Amino acid sequence of LicA1LHalA1P (A), LicA2LHalA2 P and LicA2L-NDVNPE-HalA2 P (B) chimeric 
peptides encoded by pchimeraA1, pchimeraA2 and pchimeraA2.1, respectively. The leader sequence of 
lichenicidin peptides (tagged as LicA1 and LicA2) and the haloduracin propeptides sequences (tagged as 
HalA1 and HalA2) are also represented. 
 
 
As discussed in chapter IV, the production of Bliβ and Halβ involves a proteolysis step 
after the leader peptide processing involving the removal of the six N-terminally located 
amino acids of their propeptides. LicP is the protease involved in this reaction for the Bliβ 
peptide (chapter IV). However, its counterpart in the Halβ biosynthesis was not described 
so far. The untrimmed Bliβ’ and Halβ’ correspond to the NDVNPE-Bliβ and GDVHAQ-Halβ 
peptides, respectively. Thus, the conservation identified in the Bliβ’ and Halβ’ N-termini is 
restricted to Asp-5 and Asn-6 residues. The licA2LhalA2P ORF was first designed to originate 
a chimeric peptide containing the Halβ’ sequence in the C-terminal of the LicA2 leader 
sequence (Figure 48). Nevertheless, no information is available concerning the specificity 
of LicP protease so far. Therefore, the absence of the Halβ peptide in the 
BLic5ΔA2pchimA2 extracts could have been due to a failure of the trimming of the Halβ’ 
N-terminal by the LicP protease.  In this context, a new ORF was obtained by site-directed 
mutagenesis, whose expression resulted in the chimeric peptide LicA2L-NDVNPE-HalA2P. In 
this peptide the N-terminal of Bliβ’, which is believe to be involved in the LicP catalytic 
specificity, substituted that of the Halβ’ peptide (Figure 48). The plasmid containing the 
new ORF (pchimeraA2.1) was used to transform the BLic5ΔA2 knockout mutant, originating 
the BLic5ΔA2pchimA2.1 strain. Even so, this new strain was still unable to inhibit the growth 
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of M. luteus. Also, the molecular masses of Halβ peptide or their derivatives could not be 
identified by LC-ESI-MS analysis of its extracts, where Bliα peptide was detected (Table 16). 
 
Table 16: Results obtained for the E coli BLic5 knockout mutants complemented with the lichenicidin/haloduracin 
chimeric genes. The genes encoding the lichenicidin modifying enzymes and its transporter/protease were 
maintained in all the strains. - symbols represents the absence of antagonistic activity. The molecular masses of 
2331 Da and 3043 Da correspond to the fully modified Halα and Halβ peptides. a) This mass takes in account that 
LicP is able to remove the N-terminal of Halβ’ peptide. 
MS outcome (Da) 
Strain lanA 
Colony 
bioactivity Expected Detected 
BLic5ΔA1pchimeraA1 licA1halA1 licA2 - 2331 and 3020 3020 
BLic5ΔA2pchimeraA2 licA1 licA2halA2 - 3043a)and 3250 3250 
BLic5ΔA2pchimeraA2P licA1 licA2PhalA2 - 3043 and 3250 3250 
 
 
 
6.3 Discussion 
The results herein presented revealed that the transporter/protease present in the 
haloduracin gene cluster (halT) is able to transport and remove the leader sequence of 
LicA1 and LicA2 prepropeptides when the peptides are expressed in E. coli. Previous 
studies have already demonstrated the promiscuity of LtnT in vivo, since nisin and 
angiotensin peptides fused with LctA2 leader sequence were successfully transported and 
proteolytic processed by Lactococcus lactis (Kuipers et al., 2008). In our study, no such 
fusions were made. Thus, our results suggest that the absence of HalA1 and HalA2 leader 
sequences were not critical for the export of Bliα and Bliβ peptides by HalT. Still, it is 
important to emphasize that both lichenicidin and haloduracin peptides possess the 
double glycine motif (GG/GA) N-terminally of their propeptide sequences. According to 
previous studies (Uguen et al., 2005; Ihnken et al., 2008), we believe that these motifs are 
essential for the removal of LicA1 and LicA2 leader sequences by HalT.  Similarly, Nagao 
and co-workers (2007) demonstrated that the lacticin 481 LctT was able to replace the 
function of nukacin ISK-1 NukT in the transport and leader sequence proteolysis of NukA in 
a whole-cell system.  
The replacement of licA1 and licA2 by the structural genes of the haloduracin gene 
cluster were performed to investigate the dehydratation and cyclization ability of LicM1 
and LicM2 of the haloduracin prepropeptides. The results were inconclusive, since 
molecular masses of Halα and Halβ or their derivatives (e.g. peptides with different levels of 
dehydration) could not be detected. Therefore, it was not possible to understand if LicM1 
and LicM2 were completely unable to process haloduracin prepropeptides or alternatively 
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if the host could not cope with a non-fully modified Halα and Halβ peptide. However, 
regarding the HalA2 propeptide it is important to refer that the protease responsible for 
Halβ second proteolysis step was not present and it was not possible to established if the 
LicP protease is able to process the Halβ’ N-terminus. Similar results were herein obtained in 
the experiments where the ability of haloduracin modifying enzymes HalM1 and HalM2 to 
process lichenicidin prepropeptides was evaluated. In this situation, halM1 was expressed 
in a licM1-deficient strain and halM2 in a licM2-deficient strain. LC-ESI-MS analysis revealed 
that these strains were unable to produce Bliα and Bliβ peptides, respectively, or any of its 
derivatives. Thus, it was also not possible to establish if the HalM1 and HalM2 processing of 
lichenicidin propeptides were completely or only partially inefficient. In fact, in vivo 
experiments on both class 1 and class 2 lantibiotics have demonstrated that the modifying 
enzyme are not able to process prepropeptides from distinct (even closely-related) 
biosynthetic pathways. For instance, when the complete lacticin 481 prepropeptide was 
expressed in a nukacin ISK-1-producer cell, no lacticin 481-related peptide products were 
produced (Nagao et al., 2007). The same results were obtained for class 1 lantibiotics, 
since the B. subtilis subtilin-production machinery was not able to process the nisin 
prepropeptide (Rintala et al., 1993). Also, no nukacin ISK-1 derivates were identified when 
the LctM enzyme replaced the function of NukM in the modification of NukA 
prepropeptide (Nagao et al., 2007). On the contrary, in vitro assays demonstrated that the 
LctM enzyme is able to process NukA substrate into a 4-fold dehydrated peptide, which 
was biologically active after proteolytic removal of its leader sequence (Patton et al., 
2008).  
Considering the class 1 lantibiotics subtilin and nisin, it was also hypothesized that subtilin 
machinery was incapable to process the nisin prepropeptide, since its gene products were 
not detected (Rintala et al., 1993). However, when the subtilin leader sequence was fused 
with the nisin propeptide sequence, a dehydrated but inactive product was produced by 
the subtilin biosynthetic system (Chakicherla and Hansen, 1995). Moreover, chimeras of 
lacticin 3147 leader sequence and forms of angiotensin peptides were modified, 
processed and transported by LtnM2 and LtnT in the L. lactis host (Kuipers et al., 2008). The 
same capability was demonstrated for the LctM enzyme, in in vitro assays, since it was 
able to catalyze the dehydration and cyclization of nukacin ISK-1, mutacin II and 
ruminococcin A propeptides fused with the LctA leader sequence (Patton et al., 2008). To 
clarify this aspect, the ability of lichenicidin biosynthetic machinery to cope with LicL-HalP 
chimeras was also evaluated. To accomplish this, nucleotide sequences corresponding to 
LicA1 and LicA2 leader sequences were fused with those corresponding to HalA1 and 
HalA2 structure peptides, respectively. After expression of LicA1L-HalA1P and LicA2L-HalA2P 
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chimeras with the lichenicidin machinery, no haloduracin peptides or its derivatives were 
identified by LC-MS-ESI analysis. The influence of the six N-terminal amino acids that are 
trimmed from Bliβ’ and Halβ’ peptides to produce the fully active forms was also 
evaluated. The LicA2L-HalA2P chimera possessed the Halβ’ N-terminus, whereas in LicA2L-
NDVNPE-HalA2P chimera the equivalent sequence of Bliβ’ was introduced. Still, in the 
presence of a substrate for the LicP protease, it was not possible to identify the Halβ 
peptide or its derivatives. As such we proved that these results were not affected by the 
action of LicT. So, it can be expected that even in the presence of the lichenicidin leader 
sequences, the LicM1 and LicM2 dehydration and cyclization of haloduracin is not 
completely efficient. It is believed that LanM enzymes process their peptide subtrates 
distributively and directionally, moving from the N- to the C-terminus (Lee et al., 2009; 
Oman and van der Donk, 2009a). However, the conservation of the N-terminus of 
lichenicidin and haloduracin propeptides is very low (Figure 47). Such differences are 
possibly preventing the correct dehydratation and ring formation of haloduracin 
propeptides. In fact, this could explain the unsuccessful identification of Halα and Halβ 
characteristic molecular masses as well as that of their derivatives. For instance, in chapter 
IV it was found that as a result of the perturbation of C-terminally located thioether rings in 
the Bliα and Bliβ peptides, the mutated peptide(s) or its derivatives were not detected by 
LC-ESI-MS analysis. Similar results were obtained for lacticin 3147 Ltnα and Ltnβ variants 
(Cotter et al., 2006a). We believe that the same tendency should be expected for the in 
vivo biosynthesis of haloduracin, especially considering the conservation of C-terminally 
located amino acids and ring structures between the lichenicidin and haloduracin mature 
peptides (Figure 32, page 85). According to this, a distortion in the Halα or Halβ C-terminal 
cyclization pattern would surely prevent their identification in the bacterial extracts. 
Further information provided by this system will help to establish the specificity of the 
lichenicidin biosynthetic enzymes. The exploitation of the BLic5 expression system will also 
allow the generation of other lantibiotics, including those that were not previously 
characterized from their primary producers. Indeed, a recent study demonstrated that 
nisin biosynthetic machinery can produce active forms of the PneA1 and PneA2 
propeptides, which represents a two-component lantibiotic encoded in the chromosome 
of Streptococcus pneumoniae R6 strain (Majchrzykiewicz et al., 2010). 
 
 
6.4 Experimental procedures 
The lichenicidin and haloduracin genes were amplified from Bacillus licheniformis I89 
and Bacillus halodurans C-145, respectively. The amplification reactions were performed in 
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a final volume of 25 µL, containing 1X of Herculase® II reaction buffer, 0.25 mM of dNTP’s, 
0.3 pmol/µL of each primer and 0.25 µL of Herculase® II fusion DNA polymerase (Agilent 
Technologies). Bacterial suspensions were prepared in 100 µL of distilled water and 1 µL of 
this solution was used as the DNA template for the reaction. The suspension of 
B. halodurans C-145 was previously incubated at 100 ºC for 10 min. Each of these reactions 
was performed in quadriplicate. The amplifications parameters were as follows: 1 cycle at 
95 ºC for 2 min, 30 cycles of 95 ºC for 20 sec, primer annealing temperature for 20 sec and 
72 ºC for the required extension time and a final step of 72 ºC for 3 min. The annealing 
temperature and extension time were dependent on the gene to be amplified and are 
described in Table 17. The primers used for the amplifications were designed to include 
two different restriction sites and are described in Table 18. After the amplification, the four 
independent reactions performed for each gene were pooled together, purified with the 
GeneJet PCR purification Kit (Fermentas) and eluted in 25 µL of sterile distilled water. Each 
purified PCR products was digested with the restriction enzymes listed on Table 18. Each 
reaction was performed according with the conditions described in the web-based 
software DoubleDigest (http://www.fermentas.com/en/tools/doubledigest) from 
Fermentas. After purification and concentration of the digestion reactions with the 
GeneJet PCR purification kit, the PCR fragments were ligated to the previously digested 
vector pET24-a(+), according to the T4 DNA ligase (Fermentas) suppliers’ instructions. 5 µL 
of the ligation reaction were used to transform chemically competent E. coli DH5α cells 
and the transformants were selected on LB agar plates containing Kan (50 µg/mL). Positive 
clones were screened by colony-PCR with T7prom and T7term primers as described in 
section 4.4.7.1 (page 113) applying the extension times listed on Table 17 for amplification. 
Finally, the constructed plasmids were extracted with the GeneJet plasmid extraction Kit 
(Fermentas) and sequenced to confirm the absence of mutations. 
 
Table 17: Parameters used for the amplification of lichenicidin and haloduracin biosynthetic genes. The size of the 
expected amplicons is also included. 
Amplification parameters 
Target gene 
Annealing temperature Extension time 
Expected 
amplicons 
licM1 52 ºC 3 min 3181 bp 
licM2 52 ºC 3 min 3103 bp 
halA1 52 ºC 45 sec   226 bp 
halA2 51 ºC 45 sec   219 bp 
halM1 50 ºC 3 min 3180 bp 
halM2 50 ºC 3 min 3010 bp 
licA1L-halA1P 52 ºC 45 sec   219 bp 
licA2L-halA2P 51 ºC 45 sec   201 bp 
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Table 18: Sequence of the primers used for the amplification of lichenicidin and haloduracin biosynthetic genes. 
The restriction enzymes used are also represented; the recognition sequences are highlighted in bold in the 
respective primer sequence. 
Primer 
Target  
Designation Sequence (5’   3’) 
Restriction 
Enzyme 
Comp_licM1fw AGGTCGGATCCATGAATGAAAAATCC BamHI 
licM1 
Comp_licM1rv CATAGATTCTCGAGTTAAAACACGTTTTC XhoI 
Comp_licM2fw ATCAGGATCCATGAGCATGAAAGAATTCG BamHI 
licM2 
Comp_licM2rv TAGTGCGGCCGCTCACCTGCCCGTCGGAATATC NotI 
Comp_halA1fw ATATACATATGACAAATCTTTTAAAAG NdeI 
halA1 
Comp_halA1rv TAGATCTCGAGTTAGTTGCAAGAAGGCATGCACTC XhoI 
Comp_halA2fw ATATACATATGGTAAATTCAAAAGAT NdeI 
halA2 
Comp_halA2rv TAGATCTCGAGTTAGCACTGGCTTGTACAC XhoI 
Comp_halM1fw ATCAAAGCTTTAATGAGAGAATTACAAAATGCTCTTTAC HindIII 
halM1 
Comp_halM1rv TAGATCTCGAGATGATGTTCATTGTTAATG XhoI 
Comp_halM2fw ATCAGGATCCATGAAAACTCCTCTAAC BamHI 
halM2 
Comp_halM2rv TAGATCTCGAGTCTATGTTTGATCTTATTATC XhoI 
 
 
6.4.1 Construction of the complementation strains 
The fosmids pLic5ΔM1, pLic5ΔM2 and pLic5ΔT obtained in chapter IV were isolated from 
the corresponding E. coli EPI3000 cells as described in section 4.4.5 (page 107). 2 µL of 
each plasmid were used to transform chemically competent E. coli BL21 Gold cells, to 
obtain the strains BLic5ΔM1, BLic5ΔM2 and BLic5ΔT respectively. Positive transformants 
were selected on LB agar plates containing Clo (12.5 µg/mL). Finally, the plasmids 
encoding the lichenicidin and haloduracin modifying enzymes and transporter/protease 
were transformed into each of the following BLic5 knockout mutants: i) pLicM1 and 
pHalM1 into BLic5ΔM1, ii) pLicM2 and pHalM2 into BLic5ΔM2 and iii) pLicT and pHalT into 
BLic5ΔT. The plasmids encoding the structural haloduracin genes pHalA1 and pHalA2 were 
transformed into the BLic5ΔA1 and BLic5ΔA2 strains obtained in chapter IV. Positive 
transformants were selected on LB agar plates containing Clo (12.5 µg/mL) and Kan (50 
µg/mL). 
 
 
6.4.2 Construction of BLic5 strains expressing lichenicidin-haloduracin 
chimeras 
The genes encoding the chimeras LicA1L-HalA1P and LicA2L-HalA2P were synthesized 
and provided in the pMA-T vector by GENEARTE company (Germany). Subsequently 
LicA1L-HalA1P and LicA2L-HalA2P chimeras were amplified using the primers comp_licA1fw 
and comp_halA1rv (Table 11, chapter IV and Table 18) and comp_licA2fw/comp_halA2rv 
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(Table 11, and Table 18), respectively. After the PCR amplification, the amplicons were 
digested with the appropriate restriction enzymes (Table 18 and section 4.4.8) and ligated 
to pET24-a(+) vector according to the manufacturer’s instructions. The ligation was 
transformed into chemically competent DH5α cells and positive transformants were 
selected on LB agar plates containing Clo (12.5 µg/mL) and Kan (50 µg/mL). After colony-
PCR screening with the T7prom and T7term primers (section 4.4.7.1, page 113) the inserts of 
the constructed plasmids pchimeraA1 and pchimeraA2 were sequenced prior to further 
procedures. The pchimeraA2.1 plasmid was obtained by site-directed mutagenesis as 
previously described in 4.4.9 (page 115). The primers used for amplification were 
chimeraA2fw (5’-GGTAGGAGGAAATGATGTGAATCCGGAAACAACTTGGCCTTGCG-3’) 
and chimera A2rv (5’-CGCAAGGCCAAGTTGTTTCCGGATTCACATCATTTCCTCCTACC-3’). 
Finally, pchimeraA1 was transformed into BLic5ΔA1 chemically competent cells whereas 
pchimeraA2 and pchimeraA2.1 was transformed into BLic5ΔA2 chemically competent 
cells. Positive transformants were selected on LB agar plates containing Clo (12.5 µg/mL) 
and Kan (50 µg/mL). 
 
 
6.4.3 Antagonistic activity bioassay and LC-ESI-MS analysis 
The antagonistic activity bioassays were performed against M. luteus as previously 
described in section 2.4.8 (page 61). Peptides were recovered from liquid cultures, after 
butanol extraction (see sections 3.4.5 and 4.4.6.5) and were further analysed by LC-ESI-MS 
as described in section 2.4.6 (page 60). 
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7.1 Introduction 
 
 
 
 
he recognition of rRNA genes as evolutionary chronometers and their analysis for 
the description of environmental microorganisms diversity without culturing 
techniques completely changed the concept of the microbial world 
(Handelsman, 2004). The implementation and advances of culture-independent 
phylogenetic studies demonstrated that approximately 99% of the microorganisms in 
certain environments could not grow in the classically used microbiological culturing 
methodologies (Amann et al., 1995; Lefevre et al., 2008). For instance, it was estimated 
that only 0.001–0.1 % of seawater-associated bacteria should be cultivable in defined 
media. This fraction increases to 0.25 % and 0.3 % for freshwater and soil bacteria, 
respectively (Amann et al., 1995). The cultivation-independent analysis of collective 
microbial genomes has been generally defined as metagenomics analysis (Handelsman 
et al., 1998; Simon and Daniel, 2009). 
Cultivable bacteria have been the starting point for the discovery of many natural 
products with extremely important biological activities, including toxins, antibiotics, 
antifungals, immunosuppressants, anticancer compounds and siderophores (Banik and 
Brady, 2010). The application of metagenomic methodologies allowed the identification 
of approximately 61 distinct bacterial phyla, of which 31 have no cultivable 
representatives (Vartoukian et al., 2010). Therefore, it is believed that the major sources of 
new biologically active compounds are still to be discovered from these highly diverse 
and uncultivable microorganisms. With this in mind, metagenomic approaches evolved 
from the DNA identification level to the successful heterologous expression of potential 
new compounds encoded in the genome of non-cultivable microorganisms. Examples 
include the identification of new natural products gene clusters like pederin, bryostatin 
and onnamide from metagenomic libraries constructed from beetles (Piel, 2002), 
bryozoans (Hildebrand et al., 2004) and sponges (Piel et al., 2004), respectively. Also, 
functional metagenomic studies, involving the expression-dependent screening, already 
T 
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proved their usefulness (Banik and Brady, 2010). For instance, the new antibacterials 
turbomycin A and B were isolated from a soil metagenomic library, where Escherichia coli 
was the host strain. These small cationic molecules exhibit activity against Gram-negative 
and Gram-positive bacteria, including Bacillus species, Staphylococcus aureus and 
Salmonella enterica serovar Typhimurium LT2 (Gillespie et al., 2002). An analogous 
procedure allowed the isolation and structure elucidation of the natural product 
palmitoylputrescine, active against B. subtilis. In that study, the environmental DNA (eDNA) 
pool from a bromeliad tank water was also heterologously expressed in E. coli (Brady and 
Clardy, 2004). All of this was possible due to the improvement of eDNA isolation, the 
efficient cloning of large fragments into cloning vectors and to the advanced screening 
methodologies (Kennedy et al., 2008). 
Lantibiotics and nonribosomal peptides comprise an important group of biologically 
active peptides. Thus, the recognition of their diversity in the environment, including the 
uncultured fraction of microorganisms constitutes an important field of research. Several 
studies focused on NRPS genes distribution and diversity has been published (Ehrenreich et 
al., 2005; Schirmer et al., 2005; Zhao et al., 2008). Those studies were possible due to the 
existence of conserved motifs in the NRPS domains, especially those responsible for the 
amino acid activation (A domains), which allowed the design of degenerate primers used 
for their amplification (Turgay and Marahiel, 1994). To the best of our knowledge, studies 
focused on the diversity of lantibiotic-associated genetic determinants were not published 
so far. 
In this chapter, the diversity of A domains from NRPS present in adverse environments 
such as caves and also in non-extreme environments such as lakes was investigated. With 
that purpose, A domains libraries were constructed based on eDNA isolated from water 
and soil samples of Portuguese lakes and caves, respectively. Subsequently, all the 
obtained domains were analyzed phylogenetically. The results obtained reveal a high 
diversity of A domains in these environments. Additionally, the diversity of the amino acids 
presumably activated by the identified domains was carried out by means of two 
different, yet complementary, methodologies: i) the extraction of binding pockets and 
comparison with Stachelhaus et al. (1999) and Challis et al. (2000) nonribosomal code and 
ii) the NRPS-predictor analysis described by Rausch and co-workers (2005).  
 
7.2 Results 
7.2.1 Libraries construction and sequence analysis 
Herein, A domain libraries from each sampling site were constructed as described 
under the section 2.4.4.1 (page 57). The inserted fragment of each clone was 
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subsequently amplified, and subsequently subjected to restriction fragment length 
polymorphism analysis (RFLP) in order to distinguish between samples and thus decrease 
the amount of samples for nucleotide sequencing analysis. With this approach, the initial 
libraries of Vela lake (LV), Mira lake (LM), Barrinha de Mira lake (LB), Vale do Telhado cave 
(VT) and Algar Romão cave (AR) were reduced to 11, 12, 13, 16 and 14 clones, 
respectively. The nucleotide analysis of these clones showed that 95.5 % of the fragments 
showed high homology with A domains available at the GenBank database. The 
comparative analysis of the sequences from each sampling site revealed the presence of 
duplicates with dissimilar RFLP profiles. This resulted from the different orientation of insertion 
of each PCR fragment into the multiple cloning site of the cloning vector. Therefore, the 
final analysis included 7 clones from each LV and LB libraries, 5 clones from the LM library 
and 9 clones from each of the caves’ libraries. 
 
7.2.2 Phylogenetic analysis of A domains identified in Lakes from the central 
region of Portugal  
All the A domains amplified from the freshwater eDNA revealed less than 79 % 
homology at the amino acid level with those deposited in the database. The highest 
scores were obtained with microorganisms belonging to the α−, γ− and δ-Proteobacteria, 
Cyanobacteria, Actinobacteria and Firmicutes groups. The A domains phylogenetic 
analysis revealed that the sampling site did not have much influence on the domains 
clustering (Figure 49). In fact, exactly the same or very closely related sequences were 
obtained from LV and LM and also from LV and LB eDNA. However, that was not observed 
for LB and LM samples. Approximately half of the NRPS A domains (47 %) formed 
monophyletic groups with species belonging to Cyanobacteria phylum, which also 
constituted the largest branches in the phylogenetic tree. Among them, the LV9 and LM1 
domains fell on the same cluster as OciA and NdaA proteins, which are involved in the 
biosynthesis of cyanopeptolins and nodularins by Planktothrix agardhii and Nodularia 
spumigena, respectively (Moffitt and Neilan, 2004; Rounge et al., 2007). The domains LV10 
and LM12 were also associated with the McnC and NosC cyanobacterial NRPSs, 
respectively. The first participates in the production of cyanopeptolins peptides by strains 
of the Microcystis genus and the second in the production of the cyclic peptide-
polyketide hybrids nostopeptolides by Nostoc sp. specimens (Hoffmann et al., 2003; 
Rounge et al., 2007). 
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Figure 49: Phylogenetic analysis of A domains amplified from samples collected in central Portugal lakes. 
Sequences obtained from Lake Vela, Mira and Barrinha de Mira were evidenced with triangle, square and round 
labels, respectively. The bootstrap values obtained were indicated in each of the root nodes. The protein 
accession numbers of the closest related sequences are provided after the species name. 
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Here, five domains were included in the same branch as NRPS A domains from 
Firmicutes bacteria. LV5 and LM5 domains showed the highest homology with an GrsB 
catalytic residue, involved in the gramicidin production by Bacillus brevis (Kessler et al., 
2004). The other three domains (LB33, LV20 and LM11) were phylogenetically related with 
B. cereus, Clostridium papyrosolvens and Acetivibrio cellulotycus NRPSs. Identities with 
A domains present in bacteria belonging to the Proteobacteria phylum were also 
obtained. The sequences LB16 and LV2 formed a clade with an A domain of the 
Pseudomonas entomophila NRPS responsible for the biosynthesis of the pyoverdine 
siderophore (Matthijs et al., 2009). The LB28 and LV18 domains formed a unique branch in 
the phylogenetic tree together with an uncharacterized NRPS present in the 
α−Proteobacteria Rhodopseudomonas palustris. The most unusual sequence was 
obtained from Barrinha lake sample (LB15), where the highest homology was 38% with an 
A domain identified in the Legionella-like amoebal pathogen Legionella drancourtii 
LLAP12 genome sequence (Scola et al., 2004). 
 
7.2.3 Phylogenetic analysis of A domains identified in south Portuguese caves 
All the A domains amplified from soil eDNA of the two caves revealed less than 64 % 
homology at the amino acid level with those sequences accessible in the database. The 
phylogenetic analysis of these sequences revealed that samples from VT and AR caves 
had the tendency to cluster together, being the domains AR6, AR33 and VT8 the 
exception (Figure 50). The more closely related amino acid sequences were found to be 
from a diverse group of microorganisms belonging to the α−, β−, γ- and δ-Proteobacteria, 
Cyanobacteria, Acidobacteria, Verrucomicrobia and Firmicutes. Different A domains 
found in the present study were phylogenetically associated with NRPSs already 
characterized: i) the VT4 showed the highest identity with the syringopeptin-like 
synthetases SypB from Pseudomonas syringae pv. syringae and SypC from Bradyrhizobium 
sp. and ii) the AR1 and AR4 domains were clustered together with cyanopeptolins 
producers. However, AR1 was closer to the first subunit of that NRPSs (OciA, McnA and 
NcpA) and AR4 with the second subunit OciB present in P. rubescens genome. Other 
domains closely related to cyanobacterial NRPSs included AR7, AR2, AR39, VT12 and VT19. 
Some NRPS A domains from this environment showed homology with γ− and α-
Proteobacteria such as VT20 and VT45 and VT46, respectively. A single sequence (AR37) 
was present in the clade containing β-Proteobacteria representatives. This included amino 
acid activation residues present in the Thiomonas intermedia K12 strain isolated from a 
swage pipe and in the Variovorax paradoxus EPS strain cultivated from soil (Jamieson et 
al., 2009).  
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Figure 50: Phylogenetic analysis of A domains amplified from samples recovered from portuguese caves. 
Sequences obtained from cave Vale do Telhado and Algar Romão is marked with a losangle and an inverted 
triangle labels, respectively. The bootstrap values obtained were indicated in each of the nodes. The protein 
accession numbers of the closest related sequences were provided after the name of the specie. 
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The AR6, AR33 and VT8 amino acid sequences were difficult to associate to a 
phylogenetic group, since the closest-related matches included three distinct bacterial 
groups: δ-Proteobacteria, Cyanobacteria and Firmicutes. All of these A domains shared a 
certain degree of proximity with a domain from a bacitracin-like synthetase found in the 
Stigmatella aurantiaca genome. A similar situation was identified for the VT35 domain, 
which closest homologous sequences are from a Verrucomicrobia and an Oscillatoria sp. 
NRPS. A single domain amplified from the Vale Telhado cave constituted a 
monophylogenetic group together with an uncultured bacterium isolated from the Mila 
Mountain in Tibetan plateau soil (data not published). 
 
 
7.2.4 Prediction of amino acid activation 
The crystal structure obtained for the gramicidin synthetase A (GrsA) adenylation 
domain responsible for the activation of phenylalanine allowed the recognition of 10 
residues crucial for the substrate binding and catalysis (Conti et al., 1997; Rausch et al., 
2005). Based on the conserved sequence of these binding pockets, Stachelhaus et al. 
(1999) and Challis et al. (2000) described a specificity-conferring code (referred  in the 
present study as Stachelhaus et al. code) that can be applied for the amino acid 
activation prediction of uncharacterized A domains. More recently, another methodology 
based on the physico-chemical properties of the residues lining the A domains active site 
was described by Rausch and co-workers (2005), which is herein mentioned as 
NRPSpredictor. 
 
 
 
  
 
 
 
Figure 51: Results obtained for the amino acid 
prediction of A domains amplified in this study 
according to the parameters defined by 
Stachelhaus et al. code (1999; 2000). The 
results obtained with the NRPSpredictor are 
represented with the NRPSpred designation. 
1sub specifies that only 1 substrate was 
predicted with this software, whereas >1sub 
that more than 1 substrate was predicted. 
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Here, the binding pockets of all the A domains were analyzed as described by 
Stachelhaus et al. (1999) and the resulting sequences were clustered together with those 
already known (Figure 51 and Figure 52). Considering the Stachelhaus et al. code (1999), 
the amino acid activation prediction was successful for approximately 42 % of the A 
domains obtained in the present study (Figure 51 and Figure 52) and no match was 
obtained for 19 % of the sequences (Figure 51 and Figure 52). Despite the occurrence of 
amino acid substitutions, 39 % of the sequences shared homology with the Stachelhaus et 
al. code (Figure 51 and Figure 52). Therefore, the domains belonging to these last two 
groups were also submitted to the NRPSpredictor analysis proposed by Rausch and co-
workers (2005).  
Using this approach, it was possible to identify the LV1 sequence as a probable Pro-
activating domain. For the other five domains, were predictions were not possible based 
exclusively on the Stachelhaus et al. code (LB4, LV10, LB15, AR39 and AR6), equal scoring 
values were obtained for several amino acids. Therefore, NRPSpredictor analysis permitted 
the selection of a number of amino acids that are likely activated by such domains. For 
some domains exhibiting a few amino acid variations to the known Stachelhaus et al. 
code, NRPSpredictor approach narrowed the hypothesis of activation to a single amino 
acid. This was observed for the AR2 sequence, which should be responsible for the 
insertion of a Pro into the final nonribosomal molecule. Also, AR2 extracted binding 
pockets were positioned in the same clade with those responsible for Pro activation in 
NRPSs already characterized. A similar situation was detected for LM1, LV29 and LB33 
sequences, which could be recognized as Ser-activating domains by the NRPSpredictor 
software. For the remaining samples, this approach extended the hypothesis to two, three 
or four amino acids. The clustering of the binding pockets of these sequences in the 
phylogenetic tree was generally coincident with one of those amino acids. An example 
relies on the VT35 and LV5 domains (Figure 52). According to the NRPSpredictor analysis, 
the highest score obtained was for Gly and Ala specificity. And, in fact, their signature 
sequences based on Stachelhaus et al. code fell into the same clade as those already 
described as Ala-activating domains. The prediction for the VT19 domain could not be 
assigned with either of the two applied approaches.  
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Figure 52: Phylogenetic tree with the A domain signature sequences according to Stachelhaus et al. (1999). 
Domains for which the 10 aa binding pockets were 100 % homologous to those already described were marked 
by green boxes. Pockets where no amino acid substitutions or no homology were observed are identified with 
orange and purple boxes, respectively. The results obtained for these last two groups with the NRPSprediction 
software were described after the TSVM designation. Abu, 3-aminopimelic acid; Bmt, (4R)-4-[(E)-2-butenyl]-4-
methyl-L-threonine; Dab, 2,3-diamino butyric acid; Dhb, 2,3-dihydroxy benxoic acid; Dht, dehydrothreonine; PhG, 
L-phenylglycine; PIP, L-pipecolinic acid; Sal, salicylate. 
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7.3 Discussion 
Secondary metabolites identified from microorganisms cultures have long been a major 
source of therapeutic agents, especially those associated with the battle against infection 
diseases (Zhang et al., 2009). Great examples include the penicillin, vancomycin and 
tetracycline antibiotics. Nevertheless, programs aiming the discovery of new bioactive 
natural products have been (successively) declining. One of the justifications relies in the 
fact that microorganisms have been extensively studied and that the probabilities of 
finding truly novel molecules are therefore too low to be worth the effort (Singh and 
Pelaez, 2008). Currently two major research fields are in constant evolution to counteract 
such theories. One is based on introducing metagenomic approaches, that allows access 
to compounds encoded in the genome of uncultivable microorganisms; the other is 
based on the exploitation of microbial communities living within the limit of survival 
conditions, such as deserts, deep-sea, natural caves, mines and hot springs (Schloss and 
Handelsman, 2003; Reva and Tümmler, 2008; Zhao et al., 2008). Since NRPS enzymes 
constitute a group of important drug factories from nature (Sieber and Marahiel, 2003), in 
the present study we investigated the diversity of A domains in two selected environments: 
freshwater and caves habitats. 
The totality of A domains herein amplified exhibited low similarity, at the amino acid 
level to sequences available in protein database, demonstrating that both environments 
are potential reservoirs of unique and novel biosynthetic pathways. NRPS gene clusters are 
quite ubiquitous in the bacterial genomes of Actinobacteria, Cyanobacteria, Firmicutes, 
α−, β-, and δ- Proteobacteria (Donadio et al., 2007). The most closely related A domains to 
the sequences analyzed in the present study were described for strains included in these 
bacterial groups and also from the Acidobacteria, δ-Proteobacteria and Verrucomicrobia 
phyla. The phylogenetic analysis performed revealed that approximately 42 % of the 
sequences obtained from eDNA from lake samples were included in the same cluster as 
cyanobacterial A domains. This is not surprising since the analyzed lakes represent 
eutrophic environments, which are widely characterized by the dominance of 
Cyanobacteria blooms (de Figueiredo et al., 2006; de Figueiredo et al., 2007). Also, the 
assessment of bacterial diversity from these environments by culture-independent 
methods revealed the predominance of specimens belonging to Cyanobacteria as well 
as Actinobacteria and β-Proteobacteria (de Figueiredo et al., 2007). Cyanobacteria are 
well known producers of hepatoxic substances such as microcystins and nodularins 
biosynthesized by mixed PKS-NRPS (Donadio et al., 2007; Tan, 2007). Therefore, a large 
number of nonribosomal catalytic domains from this bacterial group are presently 
available in the databases for comparison. Even so, no more than 78 % homology was 
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identified between cyanobacterial A domains and those identified in this study. Therefore, 
despite the possibility of an ancestral origin, these should integrate distinct multimodular 
enzymes that once active, can be involved in the biosynthesis of different natural 
compounds. Our results also revealed that some of the LV NRPS diversity detected in this 
study is shared with that of LM and LB. However, no similar sequences were amplified from 
LM and LB environments. The A domains amplified from the soil of VT and AR caves 
presented a lower degree of homology (64 % maximum) with NRPSs already described 
than those resulting from lake´s samples. In general, sequences from both sampling sites 
(VT and AR) did not share the same phylogenetic cluster, highlighting the differential 
diversity of thiotemplate modular systems that is present in such locations. Some of the 
most closely related sequences are described in the Acidobacteria, Verrucomicrobiota, 
Cianobacteria, α−, β- and γ-Proteobacteria. It is worth to mention the presence of several 
species associated with important biodegradative processes in nature such as nitrogen-
fixation (e.g. Bradyrhizobium sp. and Sinorhizobium sp.), sulphur-oxidation (e.g. Thiomonas 
sp.) and gas reduction (e.g. Variovorax paradoxus). Also, some clusters integrate 
A domains from siderophore-producing NRPS such as Pseudomonas syringae pv. syringae. 
Such compounds are often involved in the uptake of iron by the microorganisms, which is 
essential for critical life sustainability such as DNA synthesis. In fact, caves environments are 
characterized by the limited amount of energy supplies mainly due to their deprivation of 
sunlight and energy inputs from the surface (Barton and Jurado, 2007). The comparison of 
the16S rDNA sequences obtained from environments around the world with the closest 
cultivated representatives has shown a broad diversity of bacterial groups, including 
members of Actinobacteria, Acidobacteria, Bacteroidetes, Firmicutes, Verrucomicrobiota, 
Cianobacteria, α−, β-, γ- and δ-Proteobacteria (Schabereiter-Gurtner et al., 2004; Chen et 
al., 2009; Lamprinou et al., 2009). Some of them are predicted to be involved in metabolic 
activities that support growth in the extremely starved cave environment, such as fixing 
nitrogen gas from the atmosphere and energy uptake from the rock itself, providing a 
basis for a diverse ecosystem rather than a lifeless environment (Barton, 2006). 
Nevertheless, the phylogenetically distinct clades formed by VT and AR sequences 
indicate that the nonribosomal pathways including those amino acid activation domains 
have not been analyzed yet. 
The A domains are responsible for the selection and activation of the amino acid that 
make up the final product (Finking and Marahiel, 2004). Two different methodologies were 
applied to predict the amino acid specificity of each sequence obtained in the present 
study. It was shown that the first method, described by Stachelhaus et al. (1999) and 
Challis et al. (2000), allowed the prediction of 42 % of the A domains. 39 % of those showed 
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a high homology with binding pocket sequences described in these studies, however with 
the presence of some amino acid substitutions. In these situations, the NRPSpredictor was 
used. The results obtained, which usually did stand for more than one substrate, were 
directly associated with the corresponding Stachelhaus et al. (1999) highest homologous 
code. Moreover, NRPSpredictor was able to generate results for the completely different 
binding pockets sequences extracted (19 %). Only 3 % of the A domains specificity could 
not be addressed by either of these two approaches. Overall, the association of the two 
methodologies constitute a more powerful prediction tool as previously suggested by 
Rausch et al. (2005). Also, the amino acid substitutions herein detected as well as the 
uncertainty of most of the predictions can result from the alternative and unknown 
substrate-binding patterns existent in uncultivable fractions of microorganisms.  
Herein, the potential diversity of biosynthetic pathways involving NRPS in two distinct 
environments was demonstrated, being the caves the less explored, accessible and not 
influenced by anthropogenic activities. It is possible that such diversity can result in the 
production of novel chemical functional compounds. Thus, these locations deserve 
deeper studies based on metagenomic and also culture-dependent approaches to 
search for novel nonribosomal compounds as well as other important bioactive peptides 
(e.g. lantibiotics).  
 
 
7.4 Experimental procedures 
7.4.1 Sampling 
Samples of the lakes Vela (LV), Mira (LM) and Barrinha de Mira (LB) located in central 
Portugal were collected as described by de Figueiredo et al. (2007). Soil samples were 
collected in sterile tubes from the Vale Telhado (VT) and Algar Romão (AR) caves, which 
belong to the Algarve (south Portugal) massif karstic caves. The samples were maintained 
in the dark at 4 ºC until the DNA extraction procedure. These samples were collected by 
the speologist/biologist Ana Sofia Reboleira from the LEADER lab (University of Aveiro). 
 
7.4.2 Environmental DNA extraction 
The eDNA from lake´s water samples were provided by Dr. Daniela Figueiredo 
(Microbial Laboratory-University of Aveiro) and extracted as described by de Figueiredo et 
al. (2007). The eDNA from soil was extracted with the UltraClean® Soil DNA Isolation Kit 
(MO-BIO) according to the manufacturer´s instructions. Briefly, 1 g of soil was added to the 
2 mL Bead Solution tubes provided and gently mixed by vortexing. 60 µL of Solution S1 
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were added and the mixture inverted several times, before the addition of 200 µL of IRS 
Solution (Inhibitor Removal Solution). The tubes were placed horizontally on a flat-bed 
vortex, shaked at maximum speed for 10 min. The lysate was centrifuged at 10,000 x g for 
30 sec and the supernatant was transferred to a clean 2 mL collection tube. After addition 
of 250 µL of Solution S2, the tubes were mixed in the vortex for 5 sec, incubated at 4 ºC for 
5 min and centrifuged for 1 min at 10,000 x g. The supernatant was transferred to a clean 
2 mL collection tube, avoiding the pellet and 1.3 mL of Solution S3 was added. The mixture 
was shacked for 5 sec in the vortex and approximately 700 µL were loaded onto a Spin 
Filter. The solution was centrifuged at 10,000 x g for 1 min, the flow through discarded and 
the remaining supernatant added to the same Spin Filter and centrifuged again at 
10,000 x g for 1 min. This procedure was repeated until all the supernatant has passed 
through the filter. The DNA was washed by the addition of 300 µL of Solution S4 of the Spin 
Filter and centrifuged at the same speed for 30 sec. The flow-through was discarded and 
the excess of Solution S4 was removed by an additional centrifugation step at 10,000 x g 
for 1 min. Finally, the Spin Filter was placed in a new 2 mL collection tube and the DNA was 
eluted by the addition of 50 µL of Solution S5 to the center of the white filter membrane 
and recovered by centrifugation at 10,000 x g for 30 sec. All the DNA samples were stored 
at - 20 ºC until further use. 
 
7.4.3 Amplification and cloning of NRPS adenylation domains 
Adenylation domains were amplified from all the eDNA samples using primers MTF (5’-
GCNGGYGGYGCNTAYGTNCC-3’) and MTR (5’-CCNCGDATYTTNACYTG-3’) (Neilan et al., 
1999). These degenerate primers were constructed to target the A2 and A8 core motifs, 
respectively. Each reaction was performed in a final volume of 25 µL using the Thermo 
Extensor High-Fidelity PCR master mix, with each primer at a final concentration of 
1.5 pmol/µL. The amplification parameters were as follows: 94 ºC for 5 min, thirty-five cycles 
of 94 ºC for 30 sec, 51 ºC for 30 sec and 68 ºC for 1 min and a final extension step of 10 min 
at 68 ºC. For each sampling site, 5 independent PCR reactions were performed, mixed 
together, purified and eluted in a final elution volume of 30 µl with the Jetquick PCR 
product purification spin kit (Genomed), according to the manufacturer’s instructions. 
0.5 µL of this amplification (approximately at 30-100 ng/µL) was used for re-amplification in 
another 5 independent reactions performed as the first PCR reactions. Samples were 
loaded on a 1% agarose gel and the fragment of interest (approximately 1000 bp) was 
excised and purified with the QIAquick Gel Extraction Kit Protocol (Quiagen), as 
recommended bythe manufacturer. The purified PCR product was ligated to the pCR 2.1 
plasmid using the TA cloning kit (Invitrogen), according to the manufacturer’s instructions. 
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Briefly, the ligation reaction contained 7 µL of PCR product (approximately at 50-100 
ng/µL), 25 ng of the pCR 2.1 plasmid, 4 U of ligase and 1X of ligase bufferin a final volume 
of 10 µL and incubated overnight at 14 ºC. 5 µL of this reaction was used to transform 
chemically competent E. coli DH5α cells. Positive clones were selected based on Kan 
resistance and white/blue selection by incubation on LB agar plates containing 50 µg/mL 
of Kan and 40 µg/mL of X-Gal. 
 
Solution: 
X-Gal stock solution: dissolve 40 mg of X-Gal (Fermentas) in 1 mL of dimethylformamide. Protect the solution from 
the light covering the tube with aluminium foil and store at -20 ºC.  
 
 
7.4.4 Restriction Fragment Length Polymorphisms (RFLP) and sequencing 
For each sampling site, one hundred white colonies were randomly picked and the 
inserted fragment was amplified using the universal primers M13fw (5’- 
GTTTTCCCAGTCACGAC-3’) and M13rv (5’-CAGGAAACAGCTATGAC-3’). Each reaction 
was performed in a final volume of 12.5 µl containing 1.5 mM MgCl2, 200 µM dNTP’s, 1X 
Green GoTaq® Buffer and 0.25 U of GoTaq® Buffer (Promega), using a bacterial colony as 
DNA template. The amplification parameters were as follows: 94 ºC for 5 min, thirty-five 
cycles of 94 ºC for 30 sec, 50 ºC for 30 sec and 72 ºC for 1 min and a final extension step of 
10 min at 72 ºC. The presence of the correct amplicons (approximately 1200 bp) was 
evaluated on 1 % agarose gel electrophoresis. Positive PCR products were subjected to 
restriction fragment length polymorphism (RFLP) in order to select distinct inserts before 
sequencing. Each RFLP reaction was prepared with 5 µL of each of these PCR reactions 
(without any purification step, approximately 0.1-0.5 µg of DNA), 1X buffer TaqI and 10 U of 
TaqI enzyme (Fermentas), in a final volume of 20 µL. After incubation at 65 ºC for 1 hour, 
each digestion was loaded on a 2% agarose gel (in this step, the addition of loading 
buffer was not necessary). Electrophoresis was performed at 120 V during 1 hour.  
The pattern of the fragments digestion was analyzed with the GelCompar II software 
(Applied Maths) and only one representative of each clustered group was submitted to 
nucleotide sequencing reaction and further nucleotide sequence analysis (STABVIDA-
Portugal). 
 
7.4.5 Phylogenetic analysis 
All the sequenced A domains nucleotide sequences were first analysed using BlastX 
program (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The two sequences exhibiting the highest 
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homology with the A domains obtained in this study were selected. Sequentially, all the 
deduced amino acid sequences between two conserved core motifs (A4 and A5) were 
aligned using Clustal X. This alignment was the basis for the phylogenetic analysis 
performed withMEGA 4.1 software (Tamura et al., 2007), using as parameters the Poison 
correction model for amino acids and a bootstrap consisting of 1000 replications. 
The amino acids constituting the binding pockets of each sequence were extracted as 
described previously by Stachelhaus et al. (1999) and aligned with some of those already 
known. The alignment of these 10 amino acids was performed with the following 
parameters: gap penalty 12 and gap length penalty 6. The corresponding phylogenetic 
tree was constructed as abovementioned. The prediction of selectivity-conferring code of 
A domains by the NRPSpredictor approach (Rausch et al., 2005) was performed on the 
web-based platform http://www-ab.informatik.uni-tuebingen.de/software/NRPSpredictor.  
 
 

  
 
 
 
 
 
 
 
 
 
C H A P T E R  V I I I  
 
 
 
8 Synopsis and future 
perspectives 
 
 
 
 

Synopsis and future perspectives 
 171 
8.1 Production of antagonistic compounds by Bacillus licheniformis I89 
Bacillus licheniformis has been used for decades in the manufacture of industrial 
enzymes including proteases and α-amylase (Rey et al., 2004). Its success in certain 
industries is mainly due to the their ability to produce and secrete large quantities (20-25 
g/L) of such compounds (Schallmey et al., 2004). For instance, specific B. licheniformis 
strains are used to produce industrially the nonribosomal antibiotic bacitracin (Waschkau 
et al., 2008). The B. licheniformis I89 strain was isolated from a hot spring environment in São 
Miguel (Azores Island). Thus, this bacterium was routinely grown at 50 ºC (Mendo et al., 
2000). Extracts of I89 strain culture supernatants were able to inhibit the growth of the 
closely related Bacillus subtilis and other Gram-positive bacteria such as Micrococcus 
luteus and Staphylococcus aureus. It was also shown that the activity of the compound 
produced by B. licheniformis I89, and responsible for the inhibition observed in the above 
referred strains, was not affected by some proteases, including α-chymotrypsin and trypsin 
(Mendo et al., 2004). In the same study it was determined that a peptide with 
M= 3249.7 Da was contributing for the biological activity. The compound was designated 
as Antibiotic 89 (A89). B. licheniformis strains are known to produce several bacteriocins 
(chapter II). However, only for B. licheniformis ZJU12 an antibacterial compound within the 
molecular mass range of A89 peptide was later identified. Nevertheless, in the ZJU12 strain, 
antibacterial activity was completely abolished when the active compound was 
incubated with trypsin, whereas A89 was not affected by this protease, suggesting the 
distinctive nature of the active compounds (He et al., 2006). Considering these facts, it was 
recognized that the I89 strain was a producer of, at least, a novel antibacterial 
compound. Thus an investigation was started in order to clarify the biological origin of the 
peptide as well as to get some insights on its chemical structure. 
In the present study, the antibacterial activity of the compounds produced by 
B. licheniformis I89 was higher when cells were grown at 37 ºC and for that reason all the 
experiments and results that are reported in the present dissertation were obtained at this 
temperature. Moreover in this study it was shown that the mixture of antibacterial 
compounds produced by I89 strain (where A89 is included) is active against the Gram-
positive bacteria Enterococcus faecalis, Enterococcus faecium, Haemophilus influenzae, 
Listeria monocytogenes and Staphylococcus aureus, including a clinical methicillin-
resistant strain (MRSA), highlighting the interest of this bacterial strain and its bioactive 
compounds (chapter II). Thus, one of the aims of the present study was to separate the 
antibacterial components present in B. licheniformis I89 supernatants and obtain enough 
concentration of pure A89 peptide to proceed with further characterization procedures. 
To accomplish this objective, a protocol including solid phase extraction followed by 
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preparative HPLC and bioassay was developed. During this procedure, other compounds 
with the ability to inhibit M. luteus, the indicator strain of this study, were detected. Among 
these compounds, a peptide characterized by the molecular mass of 3020 Da, that was 
designated as B89 and selected for further characterization, similarly to A89 (chapter II). 
These results were not surprising, since it has been reported that some strains of the B. 
subtilis-group, where B. licheniformis is included, can in fact produce more than one 
antibacterial compound (Stein, 2005). To get some information of the amino acid 
composition of these two peptides, Edman degradation on the pure compounds was 
attempted, however with no success. The blockage of Edman degradation reactions has 
been associated with compounds harboring unsaturated amino acids such as Dha or Dhb 
(Holtsmark et al., 2006). Therefore, it was considered that A89 and B89 could possess such 
residues on their structure, similarly to lantibiotics. Surprisingly, during the separation 
process, it was observed that the bactericidal activity of A89 and B89 pure peptides 
against the indicator strain was decreased compared to the situation when both peptides 
were applied together, suggesting that they could act synergistically (chapter II).  
Regarding the biological nature of these compounds, it was found that the NRPSs 
present in the B. licheniformis I89 strain (lichenysin and putative siderophore) have high 
homology with those identified in the genome of B. licheniformis ATCC 14580 and 
B. licheniformis DSM13 (isogenic strains) (Rey et al., 2004; Veith et al., 2004). It was verified 
that the putative products of those enzymes do not correspond to the A89 and B89 
peptides (chapter II). However, the analysis of both of the isogenic strains genome 
revealed the presence of a putative two-component lantibiotic gene cluster, which 
product was designated as lichenicidin (Rey et al., 2004). The transcription of the licA1 
structural gene present in this cluster, followed by modification of the corresponding LicA1 
prepropeptide implying the occurrence of 7 dehydration reactions followed by the 
removal of the leader sequence (after the GG-motif) would result in the production of a 
peptide with approximately M= 3250 Da. The same principle applied to the identified licA2 
gene, but considering the occurrence of 12 dehydration reactions and the removal of the 
-NDVPE-sequence after the LicA2 leader sequence, would originate a lantibiotic with M= 
3020 Da. Therefore, considering this information, the molecular masses of the lichenicidin 
gene cluster products were coincident with those observed for the A89 and B89 peptides. 
After PCR amplification and nucleotide sequencing it was confirmed that B. licheniformis 
I89 strain also harbored the lichenicidin structural genes. Thus, it was considered that A89 
and B89 peptides corresponded to the lichenicidin two-component lantibiotic. 
Concurrently, Begley and coworkers (2009) also suggested that these peptides produced 
by B. licheniformis ATCC 14580 corresponded to the lichenicidin lantibiotics and 
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designated them as Bliα (M= 3250 Da) and Bliβ (M= 3020 Da). Their study established that 
separately, each of the peptides possessed antimicrobial activity. However, synergism was 
apparent when their individual fractions were combined, similarly to that already observed 
in the present study. Later on, Dischinger and co-workers (2009) were actually able to 
associate the B. licheniformis DSM13 lichenicidin gene cluster with the production of both 
peptides, inducing the abolishment of their production by the insertion of a resistance 
cassette in the licA1 and licA2 structural genes. Surprisingly, in these two strains the 
peptides could not be detected in the bacterial supernatant and were considered to be 
cell wall associated. The limited diffusion of lichenicidin to the supernatant was explained 
by the fact that B. licheniformis is able to produce the glutamyl polypeptide capsule which 
could trap the positively charged Bliα (+1) and Bliβ (+2) peptides (Dischinger et al., 2009). 
However, in I89 fermentations both compounds were always detected and purified from 
the bacterial supernatants, despite their identification also in cell wall extracts. Thus, either 
the I89 strain’s capsule has slight differences from that of these two type strains, or the 
production media used promoted the diffusion of the peptides. Therefore, it would be 
interesting to investigate if the Bliα and Bliβ peptides are released to the culture 
supernatant of ATCC 14580 and DSM 13 strains when grown in medium M. Similar to what 
happens with the I89 strain, the DSM 13 strain produces other antibacterial compounds, 
apart from lichenicidin, which were not characterized so far. For instance, Staphylococcus 
gallinarum Tü 3928 (producer of the gallidermin lantibiotic) and several Staphylococcus 
aureus strains (including MRSA) were exclusively inhibited by DSM 13 cell wall associated 
extracts, whereas Enterococcus faecium strains were only affected by the antibacterial 
compounds present on its culture supernatant. Yet, it is worth to mention that both extracts 
were active against M. luteus strains. Therefore, it could be hypothesized that probably 
some of the antibacterial compounds detected in the DSM 13 supernatant can also be 
produced by the B. licheniformis I89 strain. Some of these compounds might be present in 
the fractions that were identified in the present study during the separation of the 
B. licheniformis I89 supernatants but that were no further investigated (chapter II). 
Regarding the biological nature of these unidentified compounds, it would be expected 
that they will be part of the group of non-modified bacteriocins, since in the 
B. licheniformis DSM 13 genome, apart from lichenysin and one putative siderophore 
nonribosomal cluster, no polyketide synthetases or other lantibiotic gene clusters were 
identified. Therefore, the investigation of the biological and structural origin of these other 
compounds would be interesting to perform in future studies.  
Meanwhile, along the routine cultivation of B. licheniformis I89 strain on agar plates, two 
different colonies phenotypes were observed: the parental and rough colonies and new 
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simple and smooth colonies (chapter III). The factor that triggered such phenomenon 
could not identified so far. Nevertheless, it was found that the smooth phenotype was 
quite stable, since its subsequent cultivation did not result in its reversion to the rough 
phenotype, suggesting that such variation was not due to the bacterial bistability. For 
B. subtilis it was observed that spo0A (the master regulator for the beginning of the 
sporulation process) mutants develop flat colonies consisting on non-adherent cells 
(Branda et al., 2001; Hamon and Lazazzera, 2001). However, for the I89 strain it was not 
possible to correlate the morphological alteration with a difference in the sporulation rate. 
Additionally, the switch of a bacterial phenotype is normally accompanied by genetic 
alterations such as mutations, insertions or deletions. These random rearrangements can 
occasionally cause the improvement as well as the damage of some interesting 
characteristics of the parental strain, such as the abolishment of secondary metabolites 
production (Berditsch et al., 2007; Brosch et al., 2007). However, generally, the antagonistic 
activity of both phenotypes did not present major discrepancies. Nevertheless, that 
activity was found to be a consequence of a mixture of antibacterial compounds. Since 
the main focus of this thesis lies on the characterization of the Bliα and Bliβ peptides, it was 
important to understand whether the rough to smooth transition affected their production 
rate. The results revealed that a reduced abundance of the Bliβ peptide (and its 
derivative) was associated with the smooth colonies, even in medium M the medium 
selected for the peptide’s production. Yet, the reasons behind this difference were not the 
objective of the present study, and were not investigated. However, they can be part of 
the B. licheniformis I89 “domestication” process. Thus, it should be interesting in the future 
to investigate which processes were altered in the smooth variant that had a negative 
impact in the lichenicidin production. For this, the analysis of protein expression patterns of 
both phenotypes can help to clarify this aspect, since it was observed that both 
phenotypes could indeed present differences at this level. Alternatively, the transcriptome 
of both variants could be characterized by the new generation of sequencing 
technologies. The retrieved information would provide relevant data on which future 
research could be built up.  
So far, the main application of lantibiotics lies in food technology (Gálvez et al., 2007). 
Nisin was approved as biopreservative in Europe and the US and is included into a broad 
range of products (e.g. dairy products, liquid egg, bakery products, vegetables, meat and 
fish) to prevent microbial spoilage and inhibit the outgrowth of clostridial spores (Delves-
Broughton et al., 1996; Lubelski et al., 2008). Clinically, lantibiotics have been proposed for 
the treatment of infections caused by antibiotic resistant bacteria. For instance, the 
application of the class II lantibiotic mersacidin to a mouse rhinitis model was able to 
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eradicate MRSA (Kruszewska et al., 2004). In fact, the medical application of this lantibiotic 
is already in development (pre-clinical stage) in Novacta Biosystems Lda. (Hatfield, 
England) (Hancock and Sahl, 2006). The related lantibiotic actagardine showed a great 
activity against streptococci and the MIC data obtained for microbisporicin seem quite 
promising against MRSA and enterococci (Castiglione et al., 2008; Bierbaum and Sahl, 
2009). Other advantage of lantibiotics resides in its reduced susceptibility to the action of 
proteases (mainly due to the presence of the thioether rings) and therefore not prone to 
easy degradation or antibody formation (Bierbaum and Sahl, 2009). The emergence of 
antibiotic resistance and the quicker ineffectiveness of new generation conventional 
antibiotics are alarming to medical practitioners. This has been one of the major concerns 
since the beginning of antibacterial therapy, with the clinically introduction of penicillin in 
1944. At this time, approximately 6 % of the Staphylococcus aureus isolates were already 
resistant to the antibiotic and six years later this number increased to approximately 50 % 
(Livermore, 2000). Concerning the two-peptide lantibiotics, it has been highlighted that 
they have a broad range of activity and that the development of resistance is rare (in the 
case of lacticin 3147) (Bierbaum and Sahl, 2009). In this context, it would be appealing to 
carry out experiments with the lichenicidin peptides and involving a larger number of 
Gram-positive bacterial strains from each of the species that are inhibited by these 
peptides to obtain appropriate minimal inhibitory concentration (MIC) values. Also, the 
lichenicidin hemolytic and cytotoxic potential should be evaluated. Moreover, the 
development of resistance to the lichenicidin lantibiotic could be estimated by the 
continued exposure of bacterial cells to this lantibiotic.  
 
 
8.2 Biosynthesis of lichenicidin in Escherichia coli 
The construction of a B. licheniformis I89 genomic library, revealed the presence of 
some clones, containing the lichenicidin gene cluster, that were able to inhibit the growth 
of M. luteus. After the confirmation that these clones were producing both Bliα and Bliβ 
peptides, a clone designated by E. coli Lic5 was selected as a lichenicidin heterologous 
expression system. This was very surprising and overthrown the dogma of 20 years of 
research on lantibiotics: the production of bioactive lantibiotics by E. coli was not possible 
(chapter IV). In the last years, semi-in vitro biosynthesis (SIVB) of nukacin ISK-1 and bovicin 
HJ50 lantibiotics in E. coli were described (Nagao et al., 2007; Lin et al., 2010). Such systems 
combined the in vivo modification of the prepropeptide by the co-expression of the 
structural gene and the modifying enzyme followed by the in vitro cleavage of its leader 
peptide. However, in the present study, Bliα and Bliβ production was completely achieved 
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in vivo in the Gram-negative host. The application of the SIVB methodology permits the 
recovery of potentially toxic peptides avoiding at the same time the regulatory processes 
involved in the biosynthesis of several lantibiotic. On the other hand, it does not allow the 
investigation of the pathways involved in their production (e.g. export, regulation and self-
protection of the producer strain). And, for instance, the characterization of lichenicidin 
biosynthesis process was one of the major objectives of the present study. In this context, 
the generation of knockout mutants for the lichenicidin gene cluster in the original 
producer B. licheniformis I89 would have been a difficult method due to its low 
transformation efficiencies. Actually, it has been mentioned that transformation of 
B. licheniformis strains routinely requires long periods of time and great experimental efforts 
to finally obtain a desired transformant (Waschkau et al., 2008). Accordingly, the 
successful production of lichenicidin by E. coli opened up great perspectives for such 
proposes, involving less time-consuming procedures. Thus, all the genes constituting the 
lichenicidin biosynthetic cluster were deleted and the impact of these modifications in the 
production of Bliα and Bliβ was evaluated. With this approach, it was possible to establish 
that in the absence of LicA1, LicM1, LicT and LicR proteins, the synthesis of Bliα does not 
occur. Regarding Bliβ, its production was always abolished if LicA2, LicM2, LicT, LicP and 
LicY were deleted from the system. Finally, both peptides were synthesized without the 
transcription of the LicX and the LicFGEHI elements (Chapter IV). These results, together 
with the considerable amount of information available for the lantibiotics biosynthesis 
revealed that the production of Bliα and Bliβ peptides involves the following essential steps: 
i) the production of LicA1 and LicA2 prepropeptides by the expression and translation of 
licA1 and licA2 genes, respectively, ii) the LicM1 modifying enzyme dehydrates 7 Ser/Thr 
residues of the LicA1 propeptide and catalyzes the formation of thioether rings, whereas 
LicM2 would carry out the same reactions, however 12 dehydrations of Ser/Thr amino 
acids will be achieved on the LicA2 propeptide, iii) both modified prepropeptides would 
be exported and their leader peptides removed at the double Gly motif by LicT, 
producing the biological active Bliα peptide and the inactive Bliβ’ and iv) the LicP 
protease would process the trimming of the 6 N-terminally located amino acids of Bliβ’ to 
produce the biologically active Bliβ peptide (Figure 53). The precise role of LicR and LicY in 
this biological process was not investigated in the present study. However, LicR, which 
possesses a helix-turn-helix domain, should constitute a single component-signaling 
regulator. The fact that in the absence of LicR, the Bliα peptide was not produced 
indicates that this protein should promote the expression of the licA1-containing operon, 
rather than repress it as observed for the lacticin 3147 single regulator LtnR. In several class I 
lantibiotic systems such as nisin and subtilin it has been shown that the signal triggering the 
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LanR functionality is the presence of the lantibiotics in the bacterial supernatant. In the 
present work, the potential of Bliα auto-regulating its own synthesis was not evaluated. The 
influence of LicY on the Bliβ production is more difficult to predict because its counterparts 
are not commonly found in the lantibiotic gene clusters. This small protein harbors three 
transmembrane helices, which suggests its location in the membrane. Its involvement in 
the regulation of Bliβ biosynthesis is not considered, since no domains or homology with 
putative regulators were detected for LicY. In fact, LicY possesses a degree of similarity 
with an uncharacterized protein of B. halodurans genome and with a C-terminal 
processing protease from the Gram-negative Borrelia burgdorferi. Therefore, it was 
considered that LicY could be involved in the maturation of the LicP protease, which is 
also only involved in the production of the Bliβ peptide. However, this hypothesis was not 
confirmed since an active LicP was obtained by expression of the licP gene alone, and 
thus in the absence of LicY protein (chapter IV). Consequently, the role of this protein in 
the Bliβ biosynthesis would deserve to be studied in more detail. 
Regarding the putative immunity LicFGEHI elements, it was observed that their 
inactivation was not accompanied by an increase of the lichenicidin susceptibility in the E. 
coli producer strain. This was understandable, since the E. coli outer membrane forms a 
natural barrier for Bliα and Bliβ permeabilization. And, if these peptides are not able to 
reach the bacterial cytoplasm, their export back to the supernatant through the active 
ABC-transporter LicFEG will not be necessary. However, a decrease in the abundance of 
the Bliα and Bliβ peptides was identified when licFGEHI elements were not expressed 
(chapter V). It would be interesting to establish the origin of these differences in upcoming 
experiments. 
The most surprising feature of the lichenicidin production by a Gram-negative host was 
the presence of the peptides in the bacterial supernatant. The export systems of Gram-
negative bacteria have an additional impediment in the cell wall to overcome – the 
presence of an outer membrane (OM). Thus, in the beginning it was not clear if the 
presence of Bliα and Bliβ peptides in the E. coli Lic5 supernatant resulted from real transport 
or if it was due to bacterial lysis. The lantibiotics prepropeptides, including LicA1 and LicA2 
lack a typical N-terminal for the general sec secretory pathway. In Gram-negative 
bacteria, the proteins that have this property are usually secreted directly from the 
cytoplasm to the extracellular environment through a type-I sec-independent dedicated 
system. An example of that is the secretion of colicin V and hemolysin, which are non-
modified bacteriocins. For instance, the secretion of colicin V by E. coli involves the 
complex CvaB-CvaA-TolC in which CvaA and CvaB are encoded in the colicin V gene 
cluster and TolC is an E. coli outer membrane protein (Gilson et al., 1990; Skvirsky et al., 
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1995). The CvaB protein is characterized by six transmembrane domains with a typical ATP-
binding cassette on its C-terminus, whereas CvaA is a membrane fusion protein (MFP) 
comprising a N-terminal hydrophobic domain presumably responsible for its attachment to 
the inner membrane (Gilson et al., 1990; Skvirsky et al., 1995). Hwang et al. (1997) showed 
that CvaA directly interacts with CvaB and TolC, thus allowing the transport of ColV to the 
bacterial supernatant without any periplasmic intermediate sub-location. The potential 
involvement of the TolC OM protein in the Bliα and Bliβ export was also evaluated by 
expressing the lichenicidin biosynthetic cluster in cells without this gene. In such conditions, 
none of the lantibiotics were detected in the culture supernatant. Consequently it was 
confirmed that Bliα and Bliβ are actually transported through the OM, with the involvement 
of the TolC protein and their presence on the bacterial supernatant is not due to bacterial 
lysis. For this process, the ABC-transporter/protease LicT most probably will interact with the 
TolC protein to achieve the translocation of Bliα and Bliβ across the E. coli outer membrane 
(Figure 53). Whether this association requires or not a MFP, provided by the E. coli host, is a 
question that should be further explored. Alternatively, it can be considered that the LicT 
protein is anchored into the cytoplasmatic membrane by its transmembrane domains, 
being its ABC transporter C-terminus facing the cytoplasm and its N-terminus protease 
directed to the periplasmic space, where it can interact with TolC. The haloduracin 
transporter HalT also includes an N-terminal protease motif, 6 transmembrane motifs and a 
C-terminal ABC-cassette, similarly to LicT. In fact, in chapter VI of the present dissertation, it 
was demonstrated that HalT is able to substitute the LicT function on the export of the 
lichenicidin peptides. Thus, it is actually possible that their structural features are able to 
directly interact with the TolC protein. The elucidation of the precise mechanism of 
lichenicidin secretion in E. coli is therefore a key aspect that will help the understanding of 
the entire biosynthetic process in this Gram-negative host.  
In chapter V, an E. coli strain with a permeable OM was shown to be susceptible to 
lichenicidin. Also, an E. coli Lic5 strain was still able to secrete both peptides in the 
absence of the putative immunity genes licFGEHI. In this mutant, if Bliα and Bliβ were 
transported via the periplasm, the bacteria would most probably not survive. These results 
also supported the hypothesis of the periplasm-independent transport of both Bliα and Bliβ 
peptides, unless they coexist in an inactive complex composed by Bliα and the untrimmed 
Bliβ peptide (Bliβ’). The precise role of each of the licFGEHI genes in the lichenicidin self-
protection could not be evaluated in the course of this study. Nevertheless, it will be 
performed in future experiments using the lichenicidin susceptible E. coli imp4213 strain. 
This strain will be transformed with several plasmids harboring distinct combinations of 
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each of the licFGEHI genes, followed by the evaluation of the increase or decrease of 
susceptibility to lichenicidin of each of the constructed strains. 
 
 
 
Figure 53: Representation of the general biosynthetic pathway of lichenicidin Bliα and Bliβ peptides in the Gram-
negative E. coli Lic5 strain. The question marks represent the interactions, which were not completely elucidated 
in the course of this thesis. 
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8.3 Bioengineering of lantibiotics in Escherichia coli 
Due to its ribosomal origin, the construction of lantibiotic variants with potentially 
altered biological and chemical properties can be performed in a more direct fashion 
when compared to that of conventional antibiotics (Field et al., 2010). Therefore, a trans 
complementation system able to easily produce lichenicidin variants in E. coli was 
established in the present study (chapter IV). Initially, this approach was employed with 
the objective of getting some insights on the Bliα and Bliβ structures. To that end, all the Ser, 
Thr and Cys residues in the lichenicidin peptides were substituted by Ala residues using site-
directed mutagenesis of their structural genes. The molecular masses of the produced 
lichenicidin variants allowed the revision of the position of the dehydrated residues in the 
Bliβ peptide previously proposed by Begley et al. (2009) (Figure 54). Moreover the 
difference of + 1Da between the Bliα and Bliβ molecular masses obtained by high-
resolution mass spectrometry and those previously calculated suggested the presence of 
a 2-oxobutyril residue in the N-terminus of both peptides. Moreover, the MS/MS analysis of 
the wild-type peptides produced by B. licheniformis I89 and E. coli Lic5 in conjugation with 
the MS/MS analysis of a Bliβ variant, allowed the establishment of the pattern of thioether 
rings for Bliα and Bliβ that differed from that previously anticipated by Begley et al. (2009). 
Recently, the structures of Bliα and Bliβ peptides (designated by Lchα and Lchβ) produced 
by B. licheniformis VK21 strain were elucidated by NMR spectroscopy (Shenkarev et al., 
2010). The results obtained by these authors were generally in agreement with the 
structures determined in the present study, differing exclusively in the residues involved in 
the formation of the Bliα A-ring (Figure 54).  
Some of the mutated peptides were barely or even not produced. This was particularly 
obvious when changes were performed in the residues involved in the formation of the C-
terminal thioether rings. The reasons for such results can involve the incompatibility of these 
peptides with the native biosynthetic, transport, regulation or immunity machinery. To 
overcome these uncertainties, the development of a SIVB system for the lichenicidin 
production could be an appealing approach for future work. With such system, it would 
be more likely that all the mutated peptides will be recovered for bioactivity assays. In 
fact, the production of lantibiotic derivatives with enhanced and/or a wider spectrum of 
activity is one of the major goals of lantibiotics bioengineering. Nowadays, the 
identification of lantibiotics variants with enhanced activity is becoming more frequent, 
however this is only possible due to the creation of larger banks of engineered peptides 
(Field et al., 2010). For the lichenicidin peptides, these libraries are still not available and will 
constitute the aim of future studies. Moreover, the assays of antagonistic activity should be 
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enlarged to other strains besides M. luteus, including Gram-negative representatives such 
as E. coli and Pseudomonas aeruginosa. 
Regarding the lichenicidin mode of action, it was recently proved that similarly to 
lacticin 3147 and haloduracin, the two peptides can act synergistically at a molecular 
ratio of 1:1 to exert their maximal antibacterial activity (Shenkarev et al., 2010). Separately, 
Bliα and Bliβ have biological activity, but in these circumstances, higher concentrations of 
each peptide are required to obtain bacterial inhibition. These findings were quite 
surprising, since the Bliα peptide is similar to the mersacidin lantibiotic. The conserved Glu 
residue among the mersacidin-like peptides was predicted to play an essential role in lipid 
II-binding. Indeed, the substitution of BliαGlu26 by Ala resulted in abolishment of 
antibacterial activity (chapter IV). However, the minimal inhibitory concentration (MIC) of 
Bliα against M. luteus is above to 15 µg/mL, whereas for mersacidin is about 13 times lower 
(1.2 µg/mL) (Appleyard et al., 2009; Shenkarev et al., 2010). Therefore, some differences on 
their mode of action can be predicted, suggesting that the interaction between the Bliα 
peptide and the lipid II molecule is distinct from that of mersacidin and should therefore 
be further investigated. 
 
 
Figure 54: Representation of the different structures of lichenicidin peptides. A corresponds to the structures 
proposed by Begley and co-workers (2009), B corresponds to the structures proposed in the present study 
(Caetano et al., 2011) and B the NMR elucidated structures by Shenkarev et al. (2010). The differences are 
highlighted with red triangles on Bliβ peptide. 
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The heterologous systems, as those developed during the present study, are quite 
amenable to genetic manipulation and can therefore be potentially useful for the 
production of: i) compounds which have never been characterized but which gene 
clusters are known or ii) compounds that are produced in very low amounts by its original 
producers. With this in mind, the haloduracin production using the lichenicidin biosynthetic 
machinery was attempted using chimeras of HalA1 and HalA2 propeptides N-terminally 
fused with the LicA1 and LicA2 leader sequences, respectively (chapter VI). Results 
showed that the biosynthetic and/or regulatory machinery of lichenicidin was not 
malleable enough to produce biologically active Halα and Halβ peptides. Nevertheless, 
HalT was able to export and process the leader sequence of LicA1 and LicA2 fully 
modified peptides. These findings highlighted its substrate flexibility and also showed that 
Lic-leader sequences are not necessary for its functionality. Therefore, it is possible that the 
co-expression of a class II prepropeptide with the corresponding LanM and LanT (or 
alternatively LicT) proteins in E. coli can be more successful in the production of other fully 
active lantibiotics than the expression of chimeras in the presence of all the biosynthetic 
elements. 
 
 
8.4 Metagenomics and new antibacterials 
The phylogenetic analysis of the genetic elements designated as adenylation (A) 
domains involved in the biosynthetic pathway of conventional antibiotics was performed. 
For that, a cultivable-independent approach was employed to samples collected from 
different lagoons in the Central region of Portugal and also from more unusual 
environments such as caves. The applied methodology is relatively simple to perform and 
exclusively allows the recognition of potential new nonribosomal peptide synthetases, 
which can possibly produce new compounds, including new antimicrobials. A large 
diversity of A domains was retrieved from both environments. The majority of these 
sequences showed low similarities with sequences already deposited in the databases, 
highlighting the presence of potential novel nonribosomal peptide synthetases in these 
environments. The construction of metagenomic libraries, will allow the access to some of 
the compounds produced by such enzymes. In fact, some industries, including 
pharmaceuticals, are interested in exploiting the resources behind the uncultivable 
fraction of microorganisms present in several distinct environments (Lorenz and Eck, 2005). 
Additionally, the screening of such libraries based on the clones’ antibacterial bioactivity 
rather than on their genetic content will not only allow the identification of potential new 
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nonribosomal antibiotics but also and maybe more frequently of novel bacteriocins, 
including lantibiotics.  
 
 
8.5 Highlights and major conclusions of the study 
The present study contributed greatly for the characterization of some of the 
antibacterial compounds produced by B. licheniformis I89. Additionally, allowed new 
advances in the investigation of the biosynthetic machinery of some of these compounds. 
More specifically: 
- B. licheniformis was identified as a lantibiotic producer, which was not recognized 
before the beginning of this study. Herein, it was proved that the I89 strain produces the 
two-component lantibiotic peptide lichenicidin (Bliα and Bliβ).  
- The production of lichenicidin seems to be affected by the phenotypic dissociation of 
B. licheniformis I89 when it occurs. 
- For the first time, a lantibiotic was fully produced totally in vivo in the Gram-negative 
host E. coli.  
- It was established that licA1, licM1, licT, licR are involved exclusively in the Bliα 
biosynthesis, whereas licA2, licM2, licT, licP and licY are directly responsible/related with the 
Bliβ synthesis. The putative immunity genes licFGEHI and the licX are not involved in the 
lichenicidin production. 
- New components of two-peptide lantibiotics were identified: LicP and LicY. 
- It was established that the E. coli host is able to export Bliα and Bliβ through the outer 
membrane mediated by the TolC outer membrane protein. 
- The trans complementation system developed is able to produce new variants of the 
Bliα and Bliβ peptides was developed. 
- The structural features of the Bliα and Bliβ peptides were revised. 
- The biosynthetic machinery of lichenicidin did not show enough flexibility to produce 
the closely related lantibiotic haloduracin in E. coli, when directed by the lichenicidin 
leader sequences. 
Moreover, it was also established that the communities of some Portuguese lagoons 
and caves contain a high diversity of nonribosomal adenylation domains, which indirectly 
showed that these environments enclose new peptide synthetases, which can produce 
potentially novel compounds with interesting activities, such as antimicrobial peptides. 
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8.6 Future perspectives 
It is believed that this study raised more questions than answers. Therefore, the 
information retrieved, together with the implementation of new protocols should provide 
the basis for future studies, especially those regarding the biosynthesis and bioengineering 
of lantibiotics.  
The major points requiring further investigation were raised along this final chapter, and 
and are here summarized: 
- The characterization of the other B. licheniformis antibacterial compounds should be 
performed. 
- The yields of lichenicidin production by B. licheniformis I89 and E. coli Lic5/BLic5 should 
be estimated and compared. 
- The contribution of LicR and LicY to the biosynthesis of Bliα and Bliβ peptides should be 
elucidated as well as the contribution of each LicFGEHI element to the lichenicidin self-
protection mechanism. At this stage it will also be possible and appealing to perform cross-
immunity studies with other class II lantibiotics. 
- The sub-cellular location of LicP in E. coli as well as its proteolytic specificity should be 
unveiled. 
- The interaction of LanT and TolC needs to be clarified in order to the completely 
understand the export of lantibiotics by E. coli.  
- The contribution of LicFGEHI for the lichenicidin self-protection mechanism should be 
investigated.  
- The importance of the Bliα and Bliβ structure to their bioactivity should be further 
investigated by the production of new lichenicidin variants. 
- The production and purification of lichenicidin variants for bioactivity testing can 
benefit from the establishment of a SIVB system for lichenicidin accompanied by the 
introduction of a C-terminal six-histidine tag to Bliα and Bliβ peptides. 
- The extraction and/or mass spectrometry methodologies should be optimized to allow 
the identification of some lichenicidin variants, for instance those possessing additional 
amino acids.  
- The production of other lantibiotics in E. coli totally in vivo (with or without the 
expression of a full lantibiotic gene cluster) should be attempted. 
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Appendix 1 Preparation of selective agents 
 
The selective agents used in this study were prepared as stock solutions in the appropriate 
solvent and sterilized by filtration with a 0.2 µm cellulose filter, when required. All the stock 
solutions prepared are summarized in Table S1.  
 
Table S1: Summary of the stock solutions preparation for the selective agents used in this study. NR stands for non 
required. *Protect from light with foil paper. 
Selective agent Supplier Stock solution  Final 
concentration 
Solvent Sterilization 
Ampicillin Sigma 100 mg/mL 100 µg/mL Water Filtration 
Apramycin AppliChem 50 mg/mL 50 µg/mL Water Filtration 
Chloramphenicol* BDH 25 mg/mL 12.5 µg/mL Ethanol NR 
Kanamycin Gibco 100 mg/mL 50 µg/mL Water Filtration 
Tetracycline* Sigma 20 mg/mL 10 µg mL Ethanol NR 
 
 
 
 
 
 
Appendix 2 General Strains 
 
The general bacterial strains used in this study are listed in Table S2. 
Table S2: List of general strains used in this study with the reference to their genotype and supplier, when 
available. ATCC (American Type Culture Collection); DSMZ (German Collection of Microorganisms and Cell 
Cultures); FCUL (strains kindly provided by the Faculty Sciences of the University of Lisbon); INETI (Strain kindly 
provided by Dr. José C. Duarte; JIC (Jonh Innes Center); MUL (University of Lisbon Microorganims Collection); 
WWM (strains kindly supplied by Prof. Friedhelm Meinhardt from Westfälische Wilhelms-Universität Münster). 
Strain Source Genotype/Characteristics 
E. coli BL21 Gold Novagen E. coli B F–ompThsdS(rB– mB–) dcm+ TetrgalendA Hte 
E. coli BW25113 JIC lacI
+rrnBT14ΔlacZ WJ16 hsdR514ΔaraBAD AH33 ΔrhaBAD 
LD78 
E. coli DH5α MUL 
F-endA1glnV44 thi-1 
recA1relA1gyrA96deoRnupGΦ80dlacZΔM15 Δ(lacZYA-
argF)U169, hsdR17(rK- mK+), λ– 
E. coli EPI300™ -T1R Epicentre 
F- mcrA Δ(mrr-hsdRMS-mcrBC) (StrR) φ80dlacZΔM15 
ΔlacX74 recA1 endA1 araD139 Δ(ara, leu)7697 galU 
galK λ-rpsL nupG trfA tonA dhfr 
B. licheniformisI89 INETI  Lichenicidin producer (Mendo et al., 2004) 
B. licheniformisATCC 10716 FCUL Bacitracin producer 
B. licheniformisMW3 WWM B. licheniformis DSM13 (ΔhsdR1, ΔhsdR2) (Waschkau et 
al., 2008); Lichenicidin producer. 
B. haloduransDSM 18197 (C-125) DSMZ Haloduracin producer 
Micrococcus luteus ATCC 9341 MUL Indicator strain 
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Appendix 3 General Vectors 
 
 
The general vectors (plasmids and fosmids) also used in this study are listed in Table S3. 
 
 
Table S3: List of general plasmids and fosmid used in this study, where MW refers to the molecular weigh of the 
vectors. Ampicillin (Amp); Apramycin (Apra); Chloramphenicol (Clo); Erythromycin (Erm); Kanamycin (Kan); 
Tetracycline (Tet). JIC (Jonh Innes Center); UC-USA (plasmids kindly provided by Prof. Daniel Portnoy from 
University of California, USA). 
Vector Source MW Selective marker Observations 
pLTV1 UC-USA 20.6 Kb Amp
R, CloR, 
ErmR, TetR 
AmpR, CloR, ErmR associated with the Tn917 
transposon. ColE1 and oripE194TS. oripE194 
replicates at 32 ºC and segregates at 42 ºC 
(Camilli et al., 1990). 
pKSV7 UC-USA 6.9 Kb AmpR, CloR 
E. coli/Bacillus shuttle vector. ColE1 and 
oripE194TS. oripE194 replicates at 32ºC and 
segregates at 42 ºC (Smith and Youngman, 
1992).  
pET-15b Novagen 5.7 Kb AmpR 
Carries an N-terminal His•Tag® sequence 
followed by a thrombin site and three cloning 
sites. 
pET-24a(+) Novagen 5.3 Kb KanR Possess an N-terminal T7•Tag® sequence plus an 
optional C-terminal. His•Tag® sequence. 
pCR®2.1 Invitrogen 3.9 Kb KanR 
Encodes the first 146 amino acids of β-
galactosidase. Complementation in trans with 
the Ω fragment gives active β-galactosidase for 
blue-white screening. 
pKD20 JIC 6.1 Kb AmpR 
Low copy plasmid encoding the λ Red 
recombinase (γ, β, exo), which promote a greatly 
enhanced rate of recombination when using 
linear DNA. Possesses an optimized ribosome-
binding site for efficient translation of γ and 
expresses γ, β, and exo from the arabinose-
inducible ParaB promoter. It is also a temperature-
sensitive replicon to allow for its easy elimination 
(Datsenko and Wanner, 2000). 
pIJ733 JIC 4.3 Kb ApraR 
The ApraR disruption cassette was cloned into the 
EcoRV site of pBluescript SK II (+). The cassette are 
flanked by FRT sites (FLP recognition targets) 
which allows FLP-mediated excision of the 
cassette (Gust et al., 2003). 
pCC2FOS™ Epicentre 8.2 Kb CloR 
E. coli F factor-based partitioning and single-
copy origin of replication. oriV high-copy origin of 
replication. cos site for lambda packaging. loxP 
site for Cre-recombinase cleavage. 
Bacteriophage T7 RNA polymerase promoter 
flanking the cloning site. 
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Appendix 4 Preparation and transformation of chemically competent 
E. coli cells 
 
 
 
 
A4.1 Preparation of competent cells by calcium-chloride method 
Chemically competent cells were prepared using and adaptation of the procedure 
described by Sambrook and Russell (2001). The desired strain was inoculated in 10 mL of LB 
medium supplemented with the appropriated selective marker, overnight at 37 ºC, with 
aeration. The pre-culture (500 µL) was used to inoculate 50 mL of fresh LB medium 
supplemented with the appropriate antibiotic. The bacterial culture was grown at 37 ºC 
with aeration to an OD600nm of approximately 0.3 and centrifuged at 4 ºC for 2 min at 
6300 x g. The pellet was washed with 13 mL of ice-cold 0.1 M MgCl2 and centrifuged as 
above. The cells were washed again with 25 mL of 0.1 M CaCl2 solution, incubated on ice 
for 20 min and centrifuged as above. Finally the cells were resuspended in 1 mL of 
cryopreservation buffer, 50 µL were distributed in 1.5 mL microcentrifuge tubes and stored 
at -80 ºC until use. Before store cells should be immediately freeze on liquid nitrogen. 
 
Solution: 
Cryopreservation buffer: CaCl2 0.1 M, 15% (v/v) glycerol. 
 
 
 
A4.2 Transformation 
An aliquot of 50 µL of cells stored at -80 ºC were thawed on ice and the DNA was added 
(~5-100 ng of plasmid DNA or 5 µL of ligation reaction). The mixture was incubated in the 
1.5 mL microcentrifuge tube on ice for 15 min and transferred to 42 ºC for 45 sec. The tube 
was immediately placed on ice for 2 min and 1 mL of LB medium was added. The cells 
were grown for 1 hour at 37 ºC with aeration. The cells were collected by centrifugation at 
2300 x g for 1 min, resuspended in 100 µL of LB medium and finally were spread on LB agar 
plates containing the appropriate antibiotic. The plates were incubated at 37 ºC, 
overnight. 
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Appendix 5 Preparation and transformation of electrocompetent E. coli 
cells 
 
 
 
A5.1 Preparation of electrocompetent cells 
Electrocompetent cells were prepared by growing the desired strain in 10 mL of LB 
medium supplemented with the appropriated selective marker, overnight at 30 ºC, with 
aeration (160 rpm). This pre-culture (100 µL) was used to inoculate 10 mL of fresh LB 
medium containing 20 mM of MgSO4 and the appropriate antibiotic. The culture was 
grown until an OD600nm of ~0.4 at 30 ºC (due to the oriTS of pKD20) with aeration and the 
cells were pelleted by centrifugation at 3300 x g for 5 min and 4 ºC. The medium was 
decanted and the cells resuspended in 10 mL of ice-cold 10% glycerol by gentle mixing. 
This wash step was performed twice, and finally the cells were resuspended in 100 µL of 
10 % glycerol and kept at 4 ºC until use, since this procedure was always performed in the 
same day of transformation. The antibiotic used in the growth of strain E. coli 
BW25113/pKD20 was ampicillin and for E. coli BW25113/pKD20/pLIc5 were ampicillin (100 
µg/mL) and chloramphenicol (12.5 µg/mL).  
 
 
 
A5.2 Electroporation 
The freshly prepared cells were transformed by electroporation using a Bio-Rad 
GenePulser II® equipment. For the procedure, 50 µL of cells were mixed with approximately 
100-200 ng of DNA on ice. The mixture was transferred to a 0.2 cm ice-cold electroporation 
cuvette and the pulse parameters were set to: 200 Ω, 25 µF and 2,5 kV (the expected time 
constant was 4.5-4.9 ms). 1 mL of ice-cold LB medium was immediately added to the cells 
that were incubated at 30 ºC or 37 ºC (depending if replication or segregation of pKD20 
was desired, respectively) for 1 hour, with aeration. The cells were centrifuged at 2300 x g 
for 1 min, resuspended in 100 µL of LB and spread in LB agar plates containing the 
appropriated selective markers. The plates were incubated overnight at 30 ºC or 37 ºC. 
The selection of E. coli BW25113/pKD20 strains transformed with the fosmid pLic5 was 
performed with ampicillin (100 µg/mL) and chloramphenicol (12.5 µg/mL) at 30 ºC. The 
selection of E. coli BW25113/pKD20/pLic5 strains possessing the desired gene interruption 
was performed with chloramphenicol (12.5 µg/mL) and apramycin (50 µg/mL) at 37 ºC.  
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Appendix 6 Extraction of plasmid DNA 
 
 
 
A6.1 Mini-preparations 
The routine extraction of plasmid DNA from E. coli was performed with the GeneJET™ 
Plasmid Miniprep Kit (Fermentas), according with manufacturer’s instructions. Briefly, a 
bacterial culture was grown in LB medium with the appropriate selection agent, overnight 
at 37 ºC with aeration (160 rpm). 5 mL of this culture was centrifuged at 6800 x g for 2 min 
and the cells were completely resuspended in 250 µL of Resuspension Solution. The Lysis 
Solution (250 µL) was added and the tube inverted until the solution became clear and 
viscous (no more than 5 min). Neutralization was performed by the addition of 350 µL of 
the Neutralizing Solution and by immediately mixing thoroughly the solution by inverting 
the tube. The lysate was centrifuged for 5 min at 12000 x g to pellet the cellular debris and 
chromosomal DNA. The supernatant was transferred to a GeneJET™ spin column, avoiding 
the transfer of the white precipitate and centrifuged for 1 min at 12000 x g. The flow-
through was discarded and the column was placed back into the same collection tube. 
The DNA attached to the column was washed by the addition of 500 µL of Wash Solution 
followed by centrifugation for 1 min at 12000 x g. The flow-through was discarded and the 
column with the collection tube was centrifuged for an additional 1 min at the same 
speed to remove residual ethanol. Finally the column was transferred into a sterile 1.5 mL 
microcentrifuge tube. The plasmid DNA was eluted by the addition of 40 µL of sterile 
distilled water to the center of the column, incubation at room temperature for 2 min and 
centrifugation at 12000 x g for another 2 min. 
 
 
A6.2 Maxi-preparations 
If a higher concentration of plasmid DNA was required, the extraction was performed from 
an initial culture of 200 mL grown overnight at 37 ºC with aeration in LB medium 
supplemented with the appropriate antibiotic. The procedure was adapted from the 
protocol described by Sambrook and Russell (2001).  
The culture was centrifuged at 10000 x g for 6 min and the pelleted cells were 
resuspended in 6 mL of Solution I and incubated at room temperature for 5 min. To 
perform the cell lysis, 16 mL of freshly prepared Solution II containing 10 mg/mL of lysozyme 
(Roche) was added and the tube shacked vigorously in the horizontal position 5/6 times. 
The mixture was incubated on ice for 10 min and 12 mL of the alkaline Solution III were 
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subsequently added; the solution was gently mixed for 3 min. The mixture was incubated 
on ice for 10 min and the separation of plasmid DNA from the cell debris and 
chromosomal DNA was performed by centrifugation at top speed for 15 min at 4 ºC. The 
supernatant containing the plasmid DNA was recovered avoiding the white precipitate of 
residual cell debris (using a Pasteur’ pipette containing cotton at its bottom). The plasmid 
DNA was precipitated by addition of 0.6 volume of isopropanol to the filtered supernatant 
and incubated at room temperature for 15 min. The DNA was recovered by centrifugation 
at 8000 x g for 15 min and the pellet washed once with 5 mL of 70 % ethanol. The ethanol 
was removed by centrifugation in the same conditions as above and completely 
evaporated. The pellet was resuspended in 1 mL of TE containing 20 µg/mL of DNase-free 
RNase A (Roche), incubated at 37 ºC for 1 hour and extracted three times with Phenol/CIA 
(Invitrogen). The DNA was precipitated by the addition of 1/10 volume of solution III and 
0.6 volumes of isopropanol. The mixture was incubated at room temperature for 30 min 
and centrifuged at top speed for 15 min at 4 ºC. The pellet was washed with 1 mL of 70 % 
of ethanol and a last centrifugation at top speed for 5 min was performed. The 
precipitated DNA was dried in the flow chamber for 15 min to evaporate the residual 
ethanol and resuspended in 100 µL of sterile distilled water. 
 
Solutions: 
Solution I: 50 mM Tris-HCl and 10 mM EDTA. 
Solution II: 200 mM NaOH, 1% (w/v) SDS. 
Solution III: 3 M potassium acetate, pH 5.5. 
TE: 10 mM Tris-Cl, pH 8.0 and 1 mM EDTA. Final pH 8.0. 
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Appendix 7 Agarose gels handling 
 
 
A7.1 Electrophoresis of DNA 
Analysis of DNA was generally performed on agarose gel electrophoresis. The samples 
were mixed with 6X loading buffer in a proportion of 1:6 (v/v) and loaded in a 1 % agarose 
gel. The gel was prepared with 1X of TAE buffer (Bio-Rad) and EtBr (AppliChem) to a final 
concentration of 0.5 µg/mL that added before pouring the melted agarose in the running 
tray. In all the gels a DNA marker was included, either 0.5 µg of the DNA Ladder Mix 
(Fermentas) or 1 µg of the 2-Log DNA marker (New England Biolabs). Electrophoresis was 
generally performed at 5 V/cm for the desired time (normally between 1 – 1.5 hours, unless 
otherwise stated). The DNA was analized under UV light and the image acquired in the 
ATTO image acquisition system.  
 
Solutions: 
Loading Buffer 6X: 2.5 mg/mL of bromophenol blue, 2.5 mg/mL of xylene cyanol FF and 30% (v/v) glycerol. Stored 
at 4 ºC. 
 
A7.2 Purification of DNA from agarose gels 
The purification of DNA from agarose gels was performed using the QIAquick Gel 
Extraction Kit Protocol (Quiagen), according with the manufacturer’s instructions. For that, 
the DNA fragment of interest was excised from the agarose gel with a clean scalpel and 
placed in a previously weighted 1.5 mL microcentrifuge tube. The gel slice was weighted 
and 3 volumes of Buffer Q1 were added to 1 volume of agarose (considering 100 mg as 
100 mL). The tube was incubated at 50 ºC for 10 min (or at room temperature overnight) to 
completely dissolve the agarose slice. If the DNA fragment was smaller than 500 bp, 1 
volume of isopropanol was added and well mixed. The sample was applied to a QIAquick 
spin column placed in a 1 mL collection tube and centrifuged at 12000 x g for 1 min. The 
flow-through was discarded and the column placed back to the collection tube. The DNA 
was washed with 750 µL of Buffer PE and the column centrifuged for 1 min at 12000 x g. The 
flow-through was discarded and the column centrifuged in the same conditions for 1 min 
to remove residual ethanol. The DNA-containing column was placed in a 1.5 mL clean 
microcentrifuge tube and the DNA eluted in distilled water. The elution volume (between 
10 and 40 µL) was chosen according to the subsequent application. The eluted DNA was 
recovered after 2 min of incubation at room temperature by centrifugation for 2 min at 
12000 x g. The sample was stored at -20 ºC until further use. 
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Appendix 8 Purification and concentration of PCR products and 
restrictions digestions 
 
Purification and concentration of PCR products and DNA digestions were performed with 
the GeneJET™ PCR Purification Kit (Fermentas), according with manufacturer’s instructions. 
Thus, 1 volume of Binding Buffer was added to 1 volume of the PCR or restriction digestion 
reactions. When the DNA fragment was smaller than 500 bp, this mixture was 
supplemented with 1:2 volumes of isopropanol. The solution was transfered to a GeneJET™ 
purification column, centrifuged for 1 min at 12000 x g and the flow-through was 
discarded. The DNA attached to the column was washed with 700 µL of Washing buffer 
and centrifuged 1 min at 12000 x g. The flow-through was discarded; the purification 
column placed back into the collection tube and centrifuged 1 min at 12000 x g to 
completely remove any residual wash buffer. Finally, the column was transferred to a 
clean 1.5 mL microcentrifuge tube and DNA eluted in distilled water (from 20 to 40 µL). 
After 1 min incubation at room temperature, the column/tube system was centrifuge for 
2 min at 12000 x g. The collected DNA was stored at -20 ºC until use.  
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Appendix 9 Construction of the B. licheniformisI89 genomic library 
 
In order to easily access to B. licheniformis I89 genome, a genomic library was constructed 
using the high-capacity vector pCC2FOS™ and accordingly with CopyControl™ Fosmid 
Library Production Kit (Epicentre) manufacturer instructions. The pCC2FOS™ fosmid is a 
single-copy vector, which increases the likelihood that all genome was represented. Some 
DNA sequences, if cloned into high-copy vectors like a cosmid, are unstable and, thus, 
could not be represented in the library.  
 
 
A9.1 End-repair of HMW DNA 
The end-repair of the high molecular weight (HMW) DNA was performed in a reaction 
containing 1X of end-repair buffer, 0.25 mM of dNTP mix, 1 mM of ATP, 40 µg of sheared 
HMW DNA and 8 µL of End-repair Enzyme Mix, in a final volume of 160 µL. The reaction was 
incubated for 45 min at room temperature. The inactivation of the enzyme was performed 
for 10 min at 70 ºC.  
The reaction was loaded in a 1 % low-melt agarose gel, without the addition of EtBr. 100 ng 
of fosmid DNA control was loaded into the lanes adjacent to the HMW DNA. The gel was 
run at 3 5V for a period of 16 hours. After electrophoresis, the outer lanes containing the 
marker and a small portion of the lane containing the DNA were cut of and stained in an 
EtBr solution (0.5 µg/mL). Under the UV light, the position of the desired size of DNA was 
marked with a razor. The gel was reassembled and a slice 2 to 4 mm below the position of 
the fosmid control DNA was excised. The slice was weighted and stored in a 1.5 ml 
microcentrifuge tube at 4 ºC. 
 
 
A9.2 Recovery of the HMW DNA 
The blunt-end HMW DNA was extracted from the agarose using the GELase enzyme. 
Therefore, the agarose slice was melted at 70 ºC for 15 min, after what the tube was 
immediately transferred to 45 ºC. Add the appropriated volume of warmed GELase 
50 X buffer (at 45 ºC) to a 1X final concentration. Add 1U of GELase enzyme preparation 
for each 100 µL of melted agarose, assuming that 1 mg of solidified agarose yields 1 µL of 
molten agarose. Incubate the reaction at 45 ºC for 1 hour. The enzyme was inactivated at 
70 ºC for 10 min. 500 µL aliquots of the reaction were removed into sterile 1.5 mL 
microcentrifuge tubes and chilled on a ice bath for 5 min. The tubes were centrifuge at 
10000 x g for 20 min and the supernatant was removed to a 1.5 mL tube, avoiding the 
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gelatinous pellet, if present. The DNA was precipitated adding 1/10 volume of 3M NaAc 
(pH 7.0) and 2.5 volumes of ethanol. After mixing by gentle inversion the tubes were 
incubated 10 min at RT. The precipitated DNA was centrifuged for 20 min at 10000 x g and 
the supernatant was aspirated. The pellet was rinsed twice with cold, 70 % ethanol and 
centrifuged for 20 min at 10000 x g. Finally, the pellet was dried 10 min in a flow-chamber, 
with the tube opened and resuspended in 10 µL of TE buffer. The DNA concentration was 
determined using Qubit® fluorometer (Invitrogen) accordingly with manufacturer’s 
instructions.  
 
 
A9.3 Ligation to pCC2FOS vector and packaging 
Ligation of fractionated HMW DNA to pCC2FOS vector was performed in a 10 µL total 
volume reaction containing 0.5 µg of pCC2FOS DNA, 0.25 µg of HMW DNA, 1X Fast-Link 
ligation buffer, 1 mM ATP and 1 µL of Fast-Link DNA ligase. The reaction was incubated for 
4 hours at room temperature and the enzyme inactivation was performed for 10 min at 
70 ºC. One tube of the MaxPlax lambda packaging extract was thawed on ice and 25 µL 
of this extract was transferred to a sterile 1.5 mL microcentrifuge tube and placed on ice. 
The remaining 25 µL of the extract was stored at -70 ºC. 10 µL of the ligation reaction was 
added to the extract on ice and the solution was mixed by pipetting several times, 
avoiding however the introduction of air bubbles. The solution was incubated at 30 ºC for 2 
hours and the remaining 25 µL of MaxPlax lambda packaging extract was added. The 
reaction was incubated for another 2 hours at 30 ºC. After the reaction was completed, 
the phage dilution buffer (PDB) was added to a final volume of 1 mL and mixed well and 
25 µL of chloroform was added.  
 
Solution: 
PDB: 10 mM Tris-HCl [pH 8.3], 100 mM NaCl, 10 mM MgCl2. 
 
 
A9.4 Determination of the titer of the phage particles 
Before plating the library, titer of the phage particles (packaged CopyControl Fosmid 
clones) was calculated in order to determine the number of plates and dilutions required 
to obtain the library needed. Therefore, serial dilutions of the 1 mL of packaged phage 
particles were performed in PDB. 10 µL of each dilution and 10 µL of the undiluted phage 
particles, were added, individually, to 100 µL of the prepared EPI300-T1R host cells and 
incubated 1 hour at 37 ºC. The host cells were prepared as follows: on the day before use, 
5 mL of LB broth supplemented with 10 mM MgSO4 and 0.2 % maltose was inoculated with 
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EPI300-T1R cells and grown at 37 ºC. 500 µL of this culture was used to inoculate 50 mL of 
the same medium and the flask shaked at 37 ºC until reached an OD600 of 0.9. The cells 
were stored at 4 ºC until used.  
The infected EPI300-T1R cells were spread on LB agar plates containing chloramphenicol 
(12.5 µg/mL) and incubated overnight at 37 ºC. The colonies were counted and the titer of 
the packaged phage particles was calculated using the following formula: 
 
 
 
 
 
A9.5 Plating and selecting the I89 fosmid library 
The determination of the number of fosmid clones required to reasonably ensure that any 
given DNA sequence of B. licheniformis I89 was represented in the library was calculated 
using the following formula: 
N = ln (1-P ) / ln (1-f ) 
 
Where P is the desired probability (expressed as a fraction); f is the proportion of the 
genome contained in a single clone; and N is the required number of fosmid clones. 
Therefore, the number of clones required to ensure a 99 % probability of a given DNA 
sequence of B. licheniformis I89(genome = 4.2 Mb) being contained within a fosmid library 
composed of 40-kb inserts was: 
 
N = ln (1 – 0.99) / ln (1 – [4 x 104bases / 4.2 x 106bases])  
N= –4.61 / –9.55 x 10-3 
N= 482 clones 
 
Based on the titer of the phage particles previously calculated and the number of clones 
necessary, the phage particles were diluted in PDB and mixed with the prepared EPI300-
T1Rcells in a ratio of 100 µL of cells to 10 µL of diluted phage particles. The cells were 
incubated at 37 ºC for 1 hour and spread on LB agar plates containing chloramphenicol 
(12.5 µg/ml). The plates were incubated at 37 ºC overnight. The clones were picked and 
sequentially numbered to new LB agar plates containing the selective marker. All the 
clones were stored on 96-well plates at -80 ºC. 

  
 
